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1.1 Lung cancer
Lung cancer is the most prevalent form of cancer worldwide, exceeding 2.2 million new cases 
every year. The incidence will continue to rise in the upcoming years, with the expectation 
that numbers will increase to as much as 3.2 million cases in 2035 [2]. Every year since 2015 
has seen more than 13.000 patients in the Netherlands receive the diagnosis lung cancer 
[1]. When considering national disease burden based on all pathology, lung cancer takes 6th 
place in the Netherlands [3]. 
Lung cancer can be divided into different subtypes, with the vast majority of histology 
findings classified as non-small-cell lung cancer (NSCLC, totalling approximately 85%). Non-
small-cell lung cancer predominantly consists of subtypes adenocarcinoma, squamous-cell 
carcinoma, and large-cell carcinoma [4,5]. Unfortunately, this disease often only presents 
itself with symptoms at a late stage, leading to approximately 50% of diagnoses being end- 
stage disease (stage IV, Figure 1.1). Once other organs are involved – as indicated by 
disease stage IV – 5 year overall survival drops to approximately 5% (Figure 1.1). Comparing 
this to the 61% 5 year overall survival in patients with stage I disease, a stage where there’s 
no disease presence other than a primary tumor, demonstrates that early diagnosis brings 
an improved outcome. Combining late diagnosis and poor prognosis shows approximately 
80% of patients die within 5 years after having received their diagnosis [1]. Yet as even the 
earliest stage of disease remains to have very high mortality, all possibilities of improving 
outcome remain of high interest. One important aspect is to more timely and accurately 
diagnose and stage patients with a suspected or proven lung cancer. By accurate and timely 
diagnosis, unneeded disease progression and under- and overtreatment can be prevented. 
In this thesis, it is investigated how innovative technology in flexible endoscopy might help 
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Figure 1.1 – Non-small-cell lung cancer (NSCLC) statistics. Left: The distribution of disease stage at 
moment of diagnosis of patients in the Netherlands (2016). Right: Overall 5-year survival of the different 
stages of NSCLC in the Netherlands, once a diagnosis has been obtained. Source: IKNL [1].
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1.2 Lung cancer diagnosis
In the current situation, the patient most often finds its way to the department of pulmonology 
by first-line healthcare referral after having already developed advanced stage disease 
symptoms. At patient presentation, an initial suspicion of lung cancer is then further proofed 
by performing imaging such as X-ray or CT imaging. If these imaging modalities show a 
likely disease presence, it is recommended and routine clinical practice to perform a 
FluoroDeoxyGlucose – Positron Emission Tomography (FDG-PET) scan that is simultaneously 
combined with CT imaging (PET-CT scan) [6]. The FDG-PET scan allows for evaluation of 
the metabolic activity, while the CT scan gives spatial information. Together, they enable an 
assessment of both the metabolic activity of the primary tumor as well as possible lymph node 
and distant metastatic disease presence. PET-CT imaging thus allows for a first imaging-
based disease diagnosis and staging. With this information, the further needed work-up of 
(endoscopic) diagnostic modalities can be determined.
1.3 Lung cancer staging
In staging NSCLC disease extent, the tumor (T), node (N) and metastatic spread outside 
the original organ (M) are assessed. By this so-called TNM classification, disease staging 
and concurrent treatment options can be determined [7]. The T descriptor mainly involves 
tumor size, generally ranging from T1 (≤3 cm) to T4 (>7 cm). The N descriptor describes 
regional lymph node metastasis. In lung cancer, lymph nodal disease spread often follows 
specific predictable drainage patterns. The extent of nodal spread has shown prognostic 
of disease outcome, and ranges from N0-N3. N0 herein indicates absence of lymph nodal 
involvement. An N1 describes a nodal involvement maximally delimited by ipsilateral hilar or 
lymph nodes situated more peripheral in the lung. An N2 involvement indicates subcarinal 
and ipsilateral mediastinal involvement. An N3 involvement implies contralateral mediastinal 
or hilar nodes, or, involvement of any scalene or supraclavicular lymph nodes. The M 
descriptor implies distant metastasis into different organs, including the contralateral lung 
lobe and pleural or pericardial involvement. Combining the T, N and M descriptors results in 
the lung cancer stage (range I-IV). Patients with stage I-II disease, having N1 involvement 
at most, will generally receive treatment with curative intent (surgery, radiotherapy). Stage 
III disease most often includes N2/N3 involvement and will generally imply concurrent or 
sequential chemo-radiotherapy followed by immunotherapy or surgery. Stage IV – end-stage 
disease – involves distant metastasis. As there is systemic involvement, treatment of stage 
IV disease includes systemic treatment options like chemotherapy, immunotherapy or other 
targeted agents. From this staging algorithm it can be determined that disease staging and 
subsequent treatment and survival of NSCLC is mostly determined by metastatic (lymph 
nodal) involvement. 
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1.4 Advanced stage disease (Part I) 
While PET-CT imaging can enable an initial imaging based diagnosis and staging, its 
combined 62% sensitivity and 90% specificity reveals the technique is not always accurate 
in diagnosis and staging [9]. Consequently, especially the lymph nodal involvement of 
the disease should be confirmed by tissue sampling if any imaging based suspicion of 
metastasis has been raised [6]. In staging and therewith lymph node sampling of a suspected 
(advanced) disease, the three routinely utilized modalities are endobronchial ultrasound – 
transbronchial needle aspiration (EBUS-TBNA), endosophageal ultrasound – fine needle 
aspiration (EUS-FNA) and mediastinoscopy. Of these modalities, the EBUS-TBNA and EUS-
FNA procedures are least invasive, have lowest complication rates, are best tolerated, and 
most cost-effective [10]. By navigating through the natural orifice of the bronchial tree or 
oesophagus with these modalities, the lymph nodes can be assessed. These procedures 
use a video camera and ultrasound transducer positioned at the distal tip of a flexible 
endoscope to assess the differently defined anatomical lymph node regions (Figure 1.2). 
Routine clinical work-up of a suspected advanced stage disease involves combining an 
EBUS-TBNA and EUS-FNA procedure for systematically assessing all mediastinal and hilar 
lymph nodes under ultrasound guidance. Preferably, lymph node sampling is performed in 
at least zones 4L, 4R, 7, and any other lymph nodes showing increased metabolic activity 
or CT-scan based enlarged size [6,10] (Figure 1.3). Alongside PET and CT imaging, intra-
procedural ultrasound imaging findings are often used to decide on aspiration of (additional) 
nodes (e.g. [12,13]). To prevent cross-contamination of tissue samples between nodes, the 
physician should start with the lymph node most distal from the suspected tumor and from 
there work back to nodes more proximal to the tumor. If needed and possible, the tumor itself 
should also be assessed [6]. Performing a single needle aspiration of a lymph node herein 
takes at least 3 minutes [14]. A combined EBUS-EUS approach has a sensitivity of 86% and 
Figure 1.2 – Left: Image of an ultrasound video-endoscope for performing EBUS-TBNA procedures. 
Middle: Illustration of EBUS-TBNA based lymph node aspiration using a hollow needle as advanced 
through the working channel of the endoscope. Right: Clinical ultrasound image of an enlarged lymph 
node being sampled with a hollow aspiration needle. Left and middle images by Pentax [8].
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negative predictive value of 92% [15]. Thus, approximately one in seven malignant nodes 
will not be accurately identified as such by endosonographic staging. If EBUS-TBNA and/or 
EUS-FNA sampling results are negative or deemed unrepresentative and suspicion of nodal 
involvement remains, performing a mediastinoscopy is therefore indicated [6,10]
.
Figure 1.3 – Illustration depicting the lymph node regions as routinely used for TNM staging in NSCLC. 
Every number herein defines a lymph node region. Depending on the primary tumor location, these 
lymph node regions can be used for determining disease involvement and therewith staging. Image by 
Rusch et al. and the IASLC [11], re-used with permission.
In mediastinoscopy, a surgical incision and dissection of the pretracheal space is required 
for gaining access to the lymph nodes, being more invasive and having higher complication 
rates [12]. Using a rigid endoscope and rigid tools, the lymph nodes can then be sampled for 
tissue collection, allowing for an evaluation of tissue histology. As a randomized controlled 
trial showed, this sequential staging approach has highest accuracy. Where mediastinoscopy 
and endosonographic staging had only 79% and 85% sensitivity, the combined approached 
had 94% sensitivity [12].
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1.4.1 Endosonography for stratifying risk of malignancy
To increase the diagnostic yield and efficiency of endosonographically guided needle 
aspiration in EBUS-TBNA and EUS-FNA procedure, and therewith possibly avoid the necessity 
of additional staging procedures such as mediastinoscopy, it has been suggested to further 
utilize available ultrasonographical information for better differentiation of likely malignant 
lymph nodes. The first studies suggesting that endosonographic features of lymph nodes 
could help predict the chance of lymph node malignancy came after the initial introduction of 
EUS-FNA in the 1990’s [16]. However, as an expert panel report also concludes, individual 
study findings of greyscale ultrasound imaging have shown heterogeneous in accuracy thus 
far and are therefore limited in widespread use [17].
1.4.2 Ultrasound and strain elastography
Ultrasound strain elastography is a relatively new endosonographic technique, giving 
information on soft tissue by deriving tissue elasticity in real time. It provides additional 
information to conventionally used endosonographic B-mode imaging, which is based on 
imaging acoustical properties of tissues. As multiple studies in other medical specialties 
have found, a lower strain in lymph nodes or tumors was found to be correlated with higher 
chance of malignancy and could be measured by means of ultrasound strain elastography 
[18,19]. 
Ultrasound strain elastography can be performed in multiple ways. For example, pre- and 
post-strain radio-frequency (RF) signals can be used for determining elastic properties 
of soft tissue [20,21]. To be able to reconstruct the strain, backscattered signals of the 
tissue at a first acquisition (pre-compression) are compared to a second acquisition (post-
compression, Figure 1.4). The time shift between the tissue reflections at the different time 
points can then be quantified by for example a cross-correlation method. Since the speed 
of sound is considered to be constant, a time delay estimate can be transformed into a 
tissue displacement. After determining the displacement at every depth, its derivative can 
be computed for finding the relative strain [22]. The received RF signal contains not only 
the envelope but also the phase information, allowing a much more accurate quantification 
of strain than if only the envelop (echogram) were used. Since the phase information is 
available only in the axial direction and lacking in the lateral direction, strain is hard to 
determine accurately in the lateral direction [23]. Geometrically seen, the local axial strain 




Sn = Local axial strain
tn = time shift for segment n
dz = difference in axial length
c = speed of sound
(1)
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The derived axial strain measurements are not a generalized strain as used to describe 
the Young’s modulus (see Formula 2 below). To calculate the Young’s modulus, one 
needs to know both (applied) stress and (obtained) strain. As the stress cannot be 
accurately derived for the whole 2D image in ultrasound strain elastography, the strain is 
only indirectly related to the Young’s modulus (and thus an artefactual representation of it).
Young’s modules: E = tensile stress
extensional strain (2)
Figure 1.4 – Schematic illustration of how axial strain is derived from pre- to post- compression ultrasound 
imaging. On the top left, the tissue is in its initial state. A first RF signal is acquired. Top middle image: 
after introducing an axial force, a second RF signal is acquired. The displacement is calculated by using 
a cross correlation algorithm that correlates the RF signals before and after compression. The relative 
strain can be computed by taking the finite difference of tissue displacement at every depth in these two 
measurements. In endosonography, minute compression is hypothesized to be introduced by pulsation 
of the cardiovascular system.  Image adapted from Shiina et al. (2015) [24].
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The stress that is applied to create a deformation in endosonographic strain elastography is 
a result of the patient’s own pulsating heart and vasculature. The force of these deformation 
sources is unknown, as it is both patient and location dependent. However, knowing the 
lymph nodal map [11] it can be derived that lymph nodes are found in between the EBUS 
transducer and the pulsating vasculature that is causing strain. As opposed to the operator 
being the source of the palpation in the axial direction from a proximal point of view, axial 
imaging is thus theorized to be possible by using the pulsating vasculature from a distal 
point of view with reference to the EBUS endoscope, with the lymph node in between source 
and transducer. As it is a relative measure, not knowing what force is applied to obtain such 
strain, the visualized strain is normalized over every image. Although semi-quantitative, it can 
potentially provide valuable information on relative lymph node elasticity and therewith the 
chance of lymph node malignancy.
1.5 Early stage disease (Part II)
As stated before, lung cancer is one of most lethal malignancies in the Netherlands, most 
importantly because of the advanced stage disease at diagnosis. To improve survival, 
current guidelines advocate low-dose CT-based screening in a population high at risk of 
developing lung cancer. An increasing number of countries have started or are preparing 
to start a national lung screening program [25–30]. These preparations are based in part 
on the findings of lung cancer screening studies. An example of these are the American 
National Lung Screening Trial (NLST) and the recently concluded Dutch-Belgian NELSON 
screening trial. Both trials showed that a CT screening of a high risk population could reduce 
lung cancer mortality by more than 20% as compared with the radiography control group 
[26,31]. This decreased mortality could mainly be attributed to a shift towards early stage 
lung cancer findings. However, these screenings also find numerous non-malignant lesions 
situated in the peripherals of the lung. An example is the NLST, which found that 39.1% of the 
participants developed at least one lesion of more than 4 mm in diameter. Of those patients 
with lesions, 72.1% needed additional diagnostics procedures for further nodule evaluation 
[26]. The NELSON study, having different inclusion criteria and study specifications, found 
that 9.2% of the participants needed at least one additional CT scan during the 10-year 
trial [31]. Eventually however, in both NLST and the NELSION trial more than 96% of the 
suspected peripheral pulmonary lesions were found to be benign [25,26]. 
Yet even without the implementation of a CT screening for a population at risk for developing 
lung cancer, we are seeing small peripheral lesions in the lung being diagnosed increasingly 
often. With the widespread availability of CT in more recent times, scanning is more easily 
performed. A CT scan not purposefully requested for lung disease will not rarely reveal one or 
more pulmonary lesions. A pooled analysis of 11 studies showed that in 13% (range 2-24%) 
of CT scans that were not purposefully requested for lung disease, one or more pulmonary 
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lesions suspected of malignancy were found. In these CT scans, 1.5% (range 0-4.0%) of 
patients were eventually diagnosed with lung cancer [32]. At current, the early stage disease 
patients in the Netherlands are exclusively identified through these incidental findings.
1.5.2 Diagnostic algorithms
As opposed to staging advanced stage disease where lymph nodes can be reached and 
sampled under real-time guidance for confirming lung cancer, early stage disease requires a 
different approach. Early stage disease involves only the suspicion of a primary lesion, which 
is often small in size and located in the peripherals of the lung. Because of their small size 
and peripheral location, reaching them for obtaining a diagnosis and concurrently providing 
a treatment is complex. This can also partially be reflected by the fact that multiple different 
guidelines and calculators for determining on how to cope with peripheral pulmonary lesions 
exist [32–37]. 
Generally, three strategies for a suspected early stage lung cancer can be described: 
observational CT follow-up / watchful waiting, minimally invasive diagnostic techniques, 
or, (limited) surgical excision for further diagnosis and patient management. Based on 
the probability of malignancy, patient preferences and feasibility of the approach, one of 
strategies will be preferred above the other. The risk of malignancy is herein determined by 
multiple factors and can be influenced by the use of different algorithms [32–37]. Based on 
these algorithms, the British Thoracic Society (BTS) guidelines for example dictate a <10% 
risk of malignancy warrants watchful waiting, 10-70% should indicate non-surgical biopsy 
and a >70% risk of malignancy could allow for immediate surgical diagnosis. If chance 
of malignancy is deemed sufficiently high and surgical resection is considered infeasible, 
immediate radiotherapy might also be considered. The cut-offs herein are determined by 
weighing the risk of malignancy and need of tissue diagnosis against procedure effectiveness 
and invasiveness.
1.5.3 Non-surgical biopsy
Peripheral lesions that ought to be diagnosed by minimal invasive means can be subjected 
to a multitude of clinical work-up diagnostics. Differences in modality costs (and country 
variation), heterogeneous study results of the different modalities, manufacture differences, 
needed expertise, and availability of modalities all hamper a straightforward guideline in 
reaching for the peripheral pulmonary nodules. However, a clear preference for first utilizing 
an endobronchial approach exists, as it is least invasive [32–34,37]. 
1.5.4 Endobronchial approaches
The fluoroscopy (C-arm) guided transbronchial biopsy procedure using the conventional 
bronchoscope has been a widely used means for the endobronchial diagnosis of peripheral 
lesions in previous decades (pooled yield 34%, [34]). As the originally available bronchoscopes 
had diameters too big to pass beyond the segmental bifurcations, this method relied on 
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advancing biopsy tools through the working channel and into the hypothesized bronchi that 
would lead to the suspected lesion. Fluoroscopy was used as a coarse guidance method for 
tissue sampling and often no direct endobronchial visualization of accurate lesion sampling 
was possible. 
In more recent years, several more promising new modalities have become available 
that are able to provide additional guidance for endobronchial diagnosis of peripheral 
pulmonary lesions. For an overview and more thorough explanation on these modalities, see 
i.e. [38–42]. A meta-analysis by Wang et al. (2012) showed that the individual diagnostic 
yield of most readily available modalities such as virtual endoscopy navigation guidance, 
electromagnetic navigation guidance, radial endobronchial ultrasound imaging guidance, 
ultrathin bronchoscopes and a guide-sheath based approach had diagnostic yields ranging 
from 67%-73.2% and an overall pooled diagnostic yield of approximately 70% [39]. These 
modalities are already a big improvement when compared to the conventional fluoroscopy 
guided trans-bronchial biopsy. But, a diagnostic yield of approximately 70% shows that room 
for improvement remains. 
1.5.5 Transthoracic techniques
If the endobronchial approach fails to provide an outcome or is deemed infeasible, additional 
more invasive staging is often indicated [32,34,43]. TTNA, or trans thoracic needle aspiration, 
is a more invasive technique than the earlier introduced endobronchial techniques. Instead of 
an endobronchial approach, this technique encompasses a percutaneous biopsy performed 
under CT guidance. TTNA has been reported and widely accepted as the golden standard 
for diagnosis of peripheral pulmonary lesions, with a diagnostic yield of approximately 90%. 
However, by traversing the thoracic wall it is also known to have high pneumothorax rate. The 
pooled pneumothorax complication rate is found to be 18.8-25.3%, of which 6-7% requires 
a chest tube placement [32,44]. In contrast, the different endobronchial approaches have 
1.5% pooled chance of pneumothorax, requiring chest tube placement in only 0.6% [39].
1.5.6 Suboptimal diagnostics
When both endobronchial techniques as well as TTNA did not provide outcome or are 
deemed infeasible and risk of malignancy is significant, more invasive techniques and follow 
up are indicated. These techniques are not necessarily diagnostic only, as they also involve 
a therapeutic nature. The follow-up is herein based on patient characteristics as well as 
patient preferences. A suspected peripheral lesion which was not or could not be diagnosed 
by minimally invasive diagnostics is likely to be referred for surgery or radiotherapy. In the 
surgical approach, a wedge resection will generally be performed. This involves removal of 
the suspected lesion with a minority of normal lung tissue and can be deemed a diagnostic 
but also immediate therapeutic option. If this wedge shows the lesion to be malignant by 
intra-procedural frozen section analysis, a continuation of the procedure into a lobectomy 
for curative surgical treatment is likely considered. Radiotherapy is a strictly therapeutic 
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technique, irradiating the suspected lesion to kill any tumor cells without pursuing any further 
sure diagnosis of the lesion.
As the British Thoracic Society guidelines (2015) and van IJsseldijk et al. (2019) conclude, 
the lack of confirmative tissue diagnostics preceding to surgery and radiotherapy leads to a 
significant amount of patients with benign disease receiving unnecessary treatment [32,45]. 
This unnecessary treatment poses the patient with risks and reduced lung function whilst 
adding significant costs to healthcare.
All considered, the demand for safe, fast and accurate diagnostic tools is high and is 
anticipated to increase rapidly as screening programs are being initiated. Ideally, an 
endobronchial approach easily accessible and having high diagnostic accuracy would 
overcome the need of the currently used sequential increasingly invasive diagnostic and 
consecutive treatment approach. The currently available techniques herein do not seem to 
fulfil this emerging demand. 
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1.6 Thesis outline
Part I - Part I of this thesis is focused on the clinical use of endobronchial ultrasound and 
ultrasound strain elastography for predicting lymph node malignancy in an advanced 
stage lung cancer (suspicion). Chapter 2 details a first clinical study exploring the value of 
ultrasound strain elastography for predicting lymph node malignancy when a standardized 
measurement protocol is used in a single center. Chapter 3 describes the predictive value 
of strain elastography for lymph node malignancy in an international multi-center trial. Aside 
assessment of the predictive value of strain elastography alone, it further describes if strain 
elastography information can be added to clinical information such as FDG-PET and lymph 
node size to further increase the clinical value. In chapter 4, the predictive value of ultrasound 
B-mode features for lymph node malignancy is described. By collecting observer scorings on 
ultrasound features in multiple centers, the predictive value of reported ultrasound B-mode 
features are derived. The reproducibility of ultrasound B-mode feature scoring is furthermore 
given.
Part II - The second part of this thesis (chapters 5-7) elaborates on endobronchial diagnostics 
for early lung cancer staging, also termed navigation bronchoscopy. Chapter 5 describes 
the ability of a combination of navigation bronchoscopy technologies and imaging to 
accurately reach and diagnose peripheral lesions. Imaging is herein provided by cone beam 
CT systems, as often available in the interventional radiology suite and the hybrid operating 
theatre. Chapter 6 specifically describes the accuracy of the differently available navigation 
bronchoscopy tissue acquisition methodologies. The accuracy of individual cytology and 
histology sampling tools along with the value of rapid on-site evaluation of cytopathology in 
a cone beam CT guided navigation bronchoscopy setting is described. Chapter 7 describes 
the cone beam CT mediated navigation bronchoscopy in an extended series of consecutive 
patients and the forthcoming availability of a specific tailoring of imaging protocols to the 
navigation bronchoscopy procedure. By having monitored diagnostic accuracy and radiation 
exposure over time, from initialization of the procedure until having performed more than 200 
procedures, the learning curve of different facets of the procedure are described. 
In chapters 8 and 9, the work as described in chapters 2-7 of this thesis are summated and 
discussed. A future perspective with regards to the described research is given.

CHAPTER 2
Optimal endobronchial ultrasound strain 
elastography assessment strategy: 
an explorative study
Authors
R.L.J. Verhoeven, C.L. de Korte, E.H.F.M. van der Heijden.
Published in




In lung cancer staging, mediastinal lymph nodes are currently aspirated using endobronchial 
ultrasound transbronchial needle aspiration (EBUS-TBNA) based on size and FDG-PET 
avidity. EBUS strain elastography (SE) is a new technique that may help predict the presence 
of malignancy. However, a standardized assessment strategy for EBUS-SE measurement is 
lacking. 
Objectives
The aim of this study was to determine the optimal assessment strategy for investigating the 
predictive value of EBUS-SE in mediastinal lymph nodes. 
Methods
Two qualitative visual analogue scale strain scores and two semiquantitative strain 
elastography measurements (a strain histogram and strain ratio) were acquired in 120 lymph 
nodes of 63 patients with (suspected) lung cancer. The dataset was randomized into an 80% 
training dataset to determine cut-off values. Performance was consecutively tested on the 
remaining 20%, and, the overall dataset. 
Results
The semiquantitative mean histogram scoring strategy with a cut-off value of 78 (range 
0–255) showed the best and most reproducible performance in prediction of malignancy 
with 93% overall sensitivity, 75% specificity, 69% positive predictive value, 95% negative 
predictive value, and 82% accuracy. Combining the EBUS-SE mean histogram scoring 
outcome with PET-CT information increased the post-test probability of disease in relevant 
clinical scenarios, having a positive test likelihood ratio of 4.16 (95% CI 2.98–8.13) and a 
negative test likelihood ratio of 0.14 (95% CI 0.04–2.81) in suspicious lymph nodes based on 
FDG-PET or CT imaging. 
Conclusions
EBUS-SE can potentially help predict lymph node malignancy in patients with lung cancer. 
The best semiquantitative assessment method is the mean of the strain elastography 
histogram.
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2.2 Introduction
Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) has evolved from 
a diagnostic procedure to a staging procedure, and is now recommended as the first line 
staging procedure in lung cancer [9,10]. For accurate and complete staging, it is imperative 
that the endoscopist performs a full and systematic evaluation of the entire mediastinum. 
The evaluation should start in the contralateral hilum and proceed to the ipsilateral hilum, 
and preferably combine endobronchial ultrasound (EBUS) evaluation with esophageal 
ultrasound evaluation using the EBUS scope (EUSb) [10]. The goal of EBUS has herein 
shifted from the confirmation of metastatic disease to proving the absence of metastatic 
disease. Besides the available CT and FDG-PET information, ultrasound characteristics are 
often used for selecting nodes to aspirate in daily clinical practice. A study by Fujiwara et 
al. (2010) introduced B-mode ultrasound characteristics round shape, distinct lymph node 
margins, heterogeneous echogenicity and presence of a central necrosis sign as independent 
predictive markers for malignancy [46]. Later however, Evison et al. (2015) showed that 
heterogeneous echogenicity was the only significant predictor of malignancy [47]. Several 
other studies also found discording results in using these ultrasound features [48–50], resulting 
in limited widespread diagnostic application of these echo characteristics [17].
Additional tools like ultrasound strain elastography have become available that may 
help predict the probability of malignancy in mediastinal lymph nodes. Ultrasound strain 
elastography visualizes relative tissue stiffness by measuring axial tissue deformation. In 
EBUS-TBNA specifically, the periodical motion of the heart and greater vessels cause tissue 
deformation. Monitoring this tissue deformation by means of ultrasound over time enables 
a derivation of relative tissue strain which is a marker of tissue stiffness. A region of tissue 
that is heavily deformed over time when compared to another region in the same image 
is derived to be relatively soft (and thus high in strain). A region that is barely deformed 
by this same deformation force is derived to be relatively stiff (and thus low in strain). In 
ultrasound strain elastography, the received signal intensities over time are correlated to one 
another for quantifying these deformations. As current ultrasound technology only allows 
accurate cross-correlation of signal intensity along the propagation direction of ultrasound 
itself, it should however be acknowledged that it is primarily an axial measurement of strain 
(for more information, also see supplemental material). Ultrasound strain elastography 
has already shown valuable in differentiating benign from malignant lesions in thyroid and 
breast, where an external force can be used and standardized [19,51–53]. Several pilot 
studies now report that endoscopic ultrasound strain elastography can also be used for 
differentiating malignant and benign lymph nodes in the mediastinum with high accuracy, 
with lesions low in strain being more likely malignant [54–61]. However, the optimal method 
for scoring the presentation of the strain elastography values in EBUS applications remains 
unclear [62]. Several qualitative and semi-quantitative techniques have been reported so 
far. For qualitative presentation of strain, visual analogue scale (VAS-) scoring techniques 
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can be used. This is done by converting calculated relative strain into a color gradient and 
superimposing it on the B-mode image. This strain color image is then used for scoring 
the lymph node region of interest upon its major color component [55,58,59,63] or pattern-
color combination [19]. Another frequently reported method is the semi-quantitative strain 
ratio measurement [58,60,64]. This technique requires that the operator manually selects the 
lymph node region and a secondary surrounding tissue region. By doing so, a ratio of strain 
can be calculated [58,60,64,65]. A third less frequently used method is the semi-quantitative 
strain histogram scoring method. This method quantifies the relative strain found in a manually 
selected lymph node area, and presents this as a histogram of strain counts [66]. 
Ideally, every assessment is operator independent, swift and safe. Yet in EBUS several 
factors will influence measurement results as a consequence of the technological principles 
used in strain elastography (also see supplemental material). For example, the position of the 
target node in relation to the source of compression and the tip of the EBUS scope affects the 
measured axial strain in EBUS strain elastography (EBUS-SE). 
In this explorative study, we aim to determine the optimal EBUS-SE scoring and assessment 
strategy in patients with suspected or proven lung cancer. This is done by comparing the 
performance of predicting mediastinal lymph node malignancy among different scoring 
methods. We hypothesize that the strain histogram method will give the best overall predictive 
accuracy for diagnosing the lymph node malignancy since this will be the most operator 
independent and thus objective technique. We furthermore hypothesize that EBUS-SE will 
increase predictive value of mediastinal lymph node ultrasound imaging. To do so, we aim 
to explore what the clinical effect of adding EBUS-SE is on the probability of malignancy in 
combination with FDG-PET and CT imaging.
2.3 Materials and methods
2.3.1 Study subjects
All patients in the Radboud University Medical Center (Nijmegen, The Netherlands) who 
had an indication for a diagnostic or staging EBUS-TBNA procedure for suspicion of lung 
cancer were eligible and included. This study was conducted with approval of independent 
ethics committee as part of the E-predict multi-center study (NCT02488928) and all included 
patients gave informed consent. The inclusion period ranged from July 2015 to April 2016. All 
subjects had no history of prior radio- or chemotherapy and no general EBUS-TBNA contra-
indications. 
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2.3.2 Study design
The EBUS-TBNA procedures were performed according to local and international guidelines 
[6,10]. Measurements were acquired using the Hitachi Preirus Hi Vision processor (Hitachi 
corporation, Tokyo, Japan) with Hitachi Real Time Elastography software in combination with 
Pentax EB-1970UK echo-endoscopes (Pentax Medical, Tokyo, Japan). The recommended 
diagnostic work-up of our hospital was used; all nodes with short-axis size >10 mm on CT, 
ultrasound based short axis size >5 mm or FDG-PET avid nodes in at least regions 4L, 
4R and 7 were routinely aspirated. FDG-PET scans were obtained and evaluated by the 
radiologist following the European Association of Nuclear Medicine guidelines [67]. While 
Standard Uptake Values of individual lymph nodes were not routinely reported, a cut-off of 
2.5 was typically used. EBUS strain elastography measurement collection and assessment 
was performed using a standardized operating protocol (see supplemental data & Figure 
2.1.). In brief, real-time dual ultrasound B-mode and elastography imaging were used for 
data collection of both B-mode lymph node ultrasound characteristics (size, shape, margin, 
echogenicity, central hilar structure presence and coagulation necrosis sign [46]) and 
quantitative and qualitative EBUS-SE measurements. After these measurements, routine 
EBUS-TBNA sampling was performed under guidance of B-mode ultrasound alone. Cytology 
and consecutive histology (if available) of the EBUS-TBNA specimen combined with clinical 
follow-up were used as the gold standard for determining individual lymph node diagnosis.
2.3.3 EBUS Strain Elastography evaluation techniques
Qualitative evaluation - For visual scoring of strain, two visual analog scale scoring methods 
based upon earlier reports were used [55,58,63]. The first VAS system requires the operator 
to classify the image into one of five groups based upon the major color component. From 
low to high strain respectively, these scores correspond to; 1: predominantly blue, 2: blue 
and green, 3: predominantly green, 4: green and red, 5: predominantly red (see Figure 
2.2). The second qualitative VAS scoring method used a modified version of the Tsukuba 
score, a scoring system based on a combination of the visualized color and the pattern of 
the strain image. This scoring method has shown to be promising in classification of breast 
lesions [19]. Scoring was however slightly altered by the authors to accommodate for the 
differences in breast US and EBUS imaging. The operator grades the lymph node EBUS-SE 
image following a six-category classification system (Figure 2.3).
CHAPTER 228
Figure 2.1 – Summarized measurement acquisition protocol for obtaining reproducible strain 
elastography measurements. Abbreviations: Image sector – a set of subsequent imaging frames as 
automatically selected by the Hitachi Strain Elastography software upon freezing the ultrasound image; 
ROI – Region of Interest; VAS – Visual Analogue Scale. 
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Figure 2.2 – Typical examples of EBUS strain elastography imaging of 4L lymph nodes as captured by 
Hitachi – Real Time Strain Elastography software on the Preirus Hi Vision processor (Hitachi Corporation, 
Tokyo, Japan) in combination with Pentax EB-1970UK endoscope (Pentax medical, Tokyo, Japan). In 
each panel on the left, conventional B-mode image with strain map overlay in color; the yellow box is 
the manually set region of interest (ROI) selection for calculation of the strain histogram mean. The 
different colors correspond to measured relative strain. Red corresponds to high deformation, green 
to intermediate measured deformation and blue to relatively low deformation. On the right side of each 
panel, the B-mode image can be seen and used as reference. On the bottom left of each panel a strain 
rate graph is shown, to be used for quality control and frame selection of elastography measurements. 
On the bottom right of each panel the strain histogram as calculated based on the selected ROI is 
shown. Finally, the strain histogram parameters are presented in the table on the bottom of each panel. 
Panel A – D: all depict 4L lymph nodes, Panel A: EUSb approach, Panels B-D: EBUS approach. Panels 
A and B: malignant nodes. Panel C and D: benign nodes. 
Semi-Quantitative EBUS-SE evaluation - For semi-quantitative scoring of EBUS-SE, two 
measurement methods are evaluated (see data supplement). The first measurement method 
is the mean strain elastography histogram. This requires a (rectangular) hand-selection of a 
lymph node region of interest. After selection, strain values are computed from the selected 
area and relayed back to the operator through a histogram of strain counts (see Figure 2.2). 
The second semi-quantitative scoring method is the strain ratio. Herein, the lymph node 
region of interest as selected during the strain histogram method are compared against 
a hand-selected surrounding reference tissue area using the Matlab Image Processing 
Toolbox (version 9.1.0, MathWorks, Inc., Natick, MA, USA, see Figure 2.4). As opposed to 
the other methods, the strain ratio was measured after completion of the EBUS-procedure by 
one operator (RLJV) blinded for patient details and pathology outcome.
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Figure 2.3 – Modified Tsukuba score classification system used for visual analog scale scoring of lymph 
node EBUS SE, adapted from Itoh et al. (2006). The depicted typical images are all EBUS-SE lymph 
nodes images. The original Tsukuba score system as introduced for breast imaging was adjusted to 
accommodate for differences in endobronchial and breast imaging, where the scoring system was 
originally designed for [19].
2.3.4 Statistics
The performance of the different EBUS strain elastography scoring techniques was evaluated 
by a-priori randomizing the final dataset into an 80% training dataset for determining scoring 
method cut-off values and using the remaining 20% of data to test the scoring method 
performance on unseen data. To evaluate the performance of the models, sensitivity, 
specificity, negative predictive value (NPV), positive predictive value (PPV), accuracy, 
negative and positive likelihood ratios and post-test probability of malignancies (using the 
likelihood ratios) with their respective 95% confidence intervals (CI) are calculated among the 
separate and combined datasets. Area under the curve (AUC) is calculated for continuous 
variables. 
To exploratively correlate strain elastography imaging to outcome, pathology results were 
classified as malignant or benign. Patients diagnosed with granulomatous disease or 
patients of which measurement data was incomplete were excluded from the final dataset 
before randomization and analysis (Figure 2.5). The statistical computing language R and 
interface R-studio (version 1.1.414) were used for statistical analysis [68]. 
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Figure 2.4 – Visualization of user interface as programmed with Matlab for post procedure strain ratio 
extraction (version 9.1.0., Mathworks, Inc., Natick, MA, USA).. The original prospectively selected 
rectangular region of interest for calculating the strain histogram was automatically segmented and used 
to compare a retrospectively selected ellipsoid reference tissue region of interest. An input dialogue 
was additionally used for qualitative rating of the ability to select an adequate ellipsoid reference tissue 
region of interest. 
2.4 Results
In total, 150 lymph node strain elastography measurements were obtained in 81 patients. 
After exclusion of other pathologies and incomplete measurements, 120 lymph nodes in 
63 unique patients remained (Figure 2.5). A total of 45 lymph nodes herein proved to be 
malignant based on EBUS-TBNA alone (43 lymph nodes, 28 patients) or by surgical follow-
up of false negative benign EBUS-TBNA cytology findings (2 lymph nodes, 2 patients). For 
the N=75 lymph nodes (42 unique patients) eventually classified as benign, follow-up data 
was available in 61 nodes (81%). Surgical proof of benign EBUS-TBNA findings was available 
in 41 lymph nodes (55%) by either resection (15 nodes, 9 patients) or mediastinoscopy (26 
nodes, 13 patients). Long-term clinical follow-up was available in 20 lymph nodes (27%, 12 
patients) with a median follow up time of 23 months (min. 3 – max. 34). No follow-up of benign 
EBUS-TBNA findings was available in 14 lymph nodes (19%, 9 patients) due to rapid disease 
progression (6 nodes, 5 patients) and loss to follow-up (8 nodes, 4 patients). 
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Figure 2.5 – CONSORT flow diagram of the study design.
The general patient demographics and lymph node details are summarized in Table 2.1. The 
lymph nodes were randomized into the training and test dataset (Figure 2.5). The a-priori 
defined training dataset included 100 randomly selected lymph nodes. 
The remaining testing dataset consisted of 20 lymph nodes. Prevalence of malignancy or 
pre-test probability of malignant disease in both datasets was approximately equal at 0.38 
and 0.35, respectively. The results of general B-mode ultrasound feature classification are 
presented in the data supplement (Table 2E.1). In the final dataset, 79 of 120 lymph nodes 
(66%) were classified as FDG-PET positive. No PET-scan was available in 3 patients (3 lymph 
nodes), and no contrast-CT was available in 1 patient (1 lymph node).
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Table 2.1 – On the left, overall patient demographics and lymph node characterization. Lymph node 
size is given as mean (min – max) in mm. On the right, measured lymph nodes per region as counts 
(N) and as distribution of counts of malignant (mal) to benign (ben) findings. Abbreviations used: SA: 
short axis, NA: not available, NSCLC: non small cell lung cancer, SqCC: squamous cell carcinoma, 
NOS: not otherwise specified, LCNEC: large cell neuroendocrine carcinoma, EB: endobronchial, EUSb: 
Esophageal using EBUS scope, LMB: Left Main Bronchus, RMB: Right Main Bronchus, mal: malignant, 
ben: benign
Patient Demographics Measured Lymph nodes 
Study subjects 63 Region N (mal/ben) % total
Mean age 64.3 yr (range 41-83 yr) 2L 1 (1/0) 0.8%
Sex 39 Male (61%) / 24 Female (39%) 2R 2 (2/0) 1.6%
Aspirated lymph node characteristics 4L (EB) 23 (11/12) 19.2%
CT size (SA) 11.95 mm (2-41 mm) 4L (EUSb) 7 (4/3) 5.8%
FDG-PET avidity 79 FDG+ / 38 FDG- / 3 NA 4R 25 (7/18) 20.8%
US size (SA) 9.95 mm (4-26 mm) 7 (LMB) 3 (0/3) 2.5%
Lymph node pathology outcome 7 (RMB) 23 (4/19) 19.2%
Normal 75 (62.5%) 7 (EUSb) 10 (5/5) 8.3%
Malignant 45 (37.5%) 10L 0 (0/0) 0%
    NSCLC Adenocarcinoma 19 (15.8%) 10R 2 (1/1) 1.6%
    NSCLC SqCC 15 (12.5%) 11L 10 (3/7) 8.3%
    NSCLC NOS 1 (0.8%) 11R 14 (7/7) 11.7%
    Small Cell Lung Carcinoma 5 (4.2%)
    LCNEC 3 (2.5%)
   Invasive ductal carcinoma 2 (1.6%)
2.4.1 EBUS-SE scoring method assessment cut-off values
Cut-off values of all four strain elastography scoring methods were first optimized by 
analyzing performance on the training dataset using accuracy, AUC (in the cases of strain 
histogram and strain ratio scoring) and individual predictive values sensitivity, specificity, 
NPV and PPV. For the color VAS scoring system, optimal predictive performance was found if 
lymph nodes categorized as ‘predominantly blue’ or ‘blue and green’ were grouped together 
(predicting malignancy) versus all other categories grouped (predicting benign outcome, 
Figure 2.6). The modified Tsukuba scoring method performed best when placing the cut-off 
at the two lowest of five scores (Figure 2.6), grouping score 4-5 as malignant and score 1-3 
as benign. For the semi-quantitative measurements, the ROC curve analysis of the strain 
histogram method (AUC 0.846, Figure 2.6) showed a relative mean strain value of <78 (range 
0-255, with a lower value representing less strain) to be most predictive of malignancy. The 
strain ratio was most predictive of malignancy when the mean of the lymph node strain 
divided by the reference tissue strain was more than 1.67 (AUC 0.637, Figure 2.6). During 
retrospective strain scoring (also see Figure 2.4), R.L.J.V. furthermore scored the selection 
of reference tissue upon adequacy when taking into account technical and clinical boundary 
conditions. Selecting adequate reference tissue was reported qualitatively as being difficult 
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in 50% of cases. Reported causes were diverse, such as a lack of homogeneous reference 
tissue, depth dependency artefacts, or, too small regions of interest for obtaining a single 
adequate secondary measurement.
2.4.2 EBUS-SE predictive value
With above described cut-off values, the different predictive values as introduced in the 
Methods section were calculated on both datasets. The results are summarized in Table 2.2, 
calculation of likelihood ratios are furthermore presented in Supplemental Table 2E.2. The 
prospectively collected Color VAS scoring, Modified Tsukuba scoring and Strain histogram 
scoring had similar accuracies in the training dataset of 76%, 82% and 82%, respectively. 
The most notable difference in individual performance factors among these methods were 
found in sensitivity and NPV. Sensitivity and NPV are upwards of 76% in all three methods. 
Less false negatives were however found in the strain histogram method, having a sensitivity 
of 92% and NPV of 94% (being 3-16% higher than the other two methods). Consequently, 
it also had the lowest negative post-test probability of malignancy (0.06). Following the 
specificity and PPV, positive post-test probability of malignancy seems to be similar in the 
three methods at around 0.70. While performance among the three prospective methods 
seems comparable, the strain ratio most markedly has lower sensitivity (50%) and NPV (73%) 
in the training dataset, which is further reflected by the lower accuracy (71%).
When the cut-offs of the four scoring methods are consecutively used to analyze performance 
on the testing dataset, the accuracies remain within the earlier determined 95% CI of the 
training dataset (Table 2.2). However, the positive and negative post-test probability of 
malignancy as based on the likelihood ratios (Table 2E.2) do show differences. All collected 
methods except strain ratio showed no false-negatives in the test dataset. Consequently, 
both the Color VAS score and Modified Tsukuba score performed better than the 95% CI 
as deterred from the training dataset. Furthermore, we would expect a higher than 0.58 
positive post-test probability of malignancy of the Modified Tsukuba scoring method based 
on training dataset results (0.61-0.82 95% CI). 
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Figure 2.6 – Results of EBUS Strain elastography scoring through multiple methods.
Top: Distribution of malignancies and normal lymph nodes along the qualitative Color VAS scoring 
method (top left) and the modified Tsukuba scoring method (top right) in the training dataset. The width 
of column corresponds to amount of measurements as proportion of total (training dataset, n = 100). 
The count of measurements are superimposed on the columns of every score. Both VAS scores show a 
sharp decline in malignancy prevalence if the scoring does not involve a majority of lymph node tissue 
being blue (Color VAS score Blue & Blue and green, mod. Tsukuba score 4 & 5). It furthermore stands 
out that the score X in the modified Tsukuba method was used in five artefactual cases of measurements, 
whereas this was not possible in the color VAS score nor semi-quantitative strain ratio and histogram 
scoring, and lymph nodes as such will have been rated otherwise. 
Bottom: Receiver Operator Characteristic curve of strain ratio and mean of strain histogram, based on 
the training dataset. Area under the curve of the strain histogram mean is 0.846. Area under the curve of 
the strain ratio is 0.637. The top most left of both ROC’s correspond to cut-off values of <78 and >1.67 
for the strain histogram mean and strain ratio to predict malignancy, respectively. In these cases, the 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EBUS STRAIN ELASTOGRAPHY ASSESSMENT METHODS 37
2
When combining performances of both the training and test dataset, the mean of the strain 
histogram shows to best predict lymph node malignancy. It has lowest negative post-test 
probability of malignancy while accuracy is similar to the best of methods. The mean of the 
strain histogram furthermore shows similar performance when testing on new and unseen 
data. 
2.4.3 Effect of EBUS-SE on probability of malignancy assessment
Based on the analysis of the different EBUS-SE scoring methods, the strain elastography 
histogram mean scoring method is used to further investigate if EBUS-SE could be of 
potential added value in clinical workup. This is investigated by calculating the effect on 
the probability of malignancy when combined with PET-CT imaging information of both 
the abnormal and normal mediastinal lymph nodes in the overall dataset (see Figure 2.7 
& Supplemental Tables 2E.2-3). Based on available combined PET avidity and/or CT size 
≥10 mm, a group of normal (N=26) and suspicious (N=90) mediastinal lymph nodes were 
identified in our complete dataset. In these groups, probability of malignancy was 8% and 
46%, respectively. Explorative analyses shows addition of EBUS-SE histogram scoring in 
the subgroup of suspicious lymph nodes increases post-test probability of malignancy from 
46% to 73% (positive likelihood ratio 4.61, 95% CI 2.98-8.13). Oppositely, a negative EBUS-
SE histogram analysis in this group of suspicious nodes reduces the post-test probability of 
malignancy from 46% to 8% (negative likelihood ratio 0.143, 95% CI 0.04-2.81, Figure 2.7 & 
Supplemental Table 2E.3). In the subgroup of imaging normal lymph nodes, a mean EBUS 
SE histogram <78 increased the probability of malignancy from 8% to 45%. And if EBUS-
SE outcome indicated non-malignancy in the PET/CT negative lymph nodes, probability of 
malignancy dropped from 8% to 0%, negating two cases where PET-CT imaging was found 

























Effect of diagnostic tests on probability of malignancy in work-up
Prevalence PET-CT imaging EBUS-SE
Strain mean < 78
Strain mean > 78
  PET avid and/or CT ≥10mm
  PET non-avid and CT <10mm
Figure 2.7 – Graphical representation of added value of performing cumulative diagnostic tests in our 
complete dataset. The first point on the left at 0.375 corresponds to prevalence of malignancy in our 
complete dataset (116 lymph nodes). PET and/or CT imaging is able to increase probability of malignancy 
to 46% if found positive. Negative PET and CT imaging is able to decrease probability of malignancy 
from 37.5% to 7,8%. After having performed PET-CT imaging, EBUS-SE imaging is performed. In PET-
CT suspected nodes (N=90), probability of malignancy increases from 46% to 73% if EBUS-SE imaging 
is positive. If EBUS-SE imaging is negative in these suspected nodes, the probability of malignancy 
decreases to 7,9%. In normal lymph node findings based on PET-CT imaging (N=26), probability of 
malignancy decreases from 7,8% to 0% if negative on EBUS-SE imaging (>78 strain histogram mean). 
If these lymph nodes are however EBUS-SE imaging positive (<78 strain histogram mean), probability of 
malignancy increases from 7,9% to 45%.
2.5 Discussion
EBUS-SE could potentially be a sensitive technique to help predict lymph node malignancy 
in patients with lung cancer. We found that the semi-quantitative mean histogram scoring 
method with a cut-off value of 78 (range 0-255) showed the best, most objective and most 
reproducible performance in prediction of malignancy with 93% overall sensitivity, 75% 
specificity, 69% positive predictive value, 95% negative predictive value, and 82% accuracy. 
Exploratively combining lymph node relative stiffness by using the EBUS-SE histogram mean 
scoring outcome with CT and / or PET-CT information further increased confidence in post-
test probability of disease, having a positive test likelihood ratio of 4.16 (2.98-8.13 95% CI) 
and a negative test likelihood ratio of 0.14 (0.04-2.81 95% CI) in imaging suspicious lymph 
nodes. EBUS-SE scoring may thus enable a better prediction and separation of lymph nodes 
with high and low probability of disease but will not replace a tissue diagnosis. It can however 
be a helpful tool for guiding which node to aspirate in a distinct region, or ultimately, deciding 
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whether to proceed with, or omit, additional diagnostic procedures if ROSE or conclusive 
cytology results are unavailable (especially when FDG-PET information is lacking). Yet, care 
needs to be taken in interpreting these results. This explorative study is of limited size and 
further research to corroborate our findings using a standardized assessment procedure 
based on clinical findings and technological considerations is recommended.
2.5.1 Differences in EBUS-SE Scoring methods
In the qualitative scoring, both the scoring of a major color component (Color VAS method) 
and a combined scoring of pattern and color (modified Tsukuba score) perform similar in 
terms of overall accuracy. Our proposed use of the modified Tsukuba scoring system has not 
previously been introduced in EBUS applications. Even though we expected that taking into 
account both pattern and color above color alone would provide more information, it does 
not seem to be of clear additional value over the color VAS system in this dataset.
Three studies used a scoring system like the color VAS scoring system, with comparable 
results [55,59,63]. He et al. reported best accuracy if the visualized color was over 50% 
blue, then indicative of malignancy with an accuracy of 73.7%. Huang et al. (2017) and 
Izumo et al. (2014) introduced an additional cut-off; only predominantly blue lesions were 
indicative of malignancy, while predominantly non-blue lesions were indicative of benign 
lymph nodes. By leaving out an intermediary group (part-blue, part non-blue) they were 
able to report an overall accuracy in these categories of 91.4% and 96.7%, respectively. 
Leaving out uncertain cases (part blue, part non-blue) was not done in our study for accurate 
comparison of scoring methods (but see Figure 2.6). Possibly, such a method could increase 
diagnostic success.
In semi-quantitative scoring, the majority of previous pilot studies report using the strain ratio 
for scoring [58,60,64]. Our study however clearly shows that the mean value of the strain 
as obtained from the histogram has best performance. As reflected by the comparatively 
low performance of the strain ratio scoring method, we found that the strain ratio outcome 
relied heavily on the selected secondary reference tissue region in EBUS. Adequate 
selection of a uniform secondary reference tissue while taking into account the technical and 
clinical boundary conditions is difficult not only because of limited tissue uniformity but also 
heterogeneous sources of strain. Likely, this is one of the reasons why other pilot studies 
investigating EBUS-SE with strain ratios reported different cut-off values [69] and collected 
multiple measurements for combining them into one average reference value [58,60,64]. A 
potential limitation of our study is that we collected strain ratio measurements retrospectively 
rather than prospectively, which could have affected the strain ratio scoring outcome.
2.5.2 Combining EBUS-SE with other predictive variables
FDG-PET and/or CT imaging of lymph nodes in this study had sensitivities comparable to the 
reported literature [9], but a lower combined specificity of 33% (Table E2.3). This could in 
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part be explained by the systematic staging of all lymph nodes by EBUS-TBNA as applied 
in our clinical practice. Combining EBUS-SE with pre-test contrast CT and FDG-PET avidity 
however was able to improve the predictive accuracy of lymph node pathology in both PET-
CT negative and positive imaging cases. The relative stiffness as measured by EBUS-SE 
thus seems to show additional value to the metabolic and size information as given by FDG-
PET and CT. Yet again, care needs to be taken in interpreting the results of adding EBUS-SE 
information to PET and CT negative nodes, as only 26 lymph nodes of which 2 false negative 
lymph nodes were available for an exploratory analysis. While adding EBUS-SE correctly 
changed diagnosis to malignant in both cases and could be promising, additional studies 
are warranted. 
Besides PET-CT information, ultrasound B-mode characteristics as described by Fujiwara et 
al. (2010) [46] were also collected in this explorative study (Supplemental Table 2E.1). Since 
different studies have shown conflicting results in the value of these features, we did not 
integrate these into a combined predictive value nor integrate them with EBUS-SE findings 
[46–50]. Analysis of these features in our dataset showed presence of heterogeneous 
echogenicity and a central necrosis sign to be most predictive of malignancy, with positive 
likelihood ratios of 5.83 and 3.65. An AUC of 0.73 of the B-mode based size of lymph nodes 
revealed a correlation between size and malignancy. 
2.5.3 General remarks
The mean lymph node short axis diameter in this study was 9.9 mm (range 4-26 mm). This 
indicates it was not a population with bulky mediastinal disease but rather a group with low 
disease burden. Malignant lymph node involvement can be heterogeneous and microscopic. 
This is cause for concern in both TBNA and strain elastography of individual lymph nodes. 
TBNA provides only limited information about the complete node, as it samples limited 
amounts of tissue within the node. Strain elastography can provide information about the 
entire node, but is based only on the strain of tissue upon deformation. Whether elastography 
is able to differentiate between micro-metastatic disease accurately and if it may guide the 
site of aspiration within a lymph node to detect intranodal fields at risk of micro-metastatic 
disease is unclear. The current dataset does not allow this level of analysis. 
2.5.4 Observer scoring variability
A general point of concern for all EBUS-SE measurement methods is the inter- and intra-
observer variability in lymph node scoring and frame selection through different platforms. 
System settings and operator protocol can affect EBUS-SE measurement outcome (also 
Supplemental data). A standardized operating procedure is essential. In this current study, 
the prospective elastography measurements and scoring were done by one pulmonologist 
using a standardized operating protocol (EvdH). Inter-observer variability was thus minimal 
in order to adequately study differences in scoring method performance. Reproducibility of 
this technique based upon operator expertise, operator color acuity, anatomical site and 
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region needs to be further investigated. Widespread implementation of this technique can 
only be realized when system settings and operator methods are unified. Transferability of 
these findings to other diseases like for example sarcoidosis are unknown and also need to 
be studied. In doing so, we recommend to use the mean of the strain histogram for scoring 
as it showed to have best performance in this study, requires the least operator input and will 
have highest inter-observer agreement based upon technique background.
2.6 Conclusion
EBUS-SE is a sensitive technique which may help predict lymph node malignancy in patients 
with lung cancer. In this study we found that the semi-quantitative mean histogram scoring 
method with a cut-off value of 78 (range 0-255) showed the best and most reproducible 
performance in prediction of malignancy with 93% overall sensitivity, 75% specificity, 69% 
positive predictive value, 95% negative predictive value, and 82% accuracy. Combining 
EBUS-SE mean histogram scoring outcome with CT and/or PET-CT information increased 
confidence on post-test probability of disease, having a positive test likelihood ratio of 
4.16 (2.98-8.13 95% CI) and a negative test likelihood ratio of 0.14 (0.04-2.81 95% CI) 
in suspicious lymph nodes based on PET or CT imaging. We further present a standard 
operating procedure for EBUS-SE assessment and future research.
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Endobronchial ultrasound strain elastography is an ultrasound technique giving information 
on soft tissue by deriving elastic properties in real time. As Ying et al. and others state 
in their studies, the elastic modulus of lymph nodules were found to be correlating with 
tumour malignancy and could be measured by means of strain elastography [18,70,71]. 
Several pilot reports on use of these commercial techniques in EBUS have shown promising 
results [55,58–61,72–74]. To be able to reconstruct a strain image, backscattered signals 
of the tissue at a first acquisition (pre-compression) are compared to a second acquisition 
(post-compression). The time shift between the tissue reflections is then found by a cross-
correlation method. Since the speed of sound is considered to be constant, this time delay 
estimate can be transformed into a tissue displacement. When the displacement at every 
depth is known, a finite difference of these displacement estimates can be used to determine 
the relative deformation along the imaging line, also known as axial strain [22]. Due to 
technical limitations of ultrasound systems, real-time strain is hard to determine in the lateral 
scanning direction [23]. Strain elastography is thus described as being an axial deformation 
and strain measurement only, different in origin than that of other reported B-mode US 
features [46]. All major ultrasound manufacturers such as Hitachi, Philips, Siemens Toshiba 
and General Electric have now commercialized strain elastography [75–77]. Although 
these manufacturers differ in detailed approach, the basics are similar. In this supplement, 
additional considerations for using ultrasound elastography as clinical diagnostic tool in 
EBUS are given together with complementary (clinical) information to the article. 
2.9.2 Materials and methods
For acquisition of images and performing measurements in this explorative study (Figure 2.1, 
the Hitachi Preirus Hi Vision processor (Hitachi Corporation, Tokyo, Japan) with Hitachi Real 
Time Elastography (version EZU-TE5) and strain histogram software (version EZU-TESH1) 
installed were used in combination with Pentax medical - Ultrasound Video Bronchoscopes 
EB-1970UK (Pentax Medical, Tokyo, Japan). 
Technical limitations in EBUS-SE & potential sources of artefacts
The stress that is applied to create a deformation in EBUS strain elastography was derived 
to be originating from the patient’s own pulsating heart and vasculature, as manual palpation 
by means of the EBUS endoscope is impossible. The amount and direction of force of these 
deformation sources are unknown, as they are both patient and location dependent. Given 
the lymph nodal map [11], it is however derived that axial strain imaging is possible by 
using the pulsating vasculature found distal to the EBUS transducer, with the lymph node in 
between source and transducer. The scoring of strain elastography is stated to be relative, 
since the force applied to obtain strain is unknown. The software of the different commercial 
systems therefore normalize the strain in every image for both visualization and calculation. 
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This means the axial strain is semi-quantitative and will cover the entire visualized/calculated 
elasticity spectrum. By doing so, it relays how much strain is measured inside the region 
of interest when compared to surrounding tissue. When performing in-vivo imaging of 
mediastinal lymph nodes, several potential pitfalls and artefacts that are a consequence of 
the technical background of strain elastography imaging were found and are summarized 
below (also see [22,24,78,79]).
Anatomical structures - In EBUS strain elastography we ought to use the distal pulsating 
vasculature as source of stress only. One should assess if the lymph node itself is also invaded 
by vasculature, cysts, lymphatic structures or necrosis by using B-mode and Doppler. These 
structures add additional sources of strain or alternatively, are easily deformed and affect 
axial strain imaging accuracy [80]. If several structures in or out of plane are found, the 
possibility of using strain elastography should be reconsidered.
Amount of (axial) deformation - The amount of tissue deformation and movement influences 
the quality of the strain measurement. Some cases of highly enlarged pathological lymph 
nodes act as additional spring load and prevent sufficient deformation for quantification 
by the ultrasound system. This is recognizable by a generalized lack of strain rate graph 
amplitude (low strain). Alternatively, too much tissue displacement (>5%) [81,82] or non-
axial displacement disables the underlying algorithm to correlate deformation in subsequent 
images. Inaccurate findings can be recognized by a non-periodical and chaotic strain image 
and strain rate graph with high amplitude and/or a temporally incoherent visualized strain 
(for a strain rate graph example, also see the lower left of each panel in Figure 2.2). In this 
explorative study a variety of cases where pulsatile forces caused overall tissue movement 
were found. Patient or transducer movement also caused measurements to be aborted in 
several cases if applying suction or relocating the transducer did not improve imaging. 
Energy absorption - As a resultant of energy absorption and spherical dissipation, the 
deformation obtained through applied stress decreases further away from the deformation 
source. The majority of (non-linear) deformation is absorbed relatively near to the stress 
source. For measurement reproducibility, a ROI should therefore include mediastinal tissue 
together with the mediastinal lymph node, but exclude the direct vicinity of the strain source 
(i.e. pulsating vasculature). This holds for both visualizing strain as for scoring strain, as non-
linearity of scoring is potentially introduced otherwise. Last but not least, one should consider 
that the signal to noise ratio of the system becomes lower at increasing depth, giving rise to 
less accurate derivations [23,79,81]. 
Region of interest size - As stated earlier, measured strain values are normalized over 
the chosen visualized region of interest. Sufficient reference tissue should be included 
in visualization to give an accurate representation of relative strain. As Ciurea et al. and 
Havre et al. state, lesions were rated softer if the ROI for calculating strain was chosen too 
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small relative to the lesion [78,83]. To have an adequate sized reference region, Havre et 
al. suggests to make the ROI size such that the lesion will be 25-50% of total ROI size [78]. 
Based upon our experience, we suggest to use this rule of thumb conservatively, with 25% 
or less being a better estimate than 50%.
Software presets - Initial software set-up of the ultrasound processing system and variation 
in measurement technique determine reproducibility and accuracy of lesion scoring [78]. 
The visualized strain is a relative measure. In relaying the relative strain information back 
to the user, visualization can be arbitrary. However, by changing software settings and 
thus visualization, efforts to quantify strain are also affected. In using strain elastography in 
clinical practice, both the imaging protocol for performing EBUS strain elastography as the 
software settings should be standardized. This is applicable both in strain visualization as in 
performing measurements through all scoring methods. 
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2.9.3 Supplementary Figures and Tables
Table 2E.1 – Performance of US B-mode features [46] to predict the presence of lymph node malignancy. 
B-mode ultrasound features were prospectively scored on all lymph nodes (n=120). Receiver Operator 
Characteristic – Area under the curve of ultrasound based short axis size was 0.73. The 95% CI of the 
accuracy and LR+ and LR- are placed between brackets. These results are partially in conflict with 
other reported findings (i.e. [47–50]) and were therefore not used in subsequent (multi-feature) analysis. 
Abbreviations: SA - Short Axis, CHS – Central Hilar Structure, CNS – Central Necrosis sign, LR+ - Positive 
Likelihood Ratio, LR- - Negative Likelihood Ratio, Inf - Infinity.






SA Size ≥10 mm 60% 68% 53% 74% 65% (56%-73%) 1.88 (1.25-2.90) 0.59 (0.37-0.84)
Shape 93% 51% 53% 93% 67% (57%-75%) 1.89 (1.50-2.46) 0.13 (0.00–0.32)
Margin 13% 79% 27% 60% 54% (45%-63%) 0.63 (0.20–1.41) 1.10 (0.92-1.29)
Echogenicity 64% 75% 60% 78% 71% (62%-79%) 3.65 (2.19-7.14) 0.43 (0.26-0.62)
CHS 98% 13% 41% 100% 46% (37%-55%) 1.15 (1.03-1.25) 0.03 (0.00–0.46)
CNS 16% 97% 78% 66% 67% (57%-75%) 5.83 (1.56-Inf) 0.87 (0.73-0.96)
Table 2E.2 – PET, CT and EBUS-SE likelihood ratios and their 95% confidence intervals between 
brackets. Calculated with given predictive values sensitivity, specificity, NPV and PPV and Bayesian 
statistics. *Outside 95% CI as derived in training dataset. VAS – Visual Analogue Scale 
Positive Likelihood Ratio (95% CI) Negative Likelihood Ratio (95% CI)
Training dataset Validation dataset Training dataset Validation dataset
Color VAS-score 3.26 (2.02 – 5.66) 3.25 0.34 (0.17 – 0.54) 0.00*
Mod. Tsukuba score 4.14 (2.63 – 7.44) 2.60* 0.167 (0.05 – 0.33) 0.00* 
Strain histogram mean 3.81 (2.52 – 6.40) 3.25 0.10 (0.00 – 0.24) 0.00 
Strain ratio 3.10 (1.66 – 6.71) 1.86 0.60 (0.40 – 0.80) 0.84* 
Overall dataset
Color VAS-score 3.24 (2.17 – 5.31) 0.29 (0.14 – 0.47)
Mod. Tsukuba score 3.70 (2.52 – 5.99) 0.15 (0.04 – 0.29)
Strain histogram mean 3.68 (2.55 – 5.74) 0.09 (0.00 – 0.21)
Strain ratio 2.92 (1.60 – 5.82) 0.64 (0.45 – 0.82)
PET avid 1.79 (1.43 – 2.31) 0.142 (0.00 – 0.34)
CT-scan ≥10 mm 2.13 (1.63 – 2.88) 0.158 (0.04 – 0.34)
PET avid and/or 
CT-scan ≥10 mm




4.61 (2.98 – 8.13) 0.143 (0.04 – 2.81)
PET non-avid and 
CT-scan ≤10 mm,
then elastography































































































































































































































































































































































































































































































































































































































































































































































































































Predictive value of endobronchial ultrasound strain 
elastography in mediastinal lymph node staging: 
the E-predict multicenter study results
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Systematic assessment of lymph node status by endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) is indicated in (suspected) lung cancer. 
Sampling is herein guided by nodal size and FDG-PET characteristics. Ultrasound strain 
elastography (SE) might further improve risk stratification. By imaging tissue deformation 
over time, SE computes relative tissue strain. In several tissues, a lower strain (deformation) 
has been associated with a higher likelihood of malignancy. 
Objectives 
To assess if EBUS-SE can independently help predict malignancy, and when combined with 
size and FDG uptake information. 
Methods
This multicenter (n = 5 centers) prospective trial included patients with suspected or proven 
lung cancer using a standardized measurement protocol. Cytopathology combined with 
surgery or follow-up imaging (>6 months) were used as reference standard. 
Results
Between June 2016 and July 2018, 327 patients and 525 lymph nodes were included (mean 
size 12.3 mm, malignancy prevalence 0.48). EBUS-SE had an overall AUC of 0.77. A mean 
strain <115 (range 0–255) showed 90% sensitivity, 43% specificity, 60% positive predictive 
value, and 82% negative predictive value. Combining EBUS-SE (<115) with size (<8 mm) and 
FDG-PET information into a risk stratification algorithm increased the accuracy. Combining 
size and SE showed that the 48% a priori chance of malignancy changed to 11 and 70% in 
double negative or positive nodes, respectively. In the subset where FDG-PET was available 
(n = 370), triple negative and positive nodes went from a 42% a priori chance of malignancy 
to 9 and 73%, respectively. 
Conclusions
EBUS-SE can help predict lymph node malignancy and may be useful for risk stratification 
when combined with size and PET information.
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3.2 Introduction
Systematic endobronchial ultrasound (EBUS) combined with esophageal endosonographic 
evaluation (EUS/EUSb) is currently the recommended first line staging procedure in lung 
cancer [9]. During a systematic evaluation of the entire mediastinum - going from the 
contralateral hilum to the ipsilateral hilum - all lymph nodes should be carefully assessed 
[10]. Information from both CT and FDG-PET are generally used to define risk of malignancy 
in lymph nodes, subsequently guiding the sampling strategy. In routine clinical practice, 
every node which is FDG-PET avid or has a CT based short axis size ≥10 mm should be 
aspirated. And, if CT or PET-CT has shown abnormal mediastinal findings, at least three 
different mediastinal lymph node stations (4R, 4L, 7) should for example be sampled [10]. 
When no PET scan information is available or the lymph node shows low uptake, B-mode 
ultrasound characteristics and the short axis diameter as measured during EBUS/EUSb are 
often used to determine when to aspirate. However, there is no consensus on the lower limit 
in ultrasound size for aspiration. While the 10 mm short axis size as equal to CT is often used, 
cut-offs ranging from 5 to 10 mm are found across studies [13,47,84–87]. Studies assessing 
B-mode criteria such as node heterogeneity, shape and a central hilar structure have also 
been found to be contradictory in their results [17]. A recent meta-analysis found that 
ultrasound features might indeed correlate with malignancy, but should be further studied to 
determine their true predictive capability [88]. 
Endobronchial Ultrasound strain elastography (EBUS-SE) is one of relatively new ultrasound 
features. It has proven promising in risk stratification of likely malignant lymph nodes among 
different studies [89]. EBUS-SE derives tissue strain by monitoring how tissue deforms over 
time as a force is being applied. Its working principle can be best compared to classical 
palpation. In short, a region of tissue that is heavily deformed when compared to another 
region in the same image is derived to be high in strain (easily deformed). A region that is 
barely deformed when compared to another region by this same force is derived to be low 
in strain (low deformation). In EBUS-SE, this tissue deformation is measured primarily in the 
axial direction (depth direction). The periodical motion of the heart and greater vessels are 
hypothesized to exert the needed force on surrounding tissue. For calculating the relative 
strain, the received ultrasound signal needs to be monitored over time. By mapping how the 
signal varies over time (while a force is being exerted), one can compute the deformation. 
A relative strain can be derived from this deformation and is generally relayed to the user 
through a colour-coded overlay projected over the B-mode image. Several qualitative and 
semi-quantitative techniques to assess the calculated relative strain have been reported. 
We recently showed that the strain histogram method will give the best overall accuracy 
for predicting lymph node malignancy, as it is the most operator independent and thus 
objective technique [90]. More detailed information on EBUS-SE assessment technique and 
SE-technology can also be found in Chapter 2 [90,91].
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In this international, prospective multicenter study, we investigated the predictive value of 
EBUS-SE in patients with suspected or proven lung cancer in daily clinical care. Using a 
standardized measurement strategy, we assess if EBUS-SE can help predict malignancy 
in lymph nodes as an individual predictive value, and, if it can help enhance prediction by 
combining EBUS-SE information with FDG-PET information and EBUS lymph node short axis 
size. The interobserver variability is furthermore determined.
 
3.3 Materials and methods
3.3.1 Study subjects 
This prospective international multicenter study (n=5) was registered under Clinicaltrials.
gov number NCT02488928. The study was conducted in accordance with the declaration of 
Helsinki, and, ethics committee approval was obtained for each center. Patients of 18 years 
and older with an EBUS indication for a suspected or proven lung cancer were eligible. Prior 
chemo- or radiotherapy were exclusion criteria due to hypothesized tissue altering effects. 
All measurements were obtained using Pentax EB1970UK and EB19-J10U ultrasound 
bronchoscopes (Pentax Medical, Japan), and Hitachi Preirus Hi Vision US processors 
(Hitachi Corp, Japan) with unified software settings in each center. 
3.3.2 Study design
To assess if EBUS-SE can help predict lymph node malignancy, two main research questions 
were formulated. (1) Can EBUS strain elastography by itself help predict malignancy of 
mediastinal lymph nodes in a multicenter setting? Divided into two sub-questions: (a) is strain 
a predictive parameter, and (b) can it be used as a reproducible measurement technique in 
daily clinical care? And research question (2): can we improve the current risk stratification 
by further incorporating EBUS-SE information with lymph node size and FDG-PET avidity 
information? 
3.3.3 Materials and methods 
All participating centers received similar training on EBUS-SE technique and pitfalls preceding 
to study participation. Systematic EBUS-TBNA staging was performed following international 
and local guidelines [6,10,11]. EBUS-SE measurements of to-be-aspirated lymph nodes were 
acquired at the discretion of the endoscopist. A standardized measurement protocol using 
the strain histogram scoring technique was used to quantify measured lymph node strain 
as previously reported in more detail (see [90,91]). Compared to previously published data 
[90], the EBUS-SE software settings were updated. As such, the EBUS-SE mean strain cut-off 
was re-analyzed for optimal performance in the present study. Known prognostic variables 
such as FDG-PET avidity, CT size and ultrasound B-mode characteristics were collected by 
the endoscopist [46]. The local FDG-PET reports as available for the endoscopist were used 
for further analysis. No central reading on FDG-PET was performed. Strain measurement 
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reproducibility was furthermore scored subjectively by the operator as ‘heavily changing’, 
‘slightly changing’, or ‘reproducible’ based on the strain rate graph and corresponding 
colour-overlays [90].
3.3.4 Analysis 
Strain elastography measurements and corresponding case report forms were coded, 
digitalized and completed by the site investigator. The case report forms were correlated 
with strain measurements by author RV (blinded). Individual lymph node cytopathology and 
subsequent surgical results were used for correlation to EBUS-SE measurements. When 
no follow-up tissue sample was available, an imaging based clinical follow-up of at least 6 
months was used. Statistical analysis was performed using R-studio [68]. The performance 
of predictors was assessed using contingency tables and predictors derived from these, 
accompanied by their 95% confidence intervals (CI). Predictors include sensitivity, specificity, 
negative predictive value (NPV), positive predictive value (PPV), accuracy, receiver operator 
characteristic (ROC) curves, negative likelihood ratios (LR-), positive likelihood ratios (LR+) 
and pre- to post-test probabilities of malignancies calculated from these. The predictive 
value of continuous variables was assessed through the area under the curve (AUC) of the 
ROC. To analyse the added value of predictive variables to one another (chronologically), 
an ANOVA of different predictive models was made using a chi-squared test (PET alone, 
PET and EBUS short axis size combined, PET and EBUS short axis size further combined 
with EBUS-SE). Inter-observer variability of strain was assessed by comparing ROCs among 
different hospitals, adjusted for non-paired data [92]. During analysis, a relatively low false 
negative rate of imaging results was prioritized above overall accuracy for obtaining highest 
staging accuracy. 
3.4 Results
Between May 2016 – July 2018, measurements of 525 lymph nodes from 327 unique patients 
were included for study analysis (CONSORT diagram, Figure 3.1). Of the included 525 
lymph nodes on which EBUS-TBNA and elastography measurements were performed, 228 
were found malignant through initial cytopathology findings, 170 received further surgical 
verification and 127 underwent additional clinical and imaging follow-up to confirm benign 
disease. Overall prevalence of malignancy was 48%. Study demographics and lymph node 
information are shown in Tables 3.1 and 3.2, respectively. 
3.4.1 EBUS strain elastography performance
ROC analysis was performed to assess EBUS strain elastography predictive value. In Table 
3.1, ROC analysis of the mean strain as obtained from all five centers showed an AUC of 0.77 
(95% CI 0.73-0.81). The AUC of individual hospitals ranged between 0.67-0.85. Pairwise 
ROC comparison of individual hospitals showed that EBUS-SE performance did not vary 
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significantly across centers. Comparing the highest to lowest AUC and largest volume to 
smallest volume performances gave P-values of 0.072 and 0.41, respectively (Table 3.3).
In 456 out of 525 lymph nodes in this multicenter study an adequate track record on temporal 
reproducibility of EBUS-SE measurements was available. The endoscopists subjectively 
rated EBUS-SE lymph node measurements as ‘heavily changing’ in 41 measurements 
(8.9%); ‘slightly changing’ in 135 measurements (29.6%); and ‘reproducible’ in 280 (53.3%) 
measurements. To assess if strain elastography performance varied with reproducibility 
scoring, ROC comparison of the differently scored subsets was performed. No significant 
differences were found (p>0.4). To obtain a representative dataset, all measurements were 
included for analysis.
Figure 3.1 – CONSORT diagram of study inclusion.
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Distinctive cut-off values of the strain histogram mean were studied to identify clinically 
relevant scenarios. As a stand-alone predictive parameter of malignancy, a strain mean cut-
off value of <115 (range 0-255) was found most suitable, having high sensitivity (90%) and 
NPV (82%) with moderate specificity (43%) and PPV (60%, Table 3.4). Using this cut-off as 
the only criterium for predicting malignancy, the positive likelihood ratio (LR+) of 1.58 would 
change the 0.48 pre-test probability of malignancy (being equal to prevalence of disease) to 
a 0.60 post-test probability of malignancy. The found negative likelihood ratio (LR-) of 0.23 
would imply that the 0.48 pre-test probability of disease decreases to 0.18 if mean strain was 
measured to be more than 115 (Table 3.4).
3.4.2 Size and FDG-PET performance 
The variables size and FDG-PET avidity have long shown their value for lymph node 
malignancy prediction in routine clinical practice. The predictive value of these variables 
along with EBUS-SE as found in this study are summarized in Table 3.1 and Table 3.4. In 
the data subset where FDG-PET information was available (370 lymph nodes), PET avidity 
showed high sensitivity (88%) and NPV (83%) at moderate specificity (42%). Overall FDG-
PET accuracy was 61%, and, FDG-PET performance did not significantly differ across centers 
(p>0.05, Table 3.1). ROC Analysis of EBUS based lymph node short axis size showed an 
overall AUC of 0.78 (95% CI 0.74-0.82) and non-significant (p>0.05) performance differences 
across centers in pairwise ROC comparison (Table 3.1). Further analysis of different size-
based cut-offs showed how the diagnostic utility of EBUS based lymph node size varied with 
the chosen cut-off (Table 3.4). Using ≥10 mm short axis size as predictor for malignancy 
resulted in a LR- of 0.39. Sixty-five out of all 253 malignancies in this dataset would then 
be falsely classified as benign (25.7%). A size minimum of ≥8 mm as cut-off value would 
reduce false negatives to 31 in this dataset, being 12.3% of the total amount of malignancies 
(LR- 0.26). The increase in sensitivity (74 to 88%) gained by preferring the ≥8 mm criterium 
however comes at a cost of more false positives. Whereas a ≥10 mm cut-off had a LR+ of 2.2, 
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3.4.3 Clinical scenarios
Combining strain elastography with size - After assessing the different scenarios in which 
size and strain imaging could be combined in clinical practise, it was found that a lymph 
node size ≥8 mm in combination with a strain cut-off of <115 would best stratify risk of 
malignancy in this dataset. Analysis of this stratification showed that adding strain to EBUS-
measured lymph node short axis size could significantly help stratify risk of malignancy as 
compared to stratification based upon EBUS-measured short axis size alone (P<0.001). If 
using these cut-offs to assume that all lymph nodes of ≥8 mm and the subset of lymph nodes 
<8 mm that had strain <115 were considered malignant, an overall sensitivity of 95%, NPV 
86%, specificity 30% and PPV 56% was found (Table 3.4). The risk stratification methodology 
can however better be interpreted by a decision tree diagram. A more detailed visualization 
of how risk of malignancy changes with found variable outcome is shown in Figure 3.2. By 
this stratification methodology, double imaging positive lymph nodes (being ≥8 mm and low 
in strain) would have a 70% chance of being malignant in this dataset. Oppositely, double 
imaging negative lymph nodes (<8 mm and high in strain) would have an 11% chance of 
























Effect of EBUS lymph node size and strain elastography mean








Size ≥8 mm 
Size <8 mm 
Strain mean ≥115
Strain mean <115
on probability of malignancy
Figure 3.2 – Clinical scenario combining EBUS size and EBUS-SE for predicting probability of 
mediastinal lymph node malignancy. This analysis was performed on all lymph nodes where both data 
was available (n=525 lymph nodes). The initial prevalence of disease is used as starting point (pre-test 
probability of malignancy). From there, the post-test probability of malignancy is updated based upon 
the EBUS short axis size information. If EBUS size is ≥8 mm, probability of malignancy increases. If EBUS 
size is <8 mm, probability of malignancy decreases. After having obtained the intermediate EBUS size-
based probability of malignancy, the EBUS-SE measurement outcome is further included to assess the 
contribution of EBUS-SE to the probability of malignancy. A strain <115 is associated with an increase 
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Combining strain elastography with size and FDG-PET - To enable a risk stratification 
analysis using FDG-PET avidity, EBUS short axis size and EBUS-SE information, the 
subset of data where FDG-PET was available was analysed (n=370). While prevalence of 
lymph node metastases in this subset of data was slightly lower (0.42), the accuracies of 
the predictive values EBUS size and EBUS-SE did not significantly differ from that of the 
overall dataset (Table 3.4). Assessing several scenarios in this subset showed that both 
an EBUS size and EBUS-SE cut-off similar to the previous model could be used, being a 
size of 8 mm and a strain cut-off of 115. Combining FDG-PET avidity and EBUS size with 
EBUS-SE significantly enhanced lymph node malignancy prediction when compared to a 
risk stratification based upon FDG-PET and EBUS based short axis size alone (P<0.001). The 
resulting risk stratification model is shown in Figure 3.3. In all sub-scenarios where FDG-PET 
and size information have been combined, EBUS-SE increases or decreases likelihood of 
malignancy in cases of low and high strain respectively. If all three predictors were negative, 
a 9% chance of malignancy remained. If all three predictors were positive, lymph nodes had 
























Effect of FDG-PET, EBUS lymph node size and strain elastography mean on probability of malignancy

















Size ≥8 mm 
Size <8 mm 
Strain mean ≥115
Strain mean <115
  FDG-PET non-avid
Figure 3.3 – Clinical scenario combining PET, EBUS size and EBUS-SE for predicting probability of 
mediastinal lymph node malignancy. This analysis was performed on all lymph nodes where all three 
data were available (n=370 lymph nodes). The initial prevalence of disease is used as starting point (pre-
test probability of malignancy). From there, the post-test probability of malignancy is updated based 
upon FDG-PET avidity information. FDG-avid lymph nodes had an increased probability of malignancy, 
whereas non-avid lymph nodes decreased the probability of lymph nodes being malignant. From there, 
the post-test probability of malignancy is updated based on the EBUS-measured lymph node short axis 
size information. If size is ≥8 mm, probability of malignancy increases. If EBUS size is <8 mm, probability 
of malignancy decreases. Following the obtained intermediate PET and EBUS size based probability 
of malignancy, the EBUS-SE measurement is included to assess its contribution on the probability of 
malignancy. A strain <115 is associated with an increase in chance of malignancy. A strain ≥115 is 
associated with a decrease in chance of malignancy.
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3.5 Discussion
To our knowledge, this is the first study utilizing a standardized assessment protocol to 
show the added predictive value of EBUS-SE in relevant daily clinical scenarios in multiple 
centers. We confirm earlier single center studies that showed an association between 
relative strain and presence of lymph node malignancy [88,89]. In this study, we show 
that strain elastography is an independent predictive variable. Furthermore, we show that 
EBUS-SE can be used in conjunction with EBUS lymph node short axis size and FDG-PET 
information to help better select which nodes must be further evaluated. Using two clinical 
scenarios, we show how EBUS-SE can help further risk stratify chance of malignancy. The 
addition of EBUS-SE in clinical practice could increase EBUS-TBNA staging accuracy. It 
might help intra-procedural decision making in case of multiple nodes within a region or 
unrepresentative ROSE (i.e. insufficient percentage of lymphoid cells to confirm lymph node 
aspirate), and, it might help decision making on further work-up after EBUS-TBNA in case of 
unrepresentative cytology findings.
Strain elastography is a relative measure and can therefore vary with measurement technique 
and time. Standardization and training are important for EBUS-SE implementation [90]. In 
this study, the performance variability of EBUS-SE was found insignificant between centers 
and operators. Yet, we signify the need of additional technical research to further improve 
reproducibility and standardization across systems and manufacturers. Moreover, when one 
starts using EBUS-SE, efforts should be made to assess how well EBUS-SE risk stratification 
performs by their hands. It is unknown beyond the here studied population and observers 
how performance might be influenced by differences in patient cohorts and measurement 
technique settings.
Strain is a continuous variable with range 0-255, similar to EBUS size. We present scenarios 
using a distinct cut-off. Continuous variables have gradual onset rather than distinctive 
values and risk of malignancy is thus not fully reflected by one value. Again, the discussed 
scenarios were chosen because a low false negative rate was prioritized above overall 
accuracy for obtaining highest staging accuracy.
The differences in EBUS-SE performance of Nijmegen in this study and previously published 
results are not fully understood (AUC 0.75 vs. 0.846) [90]. Possibly, a more rigorous selection 
for measurement inclusion was previously applied since the protocol was kept similar. 
Although unlikely, the updated software setting could also have had a small effect. With the 
updated software settings and low false negative prioritization, we now find an optimal cut-off 
value of 115 (previously; 78). 
The present guidelines do not specifically state distinct cut-off values for aspiration of lymph 
nodes during an EBUS-staging procedure. In general, as used per CT imaging, ≥10 mm is 
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often chosen as cut-off value for increased chance of malignancy. We confirm that this size 
cut-off indeed showed good overall accuracy (70%) in predicting lymph node malignancy 
in our dataset. However, it should be considered that good overall accuracy does not 
necessarily correlate to high sensitivity. Earlier studies have used cut-off values varying from 
5 to 10 mm with success [13,47,84–87]. Based on our results we propose to at least routinely 
include nodes of ≥8 mm for aspiration when no additional predictive variables are used. 
Using this criterium in our dataset would however still result in 12.3% of malignant lymph 
nodes being missed. This is already a major step forward when compared to a 10 mm 
cut-off, which would equal to as much as 25.6% of malignant lymph nodes being missed. 
Ideally, lymph nodes smaller than 8 mm should also be considered for aspiration, but the 
more recent large multicenter trials have used this 8 mm cut-off value successfully [13,93]. 
We would recommend further research on this subject to enable adjustment of the guidelines 
accordingly. 
For assessing mediastinal lymph node involvement, FDG-PET imaging is recommended [6,9]. 
Its results cannot be omitted once available. The endoscopist is likely to aspirate avid nodes 
regardless of size or EBUS-SE. In this study, PET-imaging was available across centers as 
per their routine clinical practice. No central reading was performed, possibly affecting FDG-
PET accuracy variability. Binomial proportion testing however showed insignificant FDG-PET 
accuracy differences across centers. 
Lymph nodes were included for aspiration based on criteria other than strain elastography. 
In that respect, none of the included lymph node aspirations were carried out without an 
inclusion bias. Future work should assess SE using systematic inclusion rather than based 
to the operator’s own insights. Furthermore, additional studies should assess if a multi-
frame strain analysis that is cross-compatible across systems and manufacturers can 
be introduced to further increase temporal reproducibility, widespread availability, and, 
diagnostic performance. 
3.6 Conclusion
EBUS strain elastography helps predict malignant lymph node involvement in patients with 
lung cancer. The addition of ultrasound strain elastography to EBUS short axis size and FDG-
PET avidity further improves risk stratification for malignancy. 
3.7. Statement of Ethics
The research was conducted ethically in accordance with the latest World Medical 
Association Declaration of Helsinki. The study is registered and can be found on ClinicalTrials.
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gov (identifier: NCT02488928). The study protocol was approved by the medical ethical 
committees in both the Netherlands and Italy, where subject inclusion took place after having 
obtained informed consent. 
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Endoscopic ultrasound routinely guides lymph node evaluation for the staging of a known or 
suspected lung cancer. Characteristics seen on B-mode imaging might help the observer 
decide on the lymph nodes of risk. The influence of nodal size on the predictivity of these 
characteristics and the agreement with which operators can combine these for malignancy 
risk prediction is to be determined. 
Objectives
We evaluated (1) if prospectively scored individual B-mode ultrasound features predict 
malignancy when further divided by size and (2) assess if observers were able to reproducibly 
agree on still lymph node image malignancy risk. 
Methods
Lymph nodes as visualized by EBUS were prospectively scored for B-mode characteristics. 
Still B-mode images were furthermore collected. After collection, a repeated scoring of a 
subset of lymph nodes was retrospectively performed (n=11 observers).
Results
Analysis of 490 lymph nodes revealed the short axis size is an objective measure for stratifying 
risk of malignancy (ROC Area Under Curve 0.78). With ≥8 mm size, 210/237 malignant lymph 
nodes were correctly identified (89% sensitivity, 46% specificity, 61% positive predictive 
value, 81% negative predictive value). Secondary addition of B-mode features in <8 
mm nodes had limited value. Retrospective analysis of intra- and inter-observer scoring 
furthermore revealed significant disagreement.
Conclusions
Lymph nodes of ≥8 mm size and preferably even smaller should be aspirated regardless of 
other B-mode features. Observer disagreement in scoring both small and large lymph nodes 
suggests it is infeasible to include subjective features for stratification. Future research 
should focus on (integrating) other (semi-) quantitative values for improving prediction.
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4.2 Introduction 
Once a suspected or proven lung cancer with abnormal mediastinal findings has been 
found through CT- and/or PET-CT imaging, guidelines recommend systematic lymph nodal 
assessment and aspiration through EBUS-TBNA (Endobronchial Ultrasound - Transbronchial 
Needle Aspiration) and preferably combined with EUS-FNA (Esophageal Ultrasound - Fine 
Needle Aspiration) [10]. Whilst a minimum of 3-4 lymph node aspirations is required by 
endoscopic examination if CT and/or PET-CT has shown abnormal findings (>10 mm short axis 
size on CT and/or FDG-PET avidity), also less suspected findings on endoscopic imaging (>5 
mm short axis findings on ultrasound) might subsequently incur ultrasound guided aspiration 
[6,10,86,94]. In cases where the decision making is not clear-cut, ultrasound imaging is often 
used to help decide on which lymph nodes to aspirate. Several studies have assessed which 
routinely available endoscopic ultrasound B-mode features help differentiate malignant and 
benign lymph nodes. The five identified and studied B-mode features include size, nodal 
heterogeneity, margin distinctiveness, presence of a central necrosis sign and a central hilar 
structure [46]. As multiple studies have found, individual features or a combination thereof 
might have predictive value [46–49,88,95–98]. However, the results in these predominantly 
single center studies differ. Consequently, no formal recommendation on the widespread 
use of these features has been given [17]. 
Possible reasons for the found differences in prospective value of B-mode features might be 
differences in lymph node disease burden under study and/or a lack of consistent information 
in the features for enabling accurate prediction of malignancy. In clinical practice, one of first 
determinants on the need of sampling therefore might remain to be the CT and US based 
lymph node short axis size. The influence of the lymph node size on scoring performance 
of the other identified B-mode features is however not well established. Some single center 
studies report aspirating all lymph nodes of >5 mm short axis size (i.e. [46,86]) whereas 
several multi-centric studies report a ≥8 mm node as a lower margin for enabling aspiration 
regardless of the presence of any other features (i.e. [13,93]). It is however especially 
sub-centimeter lymph nodes which are subjected to B-mode feature evaluation, with the 
endoscopist deciding intra-procedurally to proceed with sampling or not. The predictive 
value in doing so is however complicated not only by differences in reported performance 
across studies, a disagreement in interpretation of B-mode imaging and features could also 
be a potential pitfall [95,98]. As we have moved towards systematic sampling in endoscopic 
staging in order to prevent the need of more invasive cervical mediastinoscopy staging, one 
can question if subjective scoring of ≤8 mm lymph nodes remains desirable, or, if all lymph 
node regions should be aspirated regardless.
The aim of the present study is to assess the performance characteristics of the reported 
ultrasound features evaluated during endosonography in a multi-center international study 
when further specified by lymph node size. In this study, we therein specifically assess if 
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the often used and clinically feasible 8 mm size cut-off could be further helped by B-mode 
features in deciding upon aspiration. To assess the reproducibility (inter- and intra-observer 
variability) of compounded endoscopic B-mode feature scoring for predicting lymph nodal 
malignancy, we furthermore perform a multi-observer retrospective scoring of a subset of 
lymph node images.
4.3 Materials and Methods 
4.3.1 Study subjects 
This study was performed using prospectively collected and scored ultrasound B-mode 
images as gathered during the E-predict multi-center international trial, a study as described 
in Chapter 3 evaluating the value of ultrasound strain elastography for endosonographic 
prediction of lymph node malignancy (clinicaltrials.gov identifier: NCT02488928) [99]. All 
images were acquired and prospectively scored during endoscopic ultrasound guided 
fine needle aspiration procedures (EBUS/EUS) for a known or suspected lung cancer. 
For retrospective assessment of the reproducibility (inter- and intra-observer variability) 
of compounded endoscopic B-mode feature scoring in a subset of these prospectively 
collected images, several observers from different centers with varying experience were 
recruited on a voluntary basis. 
4.3.2 Study design 
This study is two-fold: (1) We prospectively evaluate performance characteristics of the 
endoscopist-reported ultrasound B-mode features in a multi-center multi-observer fashion. 
The performance characteristics are evaluated on all lymph nodes, and, in the subsets of 
<8 mm and ≥8 mm lymph nodes. (2) We investigate the observer variability in scoring the 
combination of B-mode features for predicting lymph node malignancy. By retrospective 
scoring of a subset of still lymph node images through multiple observers, intra- and inter-
observer variability is assessed. Knowing pathology outcome, accuracy of endoscopist 
malignancy scoring (as based on compounded B-mode features) is exploratively assessed.
4.3.3 Materials and methods 
(1) Prospective collection of B-mode feature scoring was performed as part of the E-predict 
study protocol, which included 525 lymph nodes (see Chapter 3 [99]). The investigators 
of the five recruiting centers prospectively scored features after careful examination on 
dynamic imaging: echogenicity (heterogeneous versus homogeneous), shape (round 
versus oval), margins (distinct versus indistinct), coagulation necrosis sign (present versus 
absent), central hilar structure (present versus absent) [46,99]. Lymph node short axis size 
was determined by intra-procedural caliper measurements. During analysis, combined 
feature scores as described by Hylton et al. were furthermore retrospectively computed for 
obtaining the recently introduced Canada Lymph Node Score [95]. Individual lymph node 
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cytopathology, subsequent surgical results and/or 6-month clinical follow-up were used as 
reference standard.
(2) For the retrospective assessment of variability in compounded endoscopic B-mode 
feature scoring for predicting lymph nodal malignancy, repeated scoring of a subset of the 
prospectively collected lymph nodes was performed. The subset included 200 lymph node 
images randomly selected from all prospectively included lymph nodes. The prevalence of 
disease was unknown to the observers. Only one single B-mode still image was presented and 
participants were asked to classify it into ‘malignant’ or ‘benign’. Scoring was performed with 
in-house developed Mevislab software (MeVis Medical Solutions AG version 2.8.2, Bremen, 
Germany). A size measurement tool was available. Metadata (i.e. node location, patient and 
image characteristics) were removed. The observers did not receive any feedback on their 
lymph node rating. Intra-observer scorings were performed with at least one day in between 
scorings and a new random image order.
4.3.4 Analysis 
Analysis was performed with R and Rstudio [68]. To assess the influence of size on B-mode 
feature scoring, analysis was performed on the overall dataset and the subsets in which 
lymph node sizes were <8 mm and ≥8 mm. To assess the performance of B-mode features 
descriptive characteristics sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV) and accuracy along with counts are reported. For the continuous 
variable short axis size, the Receiver Operator Characteristic - Area Under the Curve (ROC-
AUC) is furthermore presented.
For retrospective analysis on observer variability, a division into differently sized lymph 
nodes was also made (8 mm cut-off). Knowing there’s considerable variation in individual 
observer learning curves in endobronchial ultrasound [100–102], we chose to further classify 
observer expertise into novice [<50 endoscopic US staging procedures], intermediate 
[50-400 procedures] and expert [>400 procedures]. Raw agreement [%] and Gwet’s 
Agreement Coefficient (AC1) – correcting for by chance agreement - were calculated to 
assess the agreement of measurements [103,104]. An AC1 value of 1 would indicate perfect 
agreement, 0 would indicate at chance agreement, <0 would indicate an agreement worse 
than as expected by chance. With no universal cut-off for determining good agreement but 
knowing its potential high impact, an AC1 minimum of 0.70 was considered desirable for 
inter-observer research and an AC1 minimum of 0.85 for intra-observer agreement.
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4.4 Results
The E-predict multi center trial enrolled 525 lymph nodes from 327 study subjects between 
May 2016 and July 2018. For patient and lymph node characteristics, see [99]. For 490 
lymph nodes (with 347 and 143 lymph nodes ≥8 mm and <8 mm, respectively) a full B-mode 
feature measurement was available for analysis. Overall prevalence of malignancy was 48%. 
Prevalence of malignancy in the ≥8 mm and <8 mm subsets were 61% and 19%, respectively. 
See Tables 4.1 and 4.2 for a summary on multi-center B-mode feature scoring performance. 
Table 4.1 – Performance of prospectively scored ultrasound features for predicting lymph node 
malignancy on the overall dataset of 490 lymph nodes (n = 490, disease prevalence 0.48). Sens. – 
Sensitivity, Spec.- Specificity, PPV – positive predictive value, NPV – negative predictive value, Acc. 
– accuracy, CI – confidence interval, TN – True Negative, TP – True positive, FN – False negative, FP – 
False positive. CHS – Central Hilar Structure, CNS – Central Necrosis sign.
Sens. Spec. PPV NPV Acc. (95% CI) TN TP FN FP
Size ≥10 mm 0.75 0.64 0.66 0.73 0.70 (0.65-0.74) 163 178 59 90
Size ≥8 mm 0.89 0.46 0.61 0.81 0.67 (0.62-0.71) 116 210 27 137
Echogenicity 0.62 0.81 0.75 0.69 0.72 (0.67-0.76) 204 147 90 49
Shape 0.68 0.60 0.61 0.67 0.64 (0.59-0.68) 151 162 75 102
Margin 0.83 0.35 0.54 0.69 0.58 (0.54-0.63) 88 197 40 165
CHS 0.91 0.29 0.54 0.77 0.59 (0.54-0.63) 73 215 22 180
CNS 0.15 0.98 0.85 0.55 0.58 (0.53-0.62) 247 35 202 6
US Canada score >3 0.64 0.82 0.77 0.71 0.73 (0.69-0.77) 208 152 85 45
US Canada score >4 0.12 0.99 0.94 0.55 0.57 (0.62-0.52) 251 29 208 2
Mean strain <115 0.90 0.44 0.60 0.82 0.66 (0.62-0.70) 111 213 24 142
4.4.1 B-mode size
Currently, the best made objective traditional B-mode feature is short axis size. In line with 
routine clinical use, it shows of value in a first identification and estimation of lymph nodes at 
risk of malignancy. As depicted in Figure 4.1, ROC-AUC of short axis size was 0.778 (95% 
confidence interval 0.737-0.819). The clinically often used 8 mm cut-off identified 210 out of 
237 malignant lymph nodes and had 137 false positives (sensitivity 89%, specificity 46%, 
PPV 61%, NPV 81%). A slightly larger 10 mm cut-off had higher overall accuracy but also 
identified only 178 out of 237 malignant lymph nodes. As a first measure for identification and 
subsequent deciding on aspiration, an 8 mm criterion is an objective feature with relatively 
high sensitivity and NPV (Tables 4.1-4.2, Figure 4.1). A smaller than 8 mm size cut-off for 
including every identified lymph node would increase the sensitivity even further, although at 
the cost of specificity (Figure 4.1). 
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Table 4.2 – Performance of prospectively scored ultrasound features for predicting lymph node 
malignancy in the subsets of data with lymph node short axis size <8 and ≥8 mm. PPV – positive 
predictive value, NPV – negative predictive value, Acc. – accuracy, CI – confidence interval, TN – True 
Negative, TP – True positive, FN – False negative, FP – False positive. CHS – Central Hilar Structure, 
CNS – Central Necrosis sign.
Sens. Spec. PPV NPV Acc. (95% CI) TN TP FN FP
Subset <8 mm (n=143, disease prevalence 0.19)
Echogenicity 0.37 0.84 0.34 0.85 0.75 (0.67-0.82) 97 10 17 19
Shape 0.44 0.78 0.32 0.86 0.71 (0.63-0.79) 90 12 15 26
Margin 0.67 0.34 0.19 0.82 0.41 (0.32-0.49) 40 18 9 76
CHS 0.81 0.28 0.21 0.86 0.38 (0.30-0.46) 32 22 5 84
CNS 0.07 1.00 1.00 0.82 0.83 (0.75-0.88) 116 2 25 0
US Canada score >3 0.07 1.00 1.00 0.82 0.83 (0.75-0.88) 116 2 25 0
Mean strain <115 0.78 0.47 0.26 0.90 0.53 (0.45-0.62) 55 21 6 61
Subset ≥8 mm (n=347, disease prevalence 0.61)
Echogenicity 0.65 0.78 0.82 0.59 0.70 (0.65-0.75) 107 137 73 30
Shape 0.71 0.45 0.66 0.50 0.61 (0.55-0.66) 61 150 60 76
Margin 0.85 0.35 0.67 0.61 0.65 (0.60-0.70) 48 179 31 89
CHS 0.92 0.30 0.67 0.71 0.67 (0.62-0.72) 41 193 17 96
CNS 0.16 0.96 0.85 0.43 0.47 (0.42-0.53) 131 33 177 6
US Canada score >3 0.71 0.67 0.77 0.61 0.70 (0.65-0.75) 92 150 60 45
US Canada score >4 0.14 0.99 0.94 0.43 0.47 (0.53-0.61) 135 29 181 2
Mean strain <115 0.91 0.41 0.70 0.76 0.71 (0.66-0.76) 56 192 18 81
4.4.2 Descriptive B-mode features
In our multicenter scoring, several B-mode features initially show of predictive value in the 
overall dataset (Table 4.1). When however looking into individual center outcomes, large 
differences in predictive value of several B-mode features were seen between centers (Table 
to be published in the online supplement of the accepted manuscript due to size limitations). 
Maximal sensitivity differences between centers were >20% for features echogenicity, 
shape and margin (overall sensitivity being 62%, 68% and 83%, respectively). A maximal 
specificity difference of 24.7% and 66.2% was furthermore seen in the features shape and 
margin, respectively (overall specificities 60% and 35%, Table to be published in the online 
supplement of the accepted manuscript). The features central hilar structure and a central 
necrosis sign had more similarity in outcome across centers. The central necrosis sign 
feature is not often found present in the different centers, but if so, a high risk of malignancy 
is warranted (specificities in all but one center: 91.7-100%, overall: 98%). The central hilar 
structure showed most conformity over all centers of classically used B-mode features other 
than size. With overall sensitivity 91%, specificity 29%, PPV 54% and NPV 77%, only 22 
out of 237 malignant lymph nodes would have gone unnoticed in this dataset. Oppositely, 
with specificity 29% and PPV 54%, it has a high number of false positives (180/253). The 
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retrospectively calculated Canada lymph node score, recombining multiple B-mode 
features, showed relatively high accuracy (73%). It’s clinical value in deciding on aspiration 































Receiver Operator Characteristic - Ultrasound Short Axis Size 
Figure 4.1 – Receiver Operator Characteristic (ROC) of ultrasound measured lymph node short axis 
size. 95% confidence intervals of sensitivity and specificity at distinct short axis sizes in grey. AUC – 
Area Under the Curve (95% confidence interval between brackets).
4.4.3 Clinical decision-making work-up
Considering the scenario where all lymph nodes ≥8 mm should be aspirated regardless of 
other imaging features - as it is the firstly available and most objective feature enabling a risk 
of prediction - further analysis of B-mode features for deciding on aspiration as specified by 
size was deemed necessary (Table 4.2). 
In the subset of lymph nodes <8 mm, prevalence of malignancy was 19% (n=143). With the 
exception of ‘margin’ and ‘central hilar structure’, all sensitivities are below 50%, indicating 
more than half of malignancies go unnoticed. The central hilar structure had most chance 
of identifying lymph node malignancy in <8 mm nodes with sensitivity 81% and NPV 86% 
(identifying 22 out of 27 lymph nodes). It however also resulted in a high number of false 
positives (84 out of 116 benign lymph nodes, Table 4.1). The ultrasound Canada score again 
had high overall accuracy, but considering disease prevalence did not show useful in further 
work-up on malignancy (sensitivity 7%).
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In the subset of lymph nodes ≥8 mm the prevalence of malignancy was 61% (n=347). 
With this high overall risk of malignancy in this subset, the need of aspiration regardless 
of features seems warranted. Yet, if a further stratification need be made, the central hilar 
structure again showed most useful with high sensitivity (92%) and moderate NPV (72%). 
Overall accuracy of lymph nodal risk estimation was however highest by echogenicity (72%) 
and a Canada score >3 (69%). Yet both echogenicity and the Canada score do not seem 
accurate enough for reliable clinical decision making, as they are neither sensitive nor 
specific enough in excluding or including malignant and benign findings with values <78% 
(Table 4.2 & Table to be published in the online supplement of the accepted manuscript).
Table 4.3 – Observer variability in retrospective scoring of a random subset of lymph nodes. Observer 
variability when only looking at malignant / benign lymph nodes and sizes <8 and ≥8 mm are presented. 
The raw agreement is first presented (%), followed by the Gwet’s AC1 coefficient.
 All lymph nodes Malignant lymph nodes Benign lymph nodes
 All <8 mm ≥8 mm All <8 mm ≥8 mm All <8 mm ≥8 mm
Lymph nodes 200 69 131 99 15 84 101 54 47
Inter-observer variability
Expert (n=5) 74/0.48 71/0.54 76/0.59 79/0.66 77/0.59 80/0.70 69/0.40 69/0.53 68/0.39
Interm. (n=3) 71/0.42 73/0.57 69/0.47 76/0.58 78/0.57 75/0.61 66/0.35 72/0.58 59/0.21
Novice (n=3) 58/0.17 63/0.28 56/0.12 58/0.17 64/0.32 57/0.15 58/0.17 63/0.28 52/0.08
Intra-observer variability
Expert 1 86/0.76 93/0.92 82/0.65 82/0.64 80/0.76 82/0.65 90/0.87 96/0.96 83/0.72
Expert 2 86/0.72 84/0.78 87/0.79 92/0.87 93/0.88 92/0.88 80/0.65 81/0.77 79/0.58
Interm. 1 80/0.60 78/0.69 80/0.69 84/0.72 87/0.76 83/0.74 75/0.52 76/0.68 74/0.57
4.4.4 Compounded B-mode scoring - observer variability
For retrospective observer scoring, five experts, three intermediate observers and three 
novices were included. Two experts and one intermediate observer performed scoring twice 
to enable intra-observer variability assessment (Table 4.3). All observers scored the dataset 
of 200 lymph nodes within 20 minutes.
Inter-observer variability – In the overall dataset, the experts (n=5) had highest agreement, 
with Gwet’s AC1 0.48 (raw agreement 74%, Table 4.3). Intermediate (n=3) AC1 was 0.42 
(raw agreement 71%). The novices (n=3) showed an AC1 of only 0.17 (raw agreement 58%). 
Division of the overall dataset into subsets with <8 and ≥8 mm size did not change raw 
agreement more than 5% as compared to the overall dataset. Analysis of observer variability 
against lymph node pathology shows experts and intermediates have more disagreement 
in scoring benign lymph nodes than malignant nodes (Table 4.3). Intermediate and expert 
observers had an AC1 0.58-0.66 (76-79% raw agreement) in malignant lymph nodes and an 
AC1 0.35-0.40 (66-69% raw agreement) in benign lymph nodes. These findings remained 
after differentiating by size.
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Intra-observer variability – The experts showed moderate intra-observer agreement in the 
overall dataset, with an AC1 0.72-0.76 (raw agreements 86%) while the intermediate had an 
AC1 of 0.60 (raw agreement 80%). The Gwet’s AC1 in intra-observer scoring of <8 mm lymph 
nodes varied from 0.69-0.92 (raw agreement 78-93%), whilst the >8 mm lymph nodes had 
AC1 0.65-0.79 (80-87% raw agreement). 
Observer accuracy – The observer variability scoring on still images was used to explore 
B-mode compounding accuracy. Accuracy of predicting lymph node malignancy based on 
still B-mode images varied from 0.47-0.58 in novice to 0.60-0.72 and 0.63-0.71 in intermediate 
and expert, respectively. A division of the dataset by an 8 mm size cut-off did not show 
unequivocal changes in overall accuracy (Table 4.4). Further evaluation of compound 
scoring shows low overall sensitivity and PPV in <8 mm lymph nodes (both <0.42), indicating 
difficulty in identifying malignant nodes in this cohort. Oppositely, a low specificity and NPV 
in ≥8 mm lymph nodes in the majority of observers indicates that benign nodes are often not 
identified in the cohort of enlarged lymph nodes.















































































































































































































































































































































































































































































































































































































































































































This study evaluates whether individual B-mode features and a compounding thereof can 
be used to accurately and reproducibly predict lymph node malignancy in a dataset of 490 
aspirated lymph nodes for which follow-up was available. While we find that the classically 
first available ultrasound short axis size is the most objective feature with reasonable 
predictive value (AUC-ROC 0.78), we also show that not one additional nor a combination of 
B-mode features is a do-it-all solution for predicting lymph node malignancy. Based on our 
findings and incorporating the purpose of endoscopic ultrasound guided needle aspiration 
as a systematic staging procedure in suspected lung cancer, we conclude that preferably all 
assessed lymph node regions should be aspirated regardless of size or features. At least all 
lymph nodes ≥8 mm should be subject to sampling regardless of other features due to a high 
prevalence of malignancy in this subgroup of nodes, but preferably smaller. In <8 mm lymph 
nodes, a central hilar structure (sensitivity 81%, NPV 86%) could also be used to stratify 
risk of malignancy, but the low specificity (28%) and considerable observer interpretation 
differences in feature scoring suggest it is of suboptimal outcome. 
Our retrospective analysis of observer variability using still images as representation of 
compounded B-mode features shows that malignancy risk estimation cannot reliably be 
performed on still B-mode images. We find a relevant inter-and intra- observer agreement 
difference, and while exploratory, find compounded feature scoring had an accuracy of less 
than 72%. We therefore recommend not to decide on risk of malignancy or further work-up 
by compounding of only B-mode features. 
Varying results have been reported on endoscopic B-mode lymph node imaging scoring 
agreement across different observers and within observers. Schmid-Bindert et al. 
retrospectively studied B-mode feature scoring through blinded procedural videos and 
reported inter-observer agreements of 88.6% and higher (n=2). Hylton et al. also had a 
database of videos, and in multiple observers (n=12) reports a raw agreement different for 
the individual features ranging from 62.6% for echogenicity to 81.7% for the central necrosis 
sign (Gwet’s AC1 0.25-0.77) [95,98]. Our retrospective study determined the reproducibility 
of endoscopists B-mode feature compounding for predicting malignancy rather than 
individual B-mode feature scoring. In that regard, our study design was dissimilar to the 
aforementioned. In studying compounding, we find there is considerable inter-observer 
variability, leading to 20% and higher expert raw disagreement over all lymph node subsets. 
Intra-observer variability is a further concern. Intra-observer agreement of the experts and 
intermediate was ≤86% in the overall dataset when presented with the exact same image (AC1 
0.72-0.76). Observer compounding of B-mode features is subject to significant variability. 
However, knowing assessment of stationary images is far from ideal and irrevocable, a 0.60-
0.72 accuracy on predicting nodal malignancy by experts and intermediates also implicates 
prediction accuracy was better than at chance agreement. Analysis however shows a low 
ENDOBRONCHIAL B-MODE ULTRASOUND SCORING VARIABILITY 77
4
sensitivity and PPV for prediction in the subset of lymph nodes <8 mm size. Unfortunate, as this 
subset is most important for further work-up risk stratification and preventing understaging. 
The currently available B-mode features do not provide sufficient information for a highly 
accurate and reproducible prediction of lymph node malignancy. As we recently reported 
and show here, strain elastography may enable a semi-quantitative way of predicting 
malignancy, increasing sensitivity and NPV better than B-mode characteristics scoring 
[99]. Future research should be conducted and focus on implementation of computer aided 
diagnosis systems which could enable more consistent outcomes and possibly enable more 
accurate predictions. Integration of (other) (semi-)quantitative ultrasound features not easily 
objectified by the endoscopist should furthermore be investigated (i.e. [105]), along with the 
possibility of combining it with multiple modalities (such as strain elastography and/or PET-
CT/CT findings [90,99]). Such systems may further allow tailoring to individual anatomical 
lymph node regions, i.e. weighing factors such as size or a presence of hilar structure 
differently.
4.5.1 Study limitations
The prospectively collected B-mode images and the scoring thereof by the observers 
were done in routine clinical practice during a multi-center trial on strain elastography. As 
systematic study inclusion and scoring of all assessed nodes was not mandatory, inclusion 
of lymph nodes could have been biased. A second limitation is the retrospective nature of 
our analysis on reproducibility, and, having only still B-mode ultrasound images available for 
scoring. Lastly, retrospective scoring was performed without taking notice of metadata (e.g. 
lymph node location, PET/CT information). This could have affected exploratively assessed 
scoring accuracy, but is not expected to negatively affect scoring variability. 
4.6 Conclusion
Aside of the ultrasound B-mode short axis size, the currently used B-mode features do 
not provide sufficient information for good prediction of lymph nodal malignancy, and, 
reproducibility in their scoring shows to be an issue. In systematic staging, preferably 
all lymph nodes should be sampled. If any decision making on which nodes need to be 
aspirated is made aside of FDG-PET findings, the objective short axis size seems a relevant 
predictor. An ≥8 mm size has shown to be a clinically feasible cut-off, and could be used 
as a starting point. In systematic sampling, even smaller lymph node should however be 
considered. Future research should focus on implementation of computer aided diagnosis 
systems and further integration of multi-modality information for possibly improving nodal 
malignancy prediction.
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Bronchoscopic diagnosis of small peripheral lung lesions suspected of lung cancer remains 
a challenge. A successful endobronchial diagnosis comprises navigation, confirmation and 
tissue acquisition. In all steps, 3D information is essential. Cone beam CT (CBCT) imaging 
can provide CT information and 3D augmented fluoroscopy imaging. We assess if CBCT 
imaging can improve navigation and diagnosis of peripheral lesions by two clinical workflows 
with a cross-over design: (1) a primary CBCT and rEBUS-based approach and (2) a primary 
electromagnetic navigation (EMN) and rEBUS-based approach.
Methods
All patients with a peripheral lung lesion biopsy indication were eligible for study inclusion and 
randomly assigned to study arms. Commercially available equipment was used. The main 
study goals were to assess CBCT confirmed navigation success and diagnostic accuracy. 
Surgery or unambiguous clinical follow-up served as golden standard. 
Results
Eighty-seven patients with 107 lesions were included. Lesion mean longest axis size in the 
CBCT arm was 16.6 mm (n=47) and 14.2 mm in the EMN arm (n=40). The primary CBCT 
approach and primary EMN approach had 76.3% and 52.2% navigation success respectively. 
Addition of EMN to the CBCT approach increased navigation success to 89.9%. Addition of 
CBCT imaging to the EMN approach significantly increased navigation success to 87.5% per 
lesion. The overall diagnostic accuracy per patient was significantly lower than navigation 
success, being 72.4%.
Conclusions
CBCT imaging is a valuable addition to navigation bronchoscopy. Although overall navigation 
success was high, the diagnostic accuracy remains to be improved. Future research should 
focus on improving the tissue acquisition methodology.
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5.2 Introduction
Small peripheral pulmonary lesions suspected of lung cancer remain a diagnostic 
challenge. Despite computed tomography (CT) screening programs being implemented 
and a preference for minimally invasive diagnostics where possible [25–30], there are no 
unambiguous guidelines on the use of technology for an endobronchial approach. Over the last 
decade, several endobronchial techniques have become available that are able to increase 
the diagnostic yield of the conventional fluoroscopy guided transbronchial biopsy approach 
(pooled yield 31.3%) [37]. Techniques such as radial ultrasound mini-probe imaging (rEBUS), 
ultrathin bronchoscopy, virtual navigation bronchoscopy and electromagnetic navigation 
bronchoscopy (EMN) have been successfully implemented in clinical routine [34]. A meta-
analysis by Wang-Memoli et al. showed that the diagnostic yield of these techniques ranged 
from 67% to 73%, and that their overall pooled diagnostic yield was approximately 70% [39]. 
The prospective multi-center NAVIGATE trial that evaluated EMN further substantiated this 
diagnostic yield in a total of 1105 patients. By EMN, in combination with fluoroscopy (91% 
of cases) and rEBUS imaging (57% of cases), they achieved a combined overall diagnostic 
yield of 73% and 67.3% in lesions smaller than 20 mm [106]. Although these are promising 
results when compared to the conventional transbronchial biopsy, a diagnostic yield of 
approximately 70% still demands further improvement. 
Navigation bronchoscopy can technically be divided into three steps; navigation, 
confirmation and acquisition [107]. A successful diagnosis can only be obtained if all 
three steps are accurately performed. The integration of robotics in endoscopy is a new 
approach that could enhance accuracy in all three steps [108,109]. Yet, as lesions become 
smaller, have no bronchus sign, or are positioned at tight angulations relative to the airway, 
precise 3D imaging information likely becomes an essential need for accurate navigation 
and (transbronchial) biopsy. Furthermore, 3D information will also enable minimal invasive 
transbronchial treatment [107,110].
Cone beam CT (CBCT) imaging is a relatively new modality in interventional pulmonology, 
but, readily available as ceiling- or floor mounted C-arm system in the interventional radiology 
unit or hybrid operating room. CBCT Imaging allows for CT imaging as well as fluoroscopy. 
An initial CBCT scan does not only provide 3D information, it can be further used to delineate 
and overlay the lesion and pathway towards the lesion on regular fluoroscopy images (Figure 
5.1 & 5.2). This overlay, also termed augmented fluoroscopy (AF), is accurately maintained 
in 3D during every movement of the C-arm. Repeated CBCT scans can provide exact 3D 
confirmation of lesion and biopsy-tool positioning. CBCT imaging can thus provide navigation 
guidance, confirmation of lesion access and biopsy guidance. Several recent studies 
investigated CBCT imaging, for its CT and fluoroscopic capabilities [111], in combination 
with ultrathin bronchoscopy and rEBUS [112], EMN [113,114], or, transthoracic needle 
aspiration [115], reaching diagnostic yields of 70-84% [111–115]. However, to the best of
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Figure 5.1 – Case example of CBCT and augmented fluoroscopy based navigation. 
Panel A: Pre-procedural PET-CT showing FDG uptake in 12x11x7 mm solid lesion in the lower right 
lobe, near the diaphragm. Panels B-D: Conformational CBCT after CBCT and AF based navigation. 
Panels E-F: Augmented fluoroscopy under two different angles for verification of biopsy positioning. 
Lesion delineated in blue. Envisioned endobronchial pathway as segmented on the workstation 
intra-procedurally augmented as purple dots. Histopathology analysis of biopsy specimens found 
granulomatous disease, further proven to be granulomatosis with polyangiitis through clinical follow-up. 
our knowledge, no studies have systematically studied if CBCT and augmented fluoroscopy 
specifically improves navigation and diagnosis in an initial electromagnetic- and rEBUS-
based navigation. Similarly, while multi-slice CT aided navigation bronchoscopy has been 
reported [111,116–120], no studies have reported how cone beam CT and an augmented 
fluoroscopy based navigation can provide for a do-it-all guidance modality.
In this study, we prospectively assess CBCT and AF image guidance for navigational 
bronchoscopy of peripheral pulmonary lesions. Using a combination of modalities in two 
separate workflows and utilizing a cross-over design, we investigate if: (1) CBCT with 
AF and rEBUS based navigation bronchoscopy can enable successful navigation and 
biopsy guidance, and (2) assess the added value of CBCT and AF imaging on a primary 
electromagnetic- and rEBUS-based navigation. In this study, navigation success is the 
primary outcome measure. If accessing the lesion by primary navigation methodology 
showed unsuccessful on CBCT imaging, a crossover between workflows was applied. 
The secondary outcome measure is diagnostic accuracy, relating true positives and true 
negatives to subjects included.
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Figure 5.2 – Case example of CBCT and augmented fluoroscopy based trans-parenchymal navigation. 
Panels A-C: Pre-procedural CT scan where a ground glass opacity of 10x9x6 mm in the right upper 
lobe is visible. Panels D-E: Multi-angle augmented fluoroscopy for verifying that the trans-parenchymal 
access tool is positioned correctly. Panel F: Utilizing the trans-parenchymal access tool for trans-
parenchymal navigation towards the lesion. Panels G-H: After completing trans-parenchymal navigation 
the distal end of the catheter resides within the lesion. Histopathological analysis of biopsy specimens 
led to a diagnosis of adenocarcinoma in situ. 
5.3 Materials and methods
5.3.1 Study subjects
This prospective single center study was approved by the local IRB. All patients with 
a peripheral pulmonary lesion suspected of lung cancer with an indication for minimally 
invasive biopsy were eligible for study inclusion. Clinical indication to perform a minimally 
invasive biopsy followed local clinical practice and was defined in our multidisciplinary tumor 
board in accordance to international guidelines [32]. Patients were eligible after informed 
consent was obtained and contra-indications for endobronchial procedures were absent. 
Patients with lesions that could be diagnosed without the need for any navigation guidance 
(i.e. <5th generation endobronchial lesions or mediastinal lymph node involvement on PET-
CT) were excluded for this study. There was no further pre-selection for study inclusion 
based on patient or lesion characteristics. Randomization into one of both study arms was 
determined by CBCT scanner room availability, which alternated weekly. The primary CBCT-
based workflow utilized a ceiling mounted Philips Allura Clarity FD20 scanner (Philips, Best, 
The Netherlands). The primary EMN-based workflow utilized Medtronic’s SuperDimension 
EMN system (version 7.0, Medtronic, Minneapolis, USA) in combination with the floor 
mounted Siemens Artis Zeego CBCT system (Siemens Healthineers, Forchheim, Germany). 
See Figure 5.3 for a CONSORT flow diagram of subject inclusion.
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5.3.2 Study design, materials and methods
Pre-procedural CT (≤1.0 mm resolution) and/or PET-CT imaging was available in all patients. 
The pre-procedural CT was used to plan a navigation trajectory on the EMN planning platform 
irrespective of the primary study approach. Procedures were performed under general 
anesthesia, preferably via laryngeal mask (and if deemed impossible, by endotracheal 
tube). Standard flexible video bronchoscopes with 2.8 mm working channel were used for 
inspection bronchoscopy and consecutive catheter guidance (EB19-J10, Pentax Medical, 
Tokyo, Japan). 
The primarily CBCT-based navigation started with an inspection bronchoscopy and a first 
CBCT scan (8s roll, Lungsuite, Philips) to identify and segment the lesion and pathway. 
The 3D segmentations were automatically overlaid during fluoroscopy at any given angle. 
This augmented fluoroscopy (AF) under multiple angles in combination with a rEBUS-based 
(UM-S20-17S Radial EBUS miniprobe, Olympus, Tokyo, Japan) confirmation was used for 
3D guidance (Figures 5.1 & 5.2). Straight catheters with steerable curette (Guide sheath 
kit, Olympus, Tokyo, Japan) or catheters with pre-formed curvature (Medtronic Extended 
Working Channel, Minneapolis, USA) were used to navigate. Additional CBCT scans were 
made if AF confirmed positioning while rEBUS imaging remained uncertain, or vice versa. 
After confirming accurate positioning, tissue sampling was performed under AF-guidance. 
If the CBCT and AF-based approach remained unsuccessful, additional EMN guidance was 
added (cross-over). 
The primary EMN workflow utilized the pre-procedurally segmented CT based pathway from 
the EMN planning platform for navigation guidance. After inspection bronchoscopy, the 
EMN system was calibrated. Navigation was consecutively performed per manufacturer’s 
instruction using catheters with pre-formed curvature (Medtronic Extended Working Channel, 
Minneapolis, USA). If positioning was estimated to be accurate by the EMN system, the 
sensor was exchanged for the rEBUS probe. If rEBUS imaging confirmed lesion access, 
further confirmatory CBCT imaging was performed (6s roll, Syngo DynaCT, Siemens 
Healthineers). If no confirmation was obtained after repeated EMN and rEBUS-based 
attempts, CBCT scanning was performed to assess needed repositioning. Once a CBCT 
was performed, CBCT and AF imaging were used for subsequent biopsy guidance, and if 
necessary; navigation guidance (cross-over).
When endobronchial access showed difficult in either approach, trans-parenchymal access 
was pursued. In all cases, this was done with help of CBCT and AF. Tools to facilitate trans-
parenchymal access varied, from TBNA needles and consecutive guide sheaths to using a 
dedicated device (Cross-Country needle, SuperDimension).
After successful navigation, tissue sampling was performed using commercially available 
tools in an identical order: brush when central in lesion, followed by needle and forceps 
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biopsy for all others, then if possible and deemed safe; cryobiopsy. Rapid on-site evaluation 
of cytopathology (ROSE) was always available for confirming lesion access. Histology 
samples were obtained regardless of ROSE outcome. 
5.3.3 Analysis
All procedural actions, conclusions, considerations and their timing were noted. Procedural 
follow-up outcomes were found through electronic health records. Navigation outcome was 
termed ’centered’ if CBCT imaging unambiguously showed center lesion access of tools. 
Navigations were termed ‘in contact with’ if CBCT imaging showed tool contact with the 
outer boundary of the lesion, but not a central access of the lesion. Navigations were termed 
unsuccessful if intra-procedural CBCT verification showed the lesion was not reached. 
Navigation success was thus defined as CBCT imaging confirmed tool positioning residing 
centrally within the lesion or in contact with the lesion (range: central – in contact with – 
unsuccessful). The diagnostic accuracy was defined on a patient level, where the count of 
true positive and true negative findings (i.e. analysis of at least one nodule corresponding 
to follow-up outcome) are related to the total amount of patients included. In case tissue 
biopsy showed malignancy, it was considered a true positive diagnosis. In case tissue 
biopsy was found to be benign or non-representative (e.g. blood, normal lung tissue), follow 
up with CT guided trans-thoracic needle aspiration, surgical biopsy or unambiguous long-
term monitoring outcome (i.e. ≥12 months) served as gold standard to provide false- or true 
negative diagnostic procedural outcome.
Statistical programming language R and Rstudio were used for analysis [68]. Our sample 
size calculation showed that, to prove a 70% diagnostic accuracy with 15% margin of error 
and 95% confidence and be further able to directly compare approaches by cross-over 
design, a minimum sample size of 40 in every study arm was needed. A binomial proportions 
test using Pearson’s chi squared test statistics was performed to assess if a study approach 
had significantly better chance of success (p<0.05). A student’s t-test was used to compare 
means.
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Figure 5.3 – CONSORT FLOW diagram of study in- and exclusion.
5.4 Results
Between December 2017 and January 2019, 87 study subjects were included. Subject 
inclusion rate for both study arms unexpectedly varied due to altering room availability, 
resulting in a slightly higher inclusion in the CBCT arm (Table 5.1, Figure 5.3). A total of 
8 study subjects were excluded from analysis due to the following reasons: visible tumor 
during inspection bronchoscopy (n=2); considerably altered lesion dimensions at procedural 
imaging (indicative of infectious disease rather than malignancy, n=3); and lack of sufficient 
follow-up (n=3). In the primary CBCT and AF based approach, 47 patients and 59 lesions 
were included. Combined, these lesions had a mean long axis diameter of 16.6 mm (1.12 cm3 
median volume). In the primary EMN approach, 40 patients and 48 lesions were included. 
Their mean lesion long axis diameter was 14.2 mm (0.80 cm3 median volume). Detailed 
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patient and lesion characteristics are summarized in Table 5.1. A comparison of essential 
parameters showed that malignancy prevalence, lesion volume and bronchus sign presence 
did not significantly differ between study arms. 
Table 5.1 – Patient and nodule characteristics across both study arms. 1 not significantly different 
between study arms. 2 Bronchus sign as assessed on pre-procedural CT (≤1 mm slice thickness) related 
to navigation outcome (range: within-edge-unsuccessful) as found by CBCT imaging. Abbreviations: 
LUL – Left Upper Lobe, RUL – Right Upper Lobe, RML – Right Middle Lobe, LLL – Left Lower Lobe, 
RLL – Right Lower Lobe.
Study characteristics Primary CBCT and AF approach Primary EMN approach
Patients (male / female) 47 (16 / 31) 40 (20 / 20)
Age (min – max) 65 years (41-85 years) 65 years (44-81 years)
Lesions 59 48
Malignancy prevalence1 
(lesions / study subjects) 83% / 83% 72.9% / 72.5%
Median lesion volume1 1.12 cm3 (0.05-19.90 cm3) 0.80 cm3 (0.15-18.80 cm3)
Mean long axis diameter1 16.6 mm (5–43 mm) 14.2 mm (7-48 mm)
Bronchus sign1,2 (@ ≤1mm CT) 62.7% 70.8%
    Within lesion navigations 71.1% (32/45) 77.8% (28/36)
    In contact with lesion 25% (2/8) 50% (3/6)
    Unsuccessful navigations 50% (3/6) 50% (3/6)
Lesion locations Overall Malignant Overall Malignant
                       LUL / RUL 9 / 29 7 / 25 15 / 15 13 / 11
                       Lingula / RML 1 / 3 1 / 2 1 / 2 0 / 2
                       LLL / RLL 8 / 9 6 / 8 5 / 10 2 / 7
5.4.1 Navigation success
Navigation success rate using CBCT with AF and rEBUS as primary guidance modality 
was 76.3%, which is significantly better than that of the primary EMN- and rEBUS-based 
approach, being 52.2% (p=0.016, Table 5.2). The addition of EMN sensor guidance to the 
primary CBCT-approach improved navigation success from 76.3% to 89.9% per lesion 
(+13.6%, p=0.043). Oppositely, addition of CBCT and AF guidance led to a 35.3% increase 
in navigation success in the primary EMN-approach, from 52.2% to 87.5% per lesion 
(p=0.0002, Table 5.2). Performing a primary CBCT and AF-based navigation resulted in a 
significantly higher fluoroscopy time and number of CBCTs when compared to a primary 
EMN approach (Table 5.3). A bronchus sign (based on ≤1 mm resolution CT) was found 
less often in unsuccessful navigations and navigations only in contact with the lesion (42% of 
cases vs 66.4% overall, p=0.006, Table 5.1).
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5.4.2 Diagnostic accuracy
Whereas combining all navigation modalities (rEBUS, EMN, CBCT) resulted in an overall 
navigation success in 93% of patients, the overall diagnostic accuracy in the combination 
of both study arms was significantly lower (72.4%, p=0.0007). The diagnostic accuracy with 
the combined use of technologies was 70.2% and 75% for the primary CBCT- and EMN-
arm, respectively (p=0.797, nonsignificant difference). For this, a mean of approximately 
10 biopsies were taken using 3.4 different biopsy tools across both study arms. Using this 
combination of biopsy tools with intermittent image verification took approximately 24 minutes 
in both study arms (Table 5.3). 
5.4.3 Navigation time
Average navigation time across study arms was 27.4 minutes (Table 5.3). Navigation time in 
the EMN arm was considerably higher than in the CBCT arm, largely due to the calibration 
time of the EMN system (5.7 minutes). In both arms a CBCT was made for verification in all 
but three primary EMN cases, where rEBUS combined with fluoroscopy gave unambiguous 
confirmation and the operator decided to perform first sampling preceding to CBCT 
verification, which then showed malignancy in ROSE. The time to obtain a CBCT was different 
in both study arms, using the two different systems. It took an average of 7.9 minutes on the 
floor mounted system (EMN-arm) and 4.3 minutes for the ceiling mounted system (p<0.0001, 
CBCT-arm, Table 5.3). Segmenting the lesion and pathway for augmentation on the work 
station after having obtained a CBCT was often done in parallel with other procedural tasks. 
This took an average of 6.4 minutes on the floor mounted system and 5.3 minutes on the 
ceiling mounted system (time from having obtained CBCT to first use of AF by physician, 
non-significant differences). 
5.4.4 Added navigation guidance
Reasons to add EMN-guidance in the CBCT-arm were a need for guidance combined with 
catheter steerability (n=7 patients) and one case where the pathway on pre-procedural 
planning could not be found during intra-operative CBCT imaging. Causes for adding 
CBCT and AF-imaging to the EMN arm were cases where the planned pathway was shown 
incorrect intra-procedurally (n=2), where EMN had difficulty distinguishing multiple parallel 
bronchi (n=1), EMN and rEBUS suggested having reached the location whilst CBCT imaging 
showed inaccurate positioning (n=5), EMN guidance showed inaccurate due to tissue 
displacement (because of e.g. lower segment breathing motion or due to scope induced 
tissue manipulation, n=4), or need for a trans-parenchymal approach (n=6). 
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Table 5.2 – Navigation outcome and diagnostic outcome for both study arms. The navigation outcome 
corresponds to the navigation success of the primary workflow on a per lesion basis. Navigation success 
was determined by tools proving center lesion access (‘Center’) or tools being in contact with but not 
centered within the lesion (‘In Contact’). The ‘Combined with EMN / CBCT’ row showcases outcome 
when all guidance modalities (CBCT + AF + EMN + rEBUS) were used in combination. The diagnostic 
accuracy is on a per subject basis (number of subjects between brackets).
Primary CBCT and AF approach Primary EMN approach
Navigation outcome Center In Contact Total Center In Contact Total
Primary navigation 66.1% 10.2% 76.3%1 50.1% 2.1% 52.2%1
Combined with EMN / CBCT +10.2% +3.4% +13.6%2 +25.0% +10.4% +35.4%2
Total (per lesion) 76.3% 13.6% 89.9%3 75.0% 12.5% 87.5%3
Total (per subject) 87.2% 8.5% 95.7%3 75.0% 15.0% 90.0%3
Diagnostic accuracy (subject) Overall Overall
Primary navigation 61.7% (29) 50% (20)
Combined with EMN / CBCT +8.5% (4) +25% (10)
Overall 70.2%4 (33) 75%4 (30)
1 Significant navigation success difference between arms (p=0.016).
2  Significant increases in navigation success by addition of EMN- to primary CBCT-based guidance and 
by addition of CBCT to primary EMN-based guidance (p=0.043 and p<0.01, respectively).
3 Nonsignificant differences in final navigation success between study arms.
4  Diagnostic accuracy significantly lower than navigation success (p<0.01, but non-significant differences 
between study arms).
5.4.5 Trans-parenchymal navigation
In both study arms combined, a trans-parenchymal approach was performed in 18 lesions. 
CBCT Image guidance was used in all these cases (Figure 5.2). In the EMN arm, trans-
parenchymal navigation was successful in 5 out of 8 lesions, with 4 leading to an accurate 
diagnosis. In the CBCT arm, it was successful in 8 out of 10 cases, resulting in an accurate 
diagnosis in 7 cases.
5.4.6 Complications
Observed complications across both study arms were; pneumothorax (n=3), COPD 
exacerbation following the procedure (n=1), moderate bleeding intra-procedurally following 
cryobiopsy (n=1) and minor fever (<4 hrs, n=1). All study subjects – except one pneumothorax 
requiring chest tube and one case of COPD exacerbation – were able to return home the 
same day.
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Table 5.3 – Procedural tool use and timing. Average times and counts as derived from procedural 
report forms. Minimum to maximum range in between brackets. Navigation time definition: from start of 
navigation modality until decision to start biopsy. Primary EMN navigation also includes the calibration 
process in timing. Biopsy time definition: From stop of navigation until the last biopsy was taken. 
Biopsy tools and samples are calculated from lesions where at least one biopsy was taken. CBCTs and 
fluoroscopy time derived from total amount of procedures. Abbreviations: NS – nonsignificant.
Procedural characteristics Primary CBCT and AF approach Primary EMN approach p 
Navigation time 26.9 min (2-69 min) 35 min (4-74 min) 0.039
EMN system calibration time - 5.7 min (3-11 min) -
Biopsy time 22.4 min (9-55 min) 25.5 min (2-50 min) NS
Number of biopsy tools 3.11 (1-7) 3.69 (1-7) 0.042
Number of tissue samples 10.0 (1-23) 9.1 (1-18) NS
CBCTs made 2.19 (1-5) 1.49 (0-3) 0.0014
CBCT preparation time 4.3 min (2-10 min) 7.9 min (3-11 min) <0.0001
CBCT segmentation time 5.3 min (2-10 min) 6.4 min (2-14 min) NS
Fluoroscopy time 9.9 min (1-22 min) 7.3 min (2-23 min) 0.021
5.5 Discussion
We show that CBCT and augmented fluoroscopy-based 3D image guidance can be used 
successfully as a primary tool for navigation bronchoscopy. The addition of CBCT and AF 
imaging to a workflow where EMN and rEBUS are already being used furthermore significantly 
improved navigation success. By combining all available guidance modalities, almost 90% 
of small lesions in these patients were reached. As a single guidance modality, CBCT 
augmented fluoroscopy guidance had a significantly higher navigation success than EMN-
guidance, but, required higher radiation dosage. However, the overall diagnostic accuracy 
remains considerably lower than the navigation success in both study arms. Improving 
the tissue acquisition methodology may be crucial to enhance navigation bronchoscopy 
success.
The discrepancy between navigation success and diagnostic accuracy as found in this study, 
is significant. We believe that the rigidity of the tools used for sampling, breathing motion 
and movement due to manipulation of the endoscope and catheter are likely to cause small 
displacements and thus reduce diagnostic accuracy. In our centimeter sized lesions, the 
used EMN system was often found inaccurate. Chen et al. reported an average of 17.6 mm 
lesion movement from inspiration to expiration, which is larger than our average lesion long 
axis diameter [121]. To our opinion, the lack of intuitiveness in combining multiple modalities 
and tools may be additional important factors in the diagnostic accuracy. In that regard 
EMN guidance is a useful tool, building on pre-existing endoscopic imaging experience, 
whilst CBCT based navigation is likely more susceptible to a learning curve. We furthermore 
cannot assess if other commercially available EMN systems would have resulted in different 
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findings. Similarly, we do not know if other technology such as robotic bronchoscopes or 
far smaller bronchoscopes with an outer diameter of <3 mm would have improved both 
navigation and diagnostic outcome. That being observed, we hypothesize that the combined 
use of technology needs to become further integrated, adaptive and intuitive.
 
While the discrepancy in navigation success to diagnostic accuracy might be caused by 
tool use [41,122], we did not design the study to compare differences in tool outcome. In this 
study we however did aim at performing systematic specimen acquisition by using tools in 
an identical order (brush when central in lesion, followed by needle and forceps biopsy for 
all others, then if possible and deemed safe; cryobiopsy). In all cases, we had both CBCT-
imaging and ROSE available for confirmation of biopsy accuracy. While CBCT had proven 
lesion access, we found that ROSE often did not provide unambiguous outcome. Despite 
this observation, in the majority of cases our final analysis would prove diagnostic. A finding 
also reported by others [122]. Interestingly, Pritchett and colleagues describe fully relying 
on ROSE while performing repeated attempts and report an impressive diagnostic yield of 
83.7% in 93 lesions with 16.0 mm median size [113]. 
We corroborate previous findings that both lesion size and bronchus sign presence are 
stringent indicators of navigation success [39,123]. Yet, the presence of a bronchus sign 
remains subject to debate as it correlates to CT imaging quality and observer interpretation. 
A bronchus sign that can only be identified by repeatedly following branching of the bronchial 
tree on high resolution CT with 0.5 mm slice thickness is likely invisible on a coarser 3 mm 
slice thickness reconstruction. 
Utilizing CBCT and AF provides for the option to meticulously reposition and verify access. 
This is not only essential for gaining accurate trans-parenchymal access but also when 
performing and monitoring endoscopic treatments [114,124,125]. A trans-parenchymal 
approach in 18 cases had 72% navigation success leading to an accurate diagnosis in 61% 
of cases in our study. During the conduct of the study, we were limited to only two differently 
curved catheters. We feel that the lack of availability of catheters with higher curvature or 
active steerability prevented lesion access in several cases, as was also postulated by 
others [109,113].
This study assigned patients to a clinical workflow based on hybrid-OR availability. Due 
to unanticipated variations in room availability, the group size ended inequal. Since the 
essential parameters affecting navigation outcome (i.e. lesion volume and bronchus sign 
presence) were found insignificantly different we feel this did not influence our conclusion. 
Furthermore, in every primary EMN case, rEBUS was extensively attempted. Only when 
proven inaccurate with CBCT, additional CBCT image guidance was used. Having CBCT 
imaging and AF available could have affected our decision making. Additionally, once a 
confirmation CBCT was made in either study arm, AF was routinely used. It is likely that 
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the addition of AF enhanced EMN diagnostic accuracy and procedure time, as it provided 
additional biopsy guidance.
5.6 Conclusions
Cone beam CT and augmented fluoroscopy imaging are highly valuable as a stand-
alone means of guiding endobronchial navigation towards peripheral pulmonary lesions. 
Furthermore, CBCT imaging can significantly enhance navigation success in a workflow 
where EMN and rEBUS are already being used. While navigation success using all guidance 
modalities is high, the diagnostic accuracy was significantly lower. Improving the tissue 
acquisition methodology may be crucial to further enhance navigation bronchoscopy 
diagnostic accuracy in the future. 
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Advanced technological aids are frequently used to improve outcome of transbronchial 
diagnostics for peripheral pulmonary lesions. Even in cases where lesion access has been 
confirmed, obtaining an accurate tissue sample however remains difficult. 
Research question
What is the accuracy of different sampling tools and the value of rapid on-site evaluation of 
cytopathology (ROSE) in navigation bronchoscopy cases where 3D-imaging has confirmed 
lesion access?
Methods
Navigation bronchoscopies where lesion access had been verified by cone beam CT and 
augmented fluoroscopy were included. Individual tool outcomes were compared against one 
another and follow-up outcome. Clinical decision-making determined tool use and sampling. 
Results
A mean of 11.39 samples using 2.93 tools were obtained in 225 lesions (median diameter 
15 mm, 195 patients). An accurate diagnosis was most often obtained by forceps (accuracy 
70.6%), followed by 1.1 mm cryoprobe (68.4%), needle aspiration (46.7%), 1.9 mm cryoprobe 
(41.2%), brush (30.3%) and lavage (23.7%). Procedural outcome corresponded to follow-
up outcome in 75.1% of lesions (80.5% of patients). Accurately diagnosed lesions were 
subjected to significantly more sampling (11.91 vs 9.72 samples, p=0.014). In cases where 
procedural outcome proved malignant, ROSE had also detected this in 47.5%. 
Interpretation
Extensive multi-modal sampling resulted in highest diagnostic accuracy. A hypothetical multi-
modal approach of only using forceps and needle aspiration provided eventual diagnostic 
outcome in 91.7% of successfully diagnosed lesions. Confirmation of malignancy on ROSE 
did not reduce number of biopsies taken nor biopsy time. Future research on how to improve 
the accuracy and effectivity of tissue sampling is needed. 
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6.2 Introduction
Despite the development and introduction of several technological platforms to help guide 
the physician in the past two decades, obtaining an accurate endobronchial diagnosis 
of small peripheral pulmonary nodules remains a challenge. These platforms allow for both 
navigation guidance towards a lesion as well as confirming accurate lesion access, which 
become increasingly important as lesions are small sized and located peripherally in the lung. 
Techniques include ultrathin bronchoscopy, virtual navigation bronchoscopy, electromagnetic 
navigation, radial endobronchial ultrasound probes (rEBUS), robotic assisted bronchoscopy 
and cone beam CT imaging (CBCT) [32,34,39,41,108,109,113,126–128]. 
Unfortunately, a confirmed successful navigation does not warrant a representative and 
accurate diagnosis. Several studies report the diagnostic yield being lower than that of 
navigation success [41,115,122,128]. A study by Coghlin et al. shows that the mean % area 
of samples obtained from visible endobronchial lung cancer on histopathology was only 33.4% 
and found that 52% of patients had one or multiple fragments collected which contained no 
tumor at all. As lesions become smaller and are of early stage, the margin of error and the 
nuance become smaller, and likely even less samples will reveal the true lesion origin.
Obtaining accurate tissue samples for analysis is made difficult due to small lesion size, tumor 
heterogeneity, and, the ability of making a clear distinction in (early state) disease pathology 
in samples of limited size. The concurrent decision-making process on which tissue sampling 
methodology to use and deciding on when sufficient material has been collected add to 
this complexity. Additional general characteristics influencing the likelihood of a diagnostic 
outcome are the positioning relative to the bronchus, lobes involved, solidness, malignancy 
presence, pleural distance and patient characteristics such as emphysema or other co-
morbidity [34,37,123,129–135]. As two editorials recently concluded, there’s however 
insufficient evidence to – in general - prefer one overall tissue acquisition method over the 
other, while several studies comparing individual technologies and concurrent methodologies 
have been published to date [41,129]. Multiple studies suggest trans-bronchial needle 
aspiration (TBNA) has good outcome [129–131], while the brush, forceps and cryobiopsy 
probes are other commonly available and successfully used means [41,129,131,134,136–
138]. One further promising addition to the routine tissue sampling methodology is Rapid On-
site Evaluation of cytopathology (ROSE), providing on-site information on cytology aspirate 
representativeness and the possibility of malignancy. It may enhance diagnostic yield and 
reduce complication rates in transbronchial and endobronchial sampling, although there is 
contradiction in results [139–141]. 
In this single institution study, we assess the different tissue acquisition methodologies and 
the value of ROSE in a cohort of patients whom have been navigated to by CBCT guided 
navigation bronchoscopy for small peripheral pulmonary nodules. This allows for a unique 
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analysis, as the 3D CBCT image verification provides for analysis of those lesions which 
have shown to be accurately accessed. By relating biopsy tool outcomes per lesion, a direct 
paired comparison of tools is enabled whilst simultaneously incorporating clinical decision 
making on tool use. Combined, we report on overall diagnostic tool accuracy and agreement 
of ROSE with final pathology outcome in a navigation bronchoscopy setting.
6.3 Methods
6.3.1 Study subjects
All patients receiving a navigation bronchoscopy under guidance of CBCT for diagnosis of a 
peripheral pulmonary lesion in the period of December 2017 – June 2020 were eligible and 
prospectively approached for written informed study consent. Study approval was obtained 
by the local institutional review board. Patients whom did not finally receive a navigation 
with CBCT imaging (and augmented fluoroscopy), patients in which a navigation setting 
was deemed unnecessary due to endobronchial findings, or, patients in whom the lesion 
could not be successfully reached as verified by 3D CBCT, were excluded for analysis. After 
exclusion, only study subjects and concurrent lesions for which successful lesion access 
had been verified remained for analysis (Figure 6.1).
6.3.2 Materials and Methods
Conventional bronchoscopes with 2.8 mm working channel (EB19-J10, Pentax Medical, 
Japan) and consecutive 2.6 mm catheters (Olympus medical guide sheath, Tokyo, Japan & 
Medtronic extended working channels, Minneapolis, USA) were used to navigate. Navigation 
was performed by one or a combination of electromagnetic navigation guidance (Medtronic 
SuperDimension), rEBUS (Olympus UM-S20-17S) and CBCT imaging with augmented 
fluoroscopy (Philips Allura/Azurion, Best, The Netherlands or Siemens Zeego, Forcheim, 
Germany). The procedures took place under general anesthesia. After navigation, lesion 
access was verified by one or a combination of rEBUS, CBCT and augmented fluoroscopy. 
After confirming navigation success, the catheter remained positioned near or within the 
lesion throughout biopsy specimen acquisition. Biopsy specimen acquisition was performed 
with intermittent augmented fluoroscopy, CBCT and/or rEBUS imaging. All tool use and the 
amount of sampling was decided upon by the endoscopy team while taking into account 
factors such as safety, hypothesized efficacy, intermittent ROSE outcome and lesion 
characteristics. With the tools that were decided upon, biopsy specimen acquisition was 
routinely performed in the following order; lavage, brushing, TBNA, followed by forceps and/
or cryobiopsy. Lavage included  injection of up to 60 ml of 0.9% saline through the catheter or 
endoscope and subsequent retrieval by aspiration until more than 20 ml had been retrieved 
for analysis. Brushing for cytopathology was performed by a pushing-pulling technique 
of the complete tool or retraction-insertion of the 1.8 mm brush in and out of the catheter 
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(Olympus BC-202D-2010 brush, Medtronic SuperDimension cytology brush or Medi-globe 
cytology brush, Achenmühle, Germany). Needle aspiration was predominantly performed 
with 18G needles (Broncus FleXNeedle, San Jose, USA) by means of a similar motion as to 
that of the brush, with suction being applied by syringe proximally. Twenty-one gauge and 
19G needles of other manufacturers were less often used, based upon commercial primary 
needle availability (Medtronic SuperDimension Aspirating Needle). Serrated or non-serrated 
oval forceps of 1.8 mm diameter were used to acquire histology specimens (Boston Scientific 
Pediatric Radial Jaw 4 or Olympus FB-233D biopsy forceps). After advancement through the 
catheter, the forceps were opened and further pushed into the lumen until traction could be 
felt, after which they were closed and retracted for histology specimen collection. Cryobiopsy 
for histopathology was available only through a 1.9 mm cryoprobe until September 2019, after 
which a 1.1 mm version also became available (Erbe Elektromedizin, Tuebingen, Germany). 
Due to probe and sample size, the 1.9 mm cryoprobe had to be removed along with catheter 
and endoscope after an initial freeze of 4-7s. Oppositely, the catheter could be left in place 
for repeated sampling with the 1.1 mm cryoprobe. Freezing during 5-9s was followed by 
removal of the 1.1 mm probe for histopathology collection. 
Individual cytology samples were divided onto two slides; one Giemsa staining which was 
also used for ROSE and one slide for Papanicolaou smearing used only for definitive analysis. 
Remaining material was collected for cell block. Separate collection containers were used for 
every sampling tool. ROSE was available for all cases, which in our center is performed by 
trained cytopathology technicians.
6.3.3 Analysis
Descriptive parameters are presented as counts and percentages, along with medians, 
means and ranges. All individual nodules in which sampling was performed were correlated 
to a procedural outcome and a golden standard follow-up outcome. Golden standard follow-
up was either a surgical resection, additional CT guided TTNA and/or clinical follow up 
combined with CT for at least 6 months. The comparative accuracy of tools was determined 
by pairing tool outcome in cases of individual lesions where two or more tools were used. The 
McNemar chi-squared test was used to test equivalence of tool accuracy. Wilcoxon testing 
was performed for comparison on not-normally distributed data. Student’s t-Tests were used 
to test accuracy differences between unpaired data. Tests with a p-value of <0.05 were 
considered significant. For evaluation of ROSE, all procedures where a malignant pathology 
was found and ROSE was performed were included for analysis. The concordance of 
overall malignant ROSE outcome by all cytological specimens was compared with both final 
cytology as well as histology outcome. R and RStudio were used for statistical analysis [68].
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Figure 6.1 – Flow diagram on study inclusion. Unsuccessful navigations were classified as those where 
imaging showed that the lesion was not successfully reached. A non-routine procedure indicated 
the primary reason for navigation bronchoscopy was other than diagnostics or different than normal 
procedural work-up due to study or clinical causes. ROSE was available only per analysis of brush 
and TBNA smears. Abbreviations: TBNA – Trans-Bronchial Needle Aspiration, ROSE – Rapid On-Site 
Evaluation of cytopathology.
6.4 Results
A total of 195 patients received successful navigation bronchoscopy as verified by CBCT and 
augmented fluoroscopy imaging, in which a total of 225 lesions were successfully reached 
(Figure 6.1, Table 6.1). Overall, 76% of patients were diagnosed with malignant disease. 
Median lesion diameter was 15.0 mm (range 5-65 mm). 
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Table 6.1 – Patient, lesion and procedural characteristics. Abbreviations: LUL – Left Upper Lobe; RUL – 
Right Upper Lobe; RML – Right Middle Lobe; LLL – Left Lower Lobe; RLL – Right Lower Lobe. 
Patients, lesions and procedural characteristics
Patients / Lesions (successfully accessed) 195 / 225
Age (mean, range) 65.2 (36-85)
Gender 65.2 (36-85)
Malignancy prevalence (pt. / lesion) 76% / 75%
Nodule size (median, range) 15 mm (5-65 mm)
Bronchus sign (lesion) 64.4%
Diagnostic accuracy procedure 80.5% (157/195)
Diagnostic accuracy lesion 75.1% (169/225)
Lesion locations LUL / RUL 62 / 77 
       / RML     / 11
LLL / RLL  32 / 43 
6.4.1 Cytology and histology accuracy
The gold standard outcome corresponded to procedural outcome (whilst navigation had 
showed successful) in 80.5% of cases on a per patient basis, and 75.1% of cases on a per 
lesion basis. The cytology findings (lavage, brush, TBNA) corresponded to gold standard 
follow-up outcome in 49.3% of lesions (107/217, Table 6.2). Histology findings (by forceps 
and cryobiopsy) were more often found accurate (72.4%), but the combination of both 
cytology and histology remained most accurate (75.1%). Analysis of data wherein both 
cytology and histology were obtained shows histology was significantly more often accurate, 
be it either malignant or benign (Table 6.2, p-value <0.01). The histology outcome by itself 
was significantly more often accurate in benign lesions than in malignant lesions (p<0.01, 
88.6% vs 66.9%, respectively). This finding did not similarly hold for cytology outcome (48.5% 
accuracy in benign lesions and 51.9% accuracy in malignant lesions, Table 6.2).
6.4.2 Tissue sampling method accuracy
Repeated sampling and choice of biopsy method were based upon clinical decision making. 
Analysis of sampling method accuracy shows lesions whom were accurately diagnosed were 
subjected to a significantly higher amount of sampling (Tables 6.3, p=0.014). An average of 
3.83 separate cytology samples (range 0-15) and 7.56 separate histology samples (range 
0-18) were acquired per procedure, equivaling an overall average of 11.39 samples (range 
1-25). Collection of samples by forceps and 1.1 mm cryobiopsy was performed an average 
of 7.08 and 6.12 times per lesion, respectively. Brush and TBNA – both enabling ROSE – 
were used for repeat sampling a respective average of 1.64 and 3.26 times. Forceps biopsy 
was most often found accurate (70.6%), followed by 1.1 mm cryoprobe findings (68.4%), 
TBNA (46.7%), 1.9 mm cryoprobe (41.2%) and tiers brush (30.3%) and lavage (23.7%). 
Further pair-wise tool comparison substantiated these accuracy findings (Table 6.4). The 
forceps showed superior accuracy when compared against all cytology techniques (lavage, 
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brush, TBNA, p<0.01), but did not show significantly better than cryobiopsy (p=0.081). 
Cryobiopsy showed significantly better accuracy than that of lavage and brush (p<0.05), 
but not TBNA (p=0.40). The 1.1 mm cryoprobe was more often accurate than the 1.9 mm 
cryoprobe (68.4% vs. 41.2%, respectively).
6.4.3 Multi-modal sampling analysis
Overall outcome showed that forceps and TBNA sampling were used most often, respectively 
having been used in 89.3% and 73.3% of lesions (Tables 6.3 & 6.4). Analysis of a multi-
modal sampling approach revealed sampling using forceps combined with TBNA would 
have provided eventual diagnostic outcome in 155 out of 169 successfully diagnosed lesions 
(91.7%). In the cases where these were not diagnostic, sampling by 1.1 mm and 1.9 mm 
cryoprobe correctly diagnosed 2 and 8 lesions whilst brushing and lavage were accurate in 
4 and 3 lesions, respectively.
Table 6.2 – Sampling outcome (per lesion) versus procedural and follow-up gold standard outcome. 
Results of Rapid On-Site Evaluation (ROSE) of cytopathology are described specifically for malignant 
disease findings as found per procedural cytopathology outcomes and overall procedural outcomes 
(being malignant). As clinical decision making decided on tool use, only cases where cytology or 
histology was available were used for calculation of accuracy. 1 Significant differences (p-value <0.01, 
McNemar chi-squared test) between accuracies of cytology and histology in benign, malignant and 
lesions overall were found when assessing paired outcomes. 2 Significant difference (p=value <0.01, 
unpaired two-sided Student’s t-test) between accuracy of histology outcomes in benign and malignant 
lesions. * Molecular analysis is only performed upon request (when clinically indicated), denoted here is 
the number of times it was possible when requested. 
Pathology outcome –per lesion basis % n
Rapid On-Site Evaluation of Cytopathology
      ROSE correlating to malignant cytopathology findings 72.1% 57/79
      ROSE correlating to procedural malignant findings
      (cytology & histology combined) 47.5% 57/120
Sampling accuracy in malignant lesions
      Cytopathology (procedural) accuracy 48.5%1 79/163
      Histopathology (procedural) accuracy 66.9%2 105/157
      Combined pathology (procedural) accuracy 71.0% 120/169
      Molecular analysis possible* 83.9% 26/31
Sampling accuracy in benign lesions
      Cytopathology (procedural) accuracy 51.9%1 28/54
      Histopathology (procedural) accuracy 88.6%2 47/53
      Combined pathology (procedural) accuracy 87.5% 49/56
Sampling accuracy – lesions overall
      Cytopathology (procedural) accuracy 49.3%1 107/217
      Histopathology (procedural) accuracy 72.4%1 152/210
      Overall pathology (procedural) accuracy 75.1% 169/225
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6.4.4 Rapid on-site evaluation of cytopathology
Rapid on-site evaluation of cytopathology was available in cases where sampling by brush 
and/or TBNA was performed (n=217). Of 79 lesions where cytology analysis was suggestive 
of malignancy, ROSE concluded similarly in 57 (69.8%). Due to the discrepancy between 
cytology results and overall pathology results, ROSE was able to conclude malignancy in 
47.5% of cases where procedural outcome showed malignancy (57/120, Table 6.2). In the 
procedures where ROSE was found suggestive of malignancy, significantly more samples 
were obtained than where it did not (respective average of 12.65 vs. 10.51 samples, 
p=0.016, Table 6.3). The biopsy time insignificantly correlated to these findings, taking an 
average of 25.1 minutes in ROSE findings suggestive of malignancy and 24.2 minutes in non-
confirmatory ROSE findings (p=0.36).
Table 6.3 – Descriptive statistics on procedural sampling techniques. Amount of sampling obtained are 
computed from cases where the instrument was used to acquire at least one sample. The accuracy are 
furthermore given by comparing the amount of times the instrument was used and led to an accurate 
diagnosis as compared against the total times it was used. On the bottom half of the table, the total 
amount of samples obtained for the different types of procedure characteristics are furthermore given; 
amount of samples when ROSE concluded malignancy, did not conclude malignancy, amount of 
samples in undiagnostic lesions and in cases where an accurate diagnosis could be obtained. 1 p-value 
= 0.016, significantly more samples were obtained when ROSE had concluded malignancy. 2 p-value = 
0.014, significantly more samples were obtained in accurate procedures. 










Cytology 3.83 4 1-15 107/217 (49.3%)
    Lavage 1.18 1 1-3 18/76 (23.7%)
    Brush 1.64 2 1-4 40/132 (30.3%)
    TBNA 3.26 3 1-11 77/165 (46.7%)
Histology 7.56 7 0-18 152/210 (72.4%)
    Forceps 7.08 7 1-18 142/201 (70.6%)
    Cryobiopsy (1.1 mm) 6.12 7 1-10 26/38 (68.4%)
    Cryobiopsy (1.9 mm) 1.15 1 1-2 21/51 (41.2%)
Samples total 11.39 11 1-25 169/225 (75.1%)
    ROSE: malignant findings 12.651 12 4-24 -
    ROSE: benign findings 10.511 10 1-25 -
    Unsuccessful diagnosis 9.722 10 1-23 -
    Successful diagnosis 11.912 12 1-25 -
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6.5 Discussion
In navigation bronchoscopies where access of lesions with a mean 15 mm size had been 
verified through (repeated) 3D-imaging, we found that procedural pathology outcome 
corresponded to follow-outcome in 80.5% per patient (75.1% of lesions). In lesions where 
an accurate diagnosis could be obtained, significantly more sampling was performed (9.72 
vs 11.91 samples, p=0.014). An accurate diagnosis was most often obtained by forceps 
(accuracy 70.6%), followed by 1.1 mm cryoprobe (68.4%), TBNA (46.7%), 1.9 mm cryoprobe 
(41.2%), brush (30.3%) and lavage (23.7%). By these findings, histology results alone were 
found representative of follow-up outcome in 72.4%, and by cytology in 49.3% of cases 
(Tables 6.3 & 6.4, p-value <0.01). Due to the discordance of cytology findings with overall 
procedural findings, and ROSE again being discordant with cytology (in 27.9% of cases), 
ROSE was able to help predict procedural malignant pathology outcome in only 47.5% of 
cases.
During the conduct of this study, catheters and (intermittent) 3D-imaging verification were 
always used. We hypothesize both were essential in maintaining meticulous positioning 
and acquiring tissue at different sites of hypothesized pathology. It is likely only a minority 
of tissue samples contains pathologic tissue, as also indicated by Coghlin et al. in biopsy 
samples of visible lung cancers [142]. The NAVIGATE study and a recent systematic review 
and meta-analysis substantiate these findings, finding a higher procedural success in cases 
of multi-modal and extensive sampling [122,143]. Our repeated sampling with tools was 
based on clinical decision making rather than being a randomized and controlled trial. With 
the differently available tools having different properties, we deemed it relevant to tailor their 
use to the situation. In general, we chose our tools based upon relative positioning of the 
catheter to the lesion and secondary adjacent structures (e.g. pleura, vessels, cavities). 
When a central position in the lesion was obtained, a brush was generally the first choice 
(followed by secondary sampling tools). When lesion position was eccentric or trans-
parenchymal access was deemed necessary, TBNA was often preferred first. The choice to 
not perform repeated TBNA, brush or lavage sampling more often was made consciously. 
EBUS-TBNA and ROSE literature has shown acquisition of more than 4 TBNA samples in 
EBUS is of minimal additional value and sufficient for enabling molecular analysis in the vast 
majority of cases [94]. While we cannot perform sampling under direct ultrasonic or video 
guidance, the motion and straightening of the catheter along with ROSE findings often being 
consistent in outcome from first to last biopsy made us decide on reducing routine TBNA use 
to 3-4 times. The choice of forceps and higher amounts of repeat biopsy when compared to 
other tools was partially based on the observation that precurved catheters as used in this 
study lost least of their curvature by forceps, consequently allowing for biopsy of different 
sites. This could also provide for an explanation why we find a significant cytology and 
histology accuracy difference in both diagnosing benign and malignant lesions (Table 6.2). 
But where cytology accuracy was similar in malignant and benign lesions (48.5 vs 51.9%, 
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respectively), histology outcome was of higher variation (66.9% vs 88.6% for malignant and 
benign outcomes, respectively). We cannot clearly explain this histology accuracy difference 
in benign and malignant findings, as it is also contrary to generalized findings of other studies 
[143]. As such, additional research remains needed.
To our knowledge, this is one of first clinical trials to report on 1.1 mm cryoprobes for peripheral 
lesion biopsy in a through-the-catheter approach. Opposite to that of the 1.9 mm cryoprobe, 
it allows for repeated sampling while retaining the catheter near the lesion. As descriptively 
reported, a combination of TBNA with forceps biopsy in a curved guide sheath deprecated 
the added value of also adding this tool to the inventory in 22 out of 24 cases where it was 
found diagnostic. It has previously been described that especially lesions non-concentrically 
positioned around the bronchus would be benefitted by the cryoprobe [134]. Our findings 
show this might be less valid for the smaller sized probe, which could be caused by its 
difference in area and tissue penetration.
Folch et al. and the NAVIGATE trial report a higher degree of sampling and multi-modal 
sampling led to higher yield [122,143]. We report routinely sampling more than 10 times per 
lesion in a multi-modal fashion and similarly see a higher amount of sampling correlating to 
finding an accurate diagnosis by procedural pathology more often (Table 6.3, p=0.014). 
Our high degree of repeat sampling was in part based on our clinical findings that lesion 
access by imaging verification was frequent, but a confirmatory diagnosis could then not 
always be made. The hypothetic TBNA and forceps only scenario as presented in this study 
however shows we would have found 91.7% of eventual diagnoses by only using these two 
modalities. It could be suggested that not all lesions require extensive multi-modal sampling. 
Yet, it can also be concluded that no commercially and readily available tool is currently a 
do-it-all tool even if lesion access has been confirmed. Therefore, multi-modal and repeated 
sampling seems to remain the recommended methodology.
As previously found, the ROSE methodology may differ among centers, with no evidence 
for preferring one above another smearing method [94]. A meta-analysis by Mondoni et al. 
found ROSE increases the procedural yield also in diagnosis of peripheral lesions. Moreover, 
previous reports have shown that molecular analysis in EBUS-TBNA can be performed more 
often in a ROSE enhanced procedure [141]. In this study, we uniquely use Cone beam 
CT imaging to verify in 3D that the lesion has been accurately accessed. Consecutively, 
extensive sampling was performed. Yet even after having (repeatedly) verified lesion access, 
a diagnosis indicative of procedural malignant outcome could be obtained by ROSE in only 
47.5% of cases (Table 6.2). The discordant findings when related to procedural and cytology 
outcome may in part be explained by differences in available material. ROSE provides outcome 
on Giemsa staining, whilst additional material is harbored within Papanicolaou staining and 
cell block. Another cause of discordance might be related to the cytopathologist’s opinion 
that analysis of peripheral pulmonary lesion smears is different to that of EBUS-TBNA, being 
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more diverse. With decreasing lesion size and less solidity, differentiating between atypical 
findings and malignancy becomes more difficult [41]. Combined, we can conclude that 
ROSE was of additional value in less than 50% of cases, and, that it was not associated with 
a reduction of total number of samples taken nor with biopsy time. Based on these outcomes 
we question if ROSE remains justified or that extensive sampling with currently available tools 
is needed regardless. 
6.6 Interpretation
This study evaluates the different tissue sampling methodologies and ROSE accuracy in a 
subset of navigation bronchoscopies where 3D-imaging had verified lesion access. With 
repeated multimodal sampling based upon clinical decision making, pathology outcome 
was found corresponding to gold standard follow-up outcome in 75.1% of lesions, resulting 
in 80.5% of patients obtaining a representative diagnosis. In lesions where an accurate 
diagnosis could be obtained, significantly more sampling was performed (9.72 vs 11.91 
samples, p=0.014). An accurate diagnosis was most often obtained by forceps (accuracy 
70.6%), followed by 1.1 mm cryoprobe (68.4%), TBNA (46.7%), 1.9 mm cryoprobe (41.2%), 
brush (30.3%) and lavage (23.7%). Analysis of a multi-modal sampling approach reveals 
sampling using only forceps and TBNA would have provided eventual diagnostic outcome 
in 91.7% of successfully diagnosed lesions. In cases where procedural pathology outcome 
proved malignant, ROSE had precedingly confirmed malignancy in only 47.5%. Confirmation 
of malignancy on ROSE did not show to reduce number of biopsies taken nor biopsy time. 
In conclusion, there is currently no single approach or methodology that is a do-it-all. Future 
research on how to improve the accuracy and effectivity of tissue sampling is needed. 
6.7 Statement of Ethics
The research was conducted ethically in accordance with the latest World Medical Association 
Declaration of Helsinki. The study protocol was approved by the independent local medical 
ethical committee (Arnhem-Nijmegen) and institutional review body before start of subject 
inclusion. Informed consent was obtained. 
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The endobronchial diagnosis of peripheral lung lesions suspected of lung cancer remains 
a challenge from a navigation as well as an adequate tissue sampling perspective. Cone 
beam CT (CBCT) guidance is a relatively new technology and allows for 3D imaging 
confirmation as well as navigation and biopsy guidance, but, also involves radiation. This 
study investigates how radiation exposure and diagnostic accuracy in the CBCT guided 
navigation bronchoscopy evolves with increasing experience, and, with a specific tailoring 
of CBCT and fluoroscopic imaging protocols towards the procedure.
Study design
In this observational clinical trial, all 238 consecutive patients undergoing a CBCT guided 
navigation bronchoscopy from the start of our CBCT guided navigation bronchoscopy 
program (Dec 2017) until June 2020 were included. Procedural dose characteristics and 
diagnostic accuracy are reported as a function of time.
Results
Procedural radiation exposure as measured by the Dose Area Product (DAP) initially was 
47.5 Gy·cm2 (effective dose 14.3 mSv) and gradually reduced to 25.4 Gy·cm2 (5.8 mSv). 
The reduction in fluoroscopic DAP was highest, from 19.0 Gy·cm2 (5.2 mSv) to 2.2 Gy·cm2 
(0.37 mSv, 88% reduction), despite a significant increase of fluoroscopy time. The diagnostic 
accuracy of navigation bronchoscopy went up from 72% to 90%.
Conclusion
A significant learning effect can be seen in the radiation safety and diagnostic accuracy of a 
CBCT and AF guided navigation bronchoscopy. With increasing experience and tailoring of 
imaging protocols to the procedure, the procedural accuracy improved while effective dose 
for patients and staff were reduced.
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7.2 Introduction
Peripheral lung lesions with intermediate to high risk of malignancy should preferably 
be diagnosed by minimal invasive means before deciding upon treatment strategy 
[32,37,144,145]. The currently available most sensitive options for obtaining samples 
from peripheral lung lesions include CT guided trans-thoracic needle biopsy (TTNB) and 
technology enhanced endobronchial approaches. CT guided TTNB has an overall sensitivity 
of approximately 90% [32,44] but is also associated with a 19-25% risk of pneumothorax [44]. 
The endobronchial approach as enhanced by different means of technology has shown a 70-
77% pooled sensitivity in meta analysis, with only a 1.5-2.0% risk of pneumothorax [39,143]. 
Recently, it was shown that utilizing intra-procedural Cone Beam CT (CBCT) image guidance 
– a relatively new technique in this field - may retain complication risk while further increasing 
the accuracy of this technology enhanced navigation bronchoscopy procedure [113,128]. 
Aside of its unique ability to acquire intra-procedural 3D information, deemed valuable for 
meticulous positioning of tools, the CBCT system can also augment a navigation pathway 
and lesion position as an overlay on 2D fluoroscopic imaging (also termed augmented 
fluoroscopy, AF). With this combination of features, CBCT has the potential to meticulously 
help guide the endoscopist during the different aspects of the procedure.
The use of CBCT imaging systems for guiding the endobronchial diagnosis of suspected 
peripheral pulmonary lesions solely relies on X-ray imaging through both augmented 
fluoroscopy imaging as well as repeated CBCT’s to navigate and confirm positioning. Since 
only few reports describe CBCT and AF use in interventional pulmonology, little is known 
about its radiation safety profile. Steinfort et al. and Casal et al. report effective CBCT guided 
bronchoscopy procedural dose ranges of 9-60.8 mSv [146] and 11-29 mSv (Dose Area 
Product, DAP: 64.6 Gy·cm2, [112]) whereas Pritchett et al. report a procedural DAP of only 
31 Gy·cm2 and an effective procedural dose estimation as low as 3 mSv [147]. 
We hypothesize the radiation exposure to both patients and staff might vary significantly, 
as it is subject to a learning curve experience. Therein, not only the endoscopist is likely 
to change its radiation use as experience increases. Tailoring of the CBCT system to the 
requirements of this relatively new field is also of likely effect. Changing system imaging 
quality and collimation options could enhance radiation safety to that purpose, without 
negatively affecting diagnostic accuracy. 
In this study, we prospectively evaluate unselected consecutive navigation bronchoscopy 
cases in order to study two (possibly interrelated) topics: (1) the radiation exposure in the 
primarily CBCT-guided navigation bronchoscopy procedure over time (with the tailoring of 
imaging protocols specific to the procedure); (2) the procedural diagnostic accuracy in the 
CBCT and AF guided navigation bronchoscopy over time. 
CHAPTER 7114
We hypothesize that more procedural experience and a specific tailoring of CBCT and 
AF imaging protocols to the navigation bronchoscopy procedure may significantly reduce 




This prospective single center study was approved by the local ethical committee. All 
consecutive patients in the period December 2017 - June 2020 without contra-indications for 
an endobronchial procedure and a peripheral pulmonary lesion for whom a minimally invasive 
biopsy was indicated and performed according to routine clinical care were eligible for study 
inclusion. In our center, CBCT and AF guidance was first choice of procedure (preferred 
above TTNA), but only indicated for those lesions where advanced navigation guidance 
and confirmation was deemed necessary (location at least beyond 2nd order branches of 
segmental bronchi). In cases where lesions were thought to be reachable by catheters under 
r-EBUS mini probe imaging (UM-S20-17S, Olympus, Tokyo, Japan) and C-arm fluoroscopy 
guidance, procedures were not performed on the CBCT imaging suite. Written informed 
consent was obtained in all cases. Patients eventually reached and diagnosed without CBCT 
imaging were excluded for this study. All procedures were performed by the same team of 
one interventional pulmonologist and one technical physician. 
7.3.2 Materials and methods
Procedures were performed under general anesthesia. Standard flexible video 
bronchoscopes with 2.8 mm working channel (EB19-J10, Pentax Medical, Tokyo, Japan) were 
used for inspection bronchoscopy and subsequent navigation guidance of commercially 
available catheters. Catheter navigation was performed only on basis of CBCT and AF 
guidance in all but the cases where electromagnetic navigation technology (EMN, Medtronic 
SuperDimension, Minneapolis, USA) was additionally used (Figure 7.1). After navigation, 
radial EBUS miniprobes and/or CBCT with AF imaging were routinely used to confirm lesion 
access. Consecutive tissue sampling was performed under guidance of AF. Biopsy tools 
included brushes, TBNA needles, biopsy forceps and cryoprobes. Rapid on-site evaluation 
of cytopathology was always available. 
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Figure 7.1 – Flow chart of study inclusion.
The navigation bronchoscopy procedures were performed on three cone beam CT systems; 
a ceiling mounted Philips Allura Clarity FD20 scanner which was later replaced by a ceiling 
mounted Philips Azurion scanner (Philips, Best, The Netherlands), and, a floor mounted 
Siemens Artis Zeego scanner (Siemens Healthineers, Forchheim, Germany). As part of a 
specific research collaboration, dedicated imaging protocols and software were installed 
and updated only on the Philips systems. Distinct periods and concurrent imaging methods 
on these imaging systems can be defined (Figure 7.1). To allow for an accurate learning 
experience description, the radiation exposure is reported only for the Philips imaging 
systems. In enabling a description of the diagnostic accuracy learning curve experience, the 
procedures on all platforms are however taken into account.
7.3.3 X-ray imaging
In short, our navigation bronchoscopy program started with imaging protocols only focusing 
on acquiring the highest imaging quality possible. However, navigation bronchoscopy is 
not all about maximum image quality and should adhere to the ALARA principle (As Low 
As Reasonably Achievable). As tools and lesions can often be distinguished from the 
surrounding lung tissue in navigation bronchoscopy after having obtained initial guidance 
information, not every detail on subsequent CBCT scans or fluoroscopy imaging is needed. 
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We therefore changed the availability of thorax CBCT scanning and AF protocols from one to 
three options. Therewith, quality and concurrent radiation dose could be dynamically decided 
upon by the endoscopist. For instance, the necessary image quality could be based on 
requiring only relative positioning information (low dose), identifying if a ground glass lesion 
had been accurately accessed (medium dose) or to identify different bronchi for navigation 
towards the lesion (high / original dose, Figure 7.2). The goal of these dedicated imaging 
protocols was to provide multiple options to the endoscopist, retaining diagnostic accuracy 
while maintaining or decreasing radiation dose. Protocol changes were made in due time 
(Figure 7.1). First low dose fluoroscopy protocols became available, afterwards, low dose 
CBCT protocols. When the Philips Allura system was replaced by the Azurion system, low 
dose fluoroscopy protocols were immediately transferred. Ten procedures however passed 
before the low dose CBCT protocols were made available on the Azurion system.
Figure 7.2 – Example images subsequently obtained from low dose (left) and normal dose (right) 
imaging protocols for navigating towards a 6x8 mm lesion found in the apical segment of the left lower 
lobe. As can be seen, artifacts alike the classically known streaking can be seen more strongly in the low 
dose protocol. Although difficult to appreciate on still images, there is also a further difference in image 
quality for i.e. allowing recognition of the smallest of bronchi that can be navigated to. Note the minor 
bleeding lateroposterior to the lesion on the image on the right after having performed initial biopsy.
7.3.4 Analysis
Primary study parameters are radiation dose and diagnostic accuracy (over time) in a primary 
CBCT and AF approach, linked to an initial – generic - imaging protocol and the forthcoming 
availability of dedicated navigation bronchoscopy imaging protocols (over time). 
Radiation exposure - To evaluate radiation exposure of navigation bronchoscopies primarily 
guided by CBCT and AF, cases where other technological modalities were used as primary 
guidance were excluded for radiation exposure analysis (Figure 7.1). Radiation dose 
information was obtained using openREM software [148]. Procedural dose was routinely 
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reported through the DAP. The retrospectively computed effective dose (in mSv) is a less 
reliable dose estimate because its computation requires several parameters that are difficult 
to estimate in a continuously changing setting such as with CBCT and AF [149]. For enabling 
comparison against other imaging modalities, a limited set of average effective doses were 
however calculated with PCXMC [150]. For quantitative analysis of radiation dose (over 
time), boxplots and Shewhart individual control charts of accumulated Dose Area Product 
and counts are presented, further tested for significant differences by Kruskal-Wallis and 
ANOVA tests.
Diagnostic accuracy - To evaluate the continuous diagnostic accuracy of a catheter-based 
navigation bronchoscopy as primarily or secondarily guided by CBCT and AF in this single 
institution setting, all navigation bronchoscopies were included (Figure 7.1). Navigation 
success is defined as cases where imaging gives no doubt about lesion access as confirmed 
by at least CBCT with AF imaging, but can also include unambiguous r-EBUS imaging or 
ROSE outcome. Malignant and specific benign findings are considered true positive and 
negative if not negated by follow-up findings, respectively. Unspecific benign findings are 
considered true negative only if definitively confirmed by follow up CT guided TTNA, surgical 
biopsy and/or decisive clinical follow-up of at least 6 months (i.e. no measurable growth). 
Unrepresentative findings or unsuccessful navigations are considered false negatives 
regardless of follow-up outcome. The diagnostic accuracy is obtained by relating summed 
number of true positives and true negatives to total number of procedures. Time-dependent 
parameters are described by moving averages (10 procedures). 
Dichotomous variables were analyzed by a Pearson chi-square test or Fisher exact test. Not 
normally distributed continuous variables were evaluated by Mann-Whitney-Wilcoxon test. 
All p-values were two-sided and considered significant if <0.05. R and R-studio were used 
for statistical analysis [68]. 
7.4 Results
Patients with informed consent were included from the initiation of our CBCT and AF guided 
navigation bronchoscopy program (December 2017) until June 2020 (n=238, Figure 7.1). 
An exclusion of patients was performed for radiation dose evaluation in cases of a missing 
radiation report (10), a non-primary CBCT and AF based navigation (58), and, cases where 
navigation bronchoscopy was not performed on the systems under study (40), leaving 100 
cases for analysis. 
Secondly, 208 patients were eligible and prospectively included for the diagnostic accuracy 
analysis in this study. These 208 patients had a total of 248 lesions that were navigated to, 
with a median long axis diameter of 13 mm (range: 5-65 mm, Table 7.1). 
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7.4.1 Radiation exposure
At the start of our CBCT and AF guided navigation bronchoscopy program, average 
procedural DAP was 47.5 Gy·cm2 (effective dose 14.3 mSv). Initial average fluoroscopic 
DAP was 19.0 Gy·cm2 (5.2 mSv) and the initial total CBCT scan DAP as a consequence of 
performing 2.47 rotations per procedure was 29.9 Gy·cm2 (9.1 mSv, 3.7 mSv per scan).  As 
experience increased and the different fluoroscopic and CBCT imaging protocols gradually 
became available (along with the replacement of the CBCT system, Figure 7.1), procedural 
DAP gradually declined from 47.5 (estimated effective dose 14.3 mSv, initial period with 
original protocols) to 25.4 Gy·cm2 (5.8 mSv, low dose CBCT and fluoroscopy protocols on 
new Azurion CBCT system). Boxplots and Shewhart individual control charts of DAP per 
period can be found in Figure 7.3 and 7.4, respectively. Table 7.2 summarizes the average 
radiation characteristics per period.
Table 7.1 – Patient, nodule and procedural characteristics. Definitions: Bronchus sign – Image feature 
showing the lesion to be directly adjacent to a bronchus. Navigation success – CBCT imaging and/or 
unambiguous r-EBUS imaging verified access of the lesion. Diagn. Acc. (pat) – Procedural outcome of 
navigation bronchoscopy corresponding to follow-up outcome (see Methods). Abbreviations: LUL – Left 
Upper Lobe, RUL – Right Upper Lobe, RML – Right Middle Lobe, LLL – Left Lower Lobe, RLL – Right 
Lower Lobe, Malign. Prev. – Malignancy prevalence.
Patient characteristics
Patients / Lesions (n) 208 / 248
Sex M/F (n, %) 114 (55%) / 94 (45%)
Age (min – max) | Length |Weight | BMI 65 y (36-85) | 1.72 m | 74.9 kg | 25.3
Nodule and procedural characteristics
Median lesion diameter (min-max) 13 mm (5–65) Lesion locations n
Bronchus sign (@ ≤1 mm CT, lesions) 60.9% LUL  / RUL 67 / 85
Median navigation time (min-max) 29 min (4 - 100) / RML      / 11
Mean biopsy time (sd) 25.6 min (10.74) LLL / RLL 37 / 48
Mean tissue samples taken (min-max) 11 (0-25)
Procedural outcome
Lesion long axis size n Nav. Success Diagn. acc. (Pat) Malign. Prev.
≤10 mm 36 91.6% (33) 69.4% (25) 75%
>10-20 mm 113 88.5% (100) 73.5% (83) 71.2%
>20-30 mm 32 100% (32) 84.4% (27) 80.6%
>30 mm 27 100% (27) 88.9% (24) 74.1%
Overall 208 92.3% 76.4% 73.7%
The most important cause of the reduction in procedural radiation exposure was an altered use 
of fluoroscopy (Figure 7.3 & 7.4 - panel B). Becoming more experienced and implementing 
lower dose fluoroscopy protocols changed average fluoroscopy DAP from 19.0 Gy·cm2 
(effective dose 5.2 mSv) to 2.2 Gy·cm2 (0.37 mSv, p<0.01). This is counterintuitive to what 
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Figure 7.3 – Boxplots of radiation dose over time and per protocol becoming available (left to right). 
Box indicates 1st to 3rd quartile, line indicating median. Panel A - Total procedure radiation dose area 
product. Panel B - Procedural Fluoroscopy dose area product. Panel C - Procedural CBCT dose area 
product. Panel D -  Individual CBCT dose area product. Panel E - Procedural fluoroscopy time (s). Panel 
F - Amount of CBCTs performed per procedure. Also see Figure 7.1 for period partitioning based on 
CBCT system and protocol availability and Figure 7.4 for corresponding Shewhart Individual Control 
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Total Procedural DAP I - Chart Procedural Fluoroscopy DAP I - Chart
Individual CBCT DAP I - ChartTotal Procedural CBCT DAP I - Chart
Fluoroscopy Time I - Chart Amount of CBCT acquisitions I-chart
Figure 7.4 – Shewhart individual control charts of procedural radiation characteristics over time. Grey 
boxes indicate upper and lower confidence limits, horizontal line indicates period mean. Partitioning by 
the grey boxes based on CBCT system and protocols becoming available (see Figure 7.1 and Figure 
7.3)
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one would expect based on the monitoring of average total procedural fluoroscopy time. The 
initial average total fluoroscopy time was 592 seconds (9.9 min), and it gradually increased 
to an average of 935 seconds (15.6 min, p<0.01, Figure 7.3 & 7.4 - panel E). 
In the last study period, the bulk of radiation exposure was caused by CBCT acquisitions. 
While the individual average CBCT scan exposure changed significantly when comparing 
first to last scanning period (from 12.1 to 8.8 Gy·cm2, p<0.01, Figure 7.3 & 7.4 - panel D), total 
CBCT scan exposure did not (from an average of 29.9 to 23.4 Gy·cm2, p=0.24, Figure 7.3 & 
7.4 - panel C). This can be attributed to an increase in average number of CBCTs performed 
per procedure, from 2.47 to 2.93 (NS, Figure 7.3 & 7.4 - panel F). 
Table 7.2 – Average radiation dose characteristics per period, as defined per imaging protocols 
available (see Figure 7.1). At first instance, the Allura CBCT imaging system was available with original 
dose imaging protocols for both fluoroscopy and CBCT (n=26). From there on, consecutive changes 
were made in system, fluoroscopy or CBCT availability. Dose Area Products (DAP) are given for every 
subsequent period in Gy·cm2. Also see corresponding Figure 7.3 & 7.4. Abbreviations: acq. – CBCT 
rotational acquisition.
Time period System Fluoroscopy CBCT Total DAP
Protocol DAP Time Protocol DAP / acq. acq.
Period 1 (n=26)
Allura
Original dose 19.0 592 s
Original dose 12.1 2.47
47.5
Period 2 (n=7)
Low dose 7.1 817 s
45.3
Period 3 (n=24) Low dose 13.6 2.0 29.8
Period 4 (n=13)
Azurion Low dose 2.2 935 s
Original dose 13.8 2.25 28.2
Period 5 (n=30) Low dose 8.8 2.93 25.4
7.4.2 Diagnostic accuracy
A primary CBCT and AF approach was performed in 150/208 cases. A primary EMN 
approach was performed in the remaining 58 cases, with 40 of these cases taking place in 
the first 87 patients during the conduct of our previous study (comparing the EMN and CBCT 
approach) [128]. The diagnostic accuracy when taking into account all 208 consecutive 
procedures was 76.4% (Table 7.1). After concluding our previous trial comparing the EMN 
and CBCT approach at the beginning of 2019 (87 patients, diagnostic accuracy 72.4%, 
[128]), a temporary drop in accuracy is seen. This drop cannot be explained solely by factors 
like bronchus sign, lesion size, malignancy prevalence or a decline in navigation success 
(all p>0.05). In the subsequent period, dynamical decision making by the endoscopy team 
led to increasing the amount of biopsy samples obtained, as CBCT remained to consistently 
show accurate lesion access (Figure 7.5). Over the next period diagnostic accuracy 
gradually rose. From November 2019 to June 2020, the overall diagnostic accuracy was 
90.6% whereas navigation success was 98.4% (n=64 procedures).
 
CHAPTER 7122
Statistical analysis of overall procedural characteristics revealed that malignancy prevalence, 
bronchus sign presence and trans-parenchymal navigation did not have a significant effect 
on overall diagnostic accuracy. Variables that were statistically related to higher diagnostic 
accuracy were higher lesion diameter (p=0.014, 9 versus 15 mm median size), navigation 
success (p<0.001) and a higher number of tissue samples having been obtained (p<0.001, 
median 10 versus 12 samples).
7.4.3 The Learning curve effect
The learning effect can be derived from combining the information from both radiation 
exposure as well as diagnostic accuracy analysis. The average procedural DAP went down 
from 47.5 Gy·cm2 (effective dose: 14.3 mSv) to 25.4 Gy·cm2 (5.8 mSv), while the diagnostic 
accuracy went up from 72% to 90%. The learning effect in radiation safety is greatest in the 
use of fluoroscopy, where the total use time went up significantly (p<0.01) while a significant 
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Figure 7.5 – Diagnostic accuracy, navigation success and amount of tissue samples over time as found 
since the introduction of a CBCT and AF based navigation bronchoscopy (n=208 procedures included 
for analysis, moving average of 10 procedures). Diagnostic accuracy and navigation success on primary 
axis (left), amount of tissue samples obtained per procedure on secondary axis (right). Moving average 
plotted using previous values only (aligned right).
7.5 Discussion 
We show in a prolonged case series that radiation exposure as well as diagnostic accuracy 
in navigation bronchoscopy guided by CBCT and AF are subject to a significant learning 
effect. An increase in experience and a tailoring of imaging protocols towards the procedure 
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significantly reduced the radiation exposure while the diagnostic accuracy was enhanced. 
Total procedural DAP went down from 47.5 Gy·cm2 (effective dose: 14.3 mSv) to 25.4 Gy·cm2 
(5.8 mSv), while the diagnostic accuracy went up from 72% to 90%.
The ALARA principle dictates to use radiation as sparsely as possible. The recent forthcoming 
availability of specific imaging protocols for navigation bronchoscopy that facilitate different 
steps of the procedure with specific imaging quality shows to help the goal of reducing 
dose. Interestingly, the significant reduction in radiation dose as seen in our study persisted 
even though the 2D fluoroscopy time and number of CBCTs performed per procedure 
increased over time (Figures 7.3 & 7.4). Arguably, the increase in use may be caused by 
awareness in the reduction of radiation dose by newer protocols. We feel having additional 
imaging options with lower dose lowered the threshold for additional (confirmatory) imaging. 
In turn, this additional confirmation might have increased our diagnostic accuracy by more 
meticulous positioning.
In an increasingly crowded technology field for aiding diagnosis of peripheral pulmonary 
lesions, the endoscopist likely has to choose between different technological guidance 
modalities or which combination to use. The endoscopist should aim for high accuracy, keep 
the amount of radiation involved as low as possible, and, simultaneously take into account 
the procedural costs.  We previously showed that using CBCT and AF only after having 
performed EMN navigation significantly reduced fluoroscopy time and amount of CBCT 
scans performed [128]. In the current study we show the radiation dose has decreased 
significantly since. And while the patient will receive both CBCT as well as fluoroscopy 
dose, the staff dose is mainly caused by fluoroscopic exposure (as they leave the area 
during CBCT). Considering the accuracy of the CBCT guided navigation bronchoscopy, the 
procedural radiation burden for the patient when related to other procedures and associated 
cost of some of the additional navigation guidance modalities, one needs to individually 
assess if having multiple navigation guidance modalities remains worthwhile.
As CBCT and AF guidance allows for biopsy with great detail, an elaborate reflection on 
technique is possible. Shortly after completing our previous study, we observed a decline in 
diagnostic accuracy (Figure 7.5). As we have real-time CBCT imaging information available 
and discuss all cases in the multi-disciplinary tumor board shortly following the procedure, we 
concluded that inadequate tissue acquisition after successful navigation was a likely cause 
of error. Following these findings, more time was spent on tissue acquisition. Consecutively, 
the diagnostic accuracy improved to as much as 90.6% in the last 64 procedures (Nov 
2019 – June 2020). We experience that having confirmed biopsy positioning on CBCT also 
provides additional certainty in case of benign pathology findings. 
7.5.1 Study limitations
The reduction in radiation dose - as time passed and the team became more experienced 
– was caused by both dedicated protocols as well as more aggressive collimation and 
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targeted imaging. Detailed collimation information was not available in our dataset and could 
therefore not be presented. Furthermore, it is difficult to evaluate how our single center results 
equate to other centers. For one, average patient BMI should be taken into account (25 in this 
study, Table 7.1), as this might significantly affect radiation use outcomes. Another limitation 
herein was our continuous awareness of radiation safety, as it was directly under study. This 
might have significantly attributed to an increased learning speed. 
7.6 Conclusion
In this single institution study, we show radiation dose of a CBCT and AF guided navigation 
bronchoscopy are of acceptable levels but also subject to a significant learning effect. 
With the implementation of new specific navigation bronchoscopy imaging protocols along 
with increasing experience, procedural radiation dose could be reduced from 47.5 Gy·cm2 
(effective dose: 14.3 mSv) to 25.4 Gy·cm2 (5.8 mSv), while the diagnostic accuracy went 
up from 72% to 90%. Concluding, navigation bronchoscopy using CBCT and augmented 
fluoroscopy-imaging as a sole technique for both navigation and sampling is a (relatively) 
safe and accurate procedure for diagnosis of small peripheral pulmonary lesions.
7.7 Statement of Ethics 
The research was conducted ethically in accordance with the latest World Medical Association 
Declaration of Helsinki. The study protocol was approved by the independent local medical 
ethical committee (Arnhem-Nijmegen) and institutional review body before start of subject 
inclusion. Informed consent was obtained. 








Lung cancer is the most prevalent form of cancer worldwide, exceeding 2.2 million new 
cases every year. The incidence will continue rising in the upcoming years, with 3.2 million 
cases expected in 2035 [2]. With approximately 13.800 new lung cancers being diagnosed 
in 2019, it is also the most prevalent form of cancer in the Netherlands. Unfortunately, the 
disease often only presents itself with symptoms at a late stage. Consequently, approximately 
50% of patients are only diagnosed at end stage disease (stage IV). Once other organs are 
involved – as indicated by disease stage IV – 5-year overall survival drops to approximately 
5%. Comparing this to the 61% 5-year overall survival in patients with stage I disease, a stage 
where there’s no disease present other than a primary tumor, shows earlier diagnosis brings 
a significantly improved outcome [1]. Yet as even the earliest stage of disease remains to 
have high mortality, all possibilities of improving outcome should be explored. To do so, one 
important aspect is to timely and accurately diagnose and stage patients with a suspected 
or proven lung cancer to prevent unneeded disease progression, under-, and overtreatment. 
In this thesis it is described how clinical technology in flexible endoscopy might help improve 
the diagnostic and staging trajectory of lung cancer. 
Part I – Endoscopic staging of suspected or proven lung cancer using 
ultrasound techniques
Flexible endoscopic procedures using the airways and esophagus are a frequently 
performed and recommended feat in diagnosis and staging of a suspected or proven lung 
cancer. Once CT and/or FDG-PET imaging have shown a primary tumor finding along with 
a likely lymph nodal involvement, a combined endobronchial and esophageal ultrasound 
guided evaluation of mediastinal and hilar lymph nodes should be systematically performed. 
These so-called EBUS-TBNA and EUS-FNA procedures use a video camera and ultrasound 
transducer positioned at the distal tip of an endoscope for allowing assessment of the 
differently defined anatomical lymph node regions. If ultrasound imaging shows lymph 
node findings, a hollow needle is inserted through the endoscope and into the tissue for 
ultrasound imaging guided needle aspiration. While PET-CT and/or CT imaging allows for an 
imaging-based diagnosis, eventual tissue diagnostics will need to provide a definite answer 
(pathological outcome). During endoscopic evaluation, all lymph nodes of the anatomically 
defined regions need to be systematically assessed. A systematic assessment implies first 
evaluating the least suspected contralateral nodes and moving back to the most suspected 
ipsilateral lymph node regions from there. At least all suspected lymph nodes as identified 
by increased FDG uptake on PET-scan and enlarged size on CT need to be aspirated by 
a hollow needle under guidance of ultrasound to obtain cells for cytological examination. 
In deciding on aspiration of additional nodes or specific nodes within an anatomical lymph 
node region, ultrasound characteristics are often used. 
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In Chapter 2 the feasibility of a relatively new technique in the endobronchial examination of 
mediastinal and hilar lymph nodes is described; ultrasound strain elastography. Ultrasound 
strain elastography visualizes relative tissue elasticity by calculating differential tissue 
motion from subsequently acquired ultrasound images while a deformation of tissue is being 
induced. The strain is calculated by monitoring the deformation of the different parts of 
imaged tissue over time. The deformation in endosonographic strain elastography is induced 
by the cardiovascular system. A lower strain – less deformation over time – is hypothesized 
to be an indication for malignancy. Chapter 2 describes how and if endobronchial ultrasound 
strain elastography can help identify malignant lymph nodes in a single center study. By 
comparing the different available methods of relaying strain information back to the user, 
the accuracy of endobronchial ultrasound strain elastography for predicting lymph node 
malignancy was explored in a single center study setting. To evaluate the different scoring 
methods, endobronchial ultrasound strain elastography measurements of 120 lymph nodes 
(63 patients) with a suspected or proven lung cancer were analyzed. Measurements were 
obtained using a standardized measurement protocol as developed preceding to study 
initiation. It was found a prediction on lymph node malignancy using ultrasound strain 
elastography was best done by relating the mean relative strain as found in the lymph nodal 
area against the full remainder of the image, enabling the most objective scoring. The lymph 
node region of interest was hand-selected by the operator. By using a normalization of the 
found strain to assure every consecutive image had at least one component with 0 strain and 
at least one component with a strain of 255, the found strain had range 0-255. Analysis of this 
scoring method revealed the Receiver Operator Characteristic – Area Under the Curve to be 
0.846. A strain cut-off of 78 (range 0-255) then showed to differentiate malignant lymph nodes 
with a sensitivity of 93%, specificity of 75%, positive predictive value of 69% and negative 
predictive value of 95% (accuracy; 82%). Lymph nodes with a mean strain <78 (range 0-255) 
showed to have higher chance of being malignant than lymph nodes which had a mean 
strain ≥78. A further exploratory analysis showed that PET-CT information can potentially be 
used in adjunct to strain elastography for better stratification of risk of malignancy.
Chapter 3 describes a prospective multi-center international study (n=5) which evaluated 
endobronchial ultrasound strain elastography and its predictive value in the clinical lung 
cancer staging work-up. In this study, a total of 327 patients equivaling a total of 525 
lymph node measurements were included according to the insights of the endoscopists. 
Malignancy prevalence in the included lymph nodes was 0.48. Analysis of the Receiver 
Operator Characteristic showed the total Area Under the Curve of ultrasound strain 
elastography for identifying lymph nodal malignancy was 0.77 in this multi-center setting. 
With this area under the curve it was concluded that strain elastography indeed shows to 
be of stand-alone predictive value. To identify malignancy with high sensitivity, the strain 
elastography cut-off value as was presented in chapter 2 however needed revision; from 
78 to 115. In this multi-center setting, strain elastography then had 90% sensitivity, 43% 
specificity and a positive and negative predictive value of 60% and 82%, respectively. As 
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strain elastography was hypothesized as an adjunct predictor after FDG-PET and CT-scan 
imaging had already become available, the predictiveness of integrating FDG-PET and size 
information with ultrasound strain elastography findings was secondarily evaluated. It was 
found that strain elastography could indeed consistently help identify malignant nodes in 
multi-modal imaging work-up. Based on these results, two decision trees were presented 
that could help in routine clinical work-up.
 
Routine clinical practice and several studies have reported using imaging features as seen 
on endosonographic B-mode imaging to help the observer decide on the lymph nodes of 
risk. It was found individual features or a combination thereof might be of predictive value 
[46–49,88,95–98]. However, the predictive value of the features as described in these 
predominantly single center studies were concluded to be differing [17]. Possibly, this was 
(at least in part) caused by a difference in how B-mode features were scored [95,98]. As 
the outcome of systematic endosonographic assessment and aspiration of lymph nodes 
can prevent the need of more invasive cervical mediastinoscopy staging and determine 
follow-up treatment, one can question if subjective scoring of features remains desirable. 
Chapter 4 describes an evaluation on the accuracy and reproducibility of subjectively 
scored endosonographic B-mode features for identifying malignant lymph nodes. In 
this chapter, specific focus is placed on the feasibility of B-mode feature scoring in sub-
centimeter lymph nodes, as larger lymph nodes should be aspirated regardless [10]. To 
assess if subjectively scored features are of value, 490 lymph nodes as prospectively scored 
during the international multi-centric study of chapter 3 were analyzed. In this dataset, the 
Area Under the Curve of the Receiver Operator Characteristic for ultrasound short axis size 
to identify lymph node malignancy was 0.78 (95% confidence interval 74-82%). The clinically 
feasible 8 mm cut-off for routine aspiration showed able to correctly identify 210 out of 237 
included malignant lymph nodes (sensitivity 89%, specificity 46%, positive predictive value 
61%, negative predictive value 81%). Adding the suggested subjectively scored B-mode 
criteria was feasible but deemed of limited value. As well known to the frequent ultrasound 
user, ultrasound is prone to observer interpretation variability. A secondary retrospective 
scoring of a subset of the collected lymph nodes images (n=200) was performed to assess 
observer variability. A significant observer variability was found when both experts (>400 
procedures, n=5) and experienced endoscopists (50-400 procedures, n=3) were asked to 
retrospectively classify lymph nodes into malignant or benign based on combined B-mode 
features. The average inter-observer raw agreement in expert and intermediately experienced 
observer was 71-74% (Gwet’s AC1 0.42-0.48) while the intra-observer raw agreement was 
80-86% (Gwet’s AC1 0.60-0.76). As the agreement was found to be different for the different 
subsets of nodes (i.e. <8 mm, ≥8 mm, benign nodes, malignant nodes), risk stratification 
by means of subjective (B-mode) characteristics was concluded to be of non-uniform and 
limited predictive value. 
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Part II – Clinical technology for the diagnosis of peripheral pulmonary 
lesions
Imaging modalities like CT are increasingly often performed in routine clinical care for a 
plurality of diseases or follow-up thereof. Imaging where the lungs have also been depicted 
reveal the presence of a pulmonary lesion in an average of 13% of CT-scans [32]. When such 
imaging accidentally reveals a pulmonary nodule without further mediastinal and/or hilar 
lymphadenopathy, the risk of benign disease is more likely than that of malignant disease. 
Yet, the diagnosis of a malignancy will eventually be made in approximately 1.5% of these 
patients [32]. Knowing the potential benefit when diagnosing early stage lung cancer (stage 
I-II), residing at a far better treatable stage as compared to more advanced disease, follow-
up of accidental findings is warranted. The same potential benefit of such early findings is 
also the reasoning why an increasing number of countries have started or are preparing to 
start a national lung screening program [25–30]. Studies show that the lung-cancer related 
mortality risk in a high-risk population can be reduced by at least 20% if a CT-screening 
is to be introduced [26,31]. These CT-scans in both routine clinical practice as well as a 
screening setting detect numerous nodules and rapidly increase the demand for minimal 
invasive accurate and safe diagnostic and therapeutic procedures.
The strategy for obtaining a tissue diagnosis of a peripheral pulmonary lesion is not clear cut, 
as there’s no single ‘do it all means’ for safely doing so. Potential minimally invasive options 
are a trans-thoracic CT guided needle biopsy approach and an endobronchial approach. 
The trans-thoracic needle approach has a high pooled sensitivity of 91% and negative 
predictive value of 80%, but also results in health complications such as a pneumothorax in 
more than 20% of cases [32,44]. The historically used alternative endobronchial approach 
utilizes the airways for navigation and consecutive biopsy of a peripheral pulmonary 
nodule under guidance of x-ray fluoroscopic imaging. It is a safe method, but also is of 
poor sensitivity (pooled yield 34%) [34]. The forthcoming availability of new technology in 
the past decades has however helped the endoscopist to increase the sensitivity of the 
endobronchial approach to approximately 70-80%, while retaining the complication rate at 
less than 2.0%. Reported technologies for doing so are based on electromagnetic tracking 
of tools, miniaturized ultrasound probes for verification of nodule access, virtual endoscopy 
navigation guidance, robotic assistance and/or ultrathin bronchoscopes [39,41]. 
Chapter 5 describes the introduction of a combination of technologies in order to assess 
if these can help improve the physician in obtaining a safe and accurate endobronchial 
diagnosis of peripheral pulmonary lesions. In a comparison of workflows, the added value 
of the differently available technologies was assessed. The first methodology for navigating 
towards peripheral pulmonary lesions consisted of combining electromagnetic navigation 
technology with endobronchial mini-probe ultrasound imaging for navigation and confirming 
nodule access. The second methodology performed navigation by using a cone beam 
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CT imaging system in combination with the same ultrasound imaging mini-probe for local 
confirmation of access. After finding either navigation success or failure by the primary 
methodology of navigation, lesion access was verified by cone beam CT imaging as a 
golden standard. A total of 87 patients with 107 pulmonary nodules were included in the 
two workflows. By a primary electromagnetic navigation technology approach, 52.2% of 
lesions were accurately reached. By a cone beam CT guided navigation, 76.3% of lesions 
were accurately reached. Being able to combine technology guidance after having initially 
confirmed an unsuccessful navigation on CBCT imaging showed to increase navigation 
success to 87.5-89.9% in both arms. Obtaining adequate tissue that was representative 
of follow-up outcome after a successful navigation was found not self-evident. Patient 
follow-up revealed that only 72.4% of navigation bronchoscopies eventually resulted in 
an accurate patient diagnosis. The overall pneumothorax rate was 3.4%. Based on these 
outcomes it is concluded that the navigation bronchoscopy workflows under study are safe, 
and, the preferential primary workflow for diagnosis of lesions is the cone beam CT imaging 
enhanced procedure. Due to the >15% difference in having successfully reached the lesion 
and obtaining a representative diagnosis, it is secondarily found that there is both a need to 
improve navigation guidance as well as tissue sampling accuracy.
Chapter 5 describes that there is a difference between successfully reaching the peripheral 
pulmonary nodule and obtaining an accurate diagnosis. Several factors might be to blame. 
Chapter 6 describes an evaluation of the differently available endobronchial tissue sampling 
tools and rapid on-site evaluation of cytopathology for their yield in procedures where 
lesion access had been confirmed. This was done by a direct comparison of instruments 
and procedure reports in a total of 195 successful navigation bronchoscopy procedures. 
In these 195 procedures, 225 lesions with a median long axis size of 15.0 mm (range 
5-65 mm) were sampled with either one or multiple instruments. It was therein found that 
sampling outcome corresponded to follow-up outcome in 75.1% of lesions, which resulted 
in a diagnosis in 80.5% of study subjects. Histology findings - as obtained from cryobiopsy 
and forceps sampling - were found to result in an accurate diagnosis in 72.4% of instances. 
Cytology findings - considering broncho-alveolar lavage, brush and trans-bronchial needle 
aspiration – correlated to gold standard follow-up outcome in 49.3% of lesions. Analysis of 
cases where both cytology and histology were obtained showed histology was significantly 
more often accurate in all lesions, be it malignant or benign (p-value <0.01). Histology 
outcomes by themselves furthermore showed accurate significantly more often in benign 
lesions than in malignant lesions (88.6% vs 66.9%, respectively). These findings did not 
similarly hold for cytology outcome (48.5% vs 51.9%, respectively). In lesions where an 
accurate diagnosis was obtained, significantly more sampling was performed (9.72 vs 11.91 
samples, p=0.014). An accurate diagnosis was most often obtained by forceps (accuracy 
70.6%), followed by 1.1mm cryoprobe (68.4%), trans-bronchial needle aspiration (46.7%), 
1.9mm cryoprobe (41.2%), brush (30.3%) and lavage (23.7%). As a consequence of the 
49.3% overall cytology sampling accuracy and a discordance of ROSE with final malignant 
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cytology findings (27.9%), ROSE was found to be correlating to procedural malignant finding 
outcome in only 47.5% of lesions. Confirmation of malignancy on ROSE also did not reduce 
amount of biopsies taken nor biopsy time. The results as described in Chapter 6 show there 
is currently no single approach or methodology that is a do-it-all for obtaining an adequate 
tissue diagnosis, and, that additional research is therefore warranted.
Chapter 7 describes the changes in the radiation exposure and diagnostic accuracy of the 
cone beam CT guided navigation bronchoscopy procedure with increasing experience and 
the tailoring of imaging protocols to the navigation bronchoscopy setting in a single institution 
study. The potential learning curve experience of both radiation exposure and diagnostic 
accuracy were obtained by analyzing all consecutive cone beam CT guided navigation 
bronchoscopy procedures as performed at the Radboudumc (Dec 2017 – June 2020). It 
was found that radiation dose during the initial introduction phase of the cone beam CT 
guided navigation bronchoscopy (Chapter 5) were of acceptable levels (dose area product 
47.5 Gy·cm2, effective dose: 14.3 mSv). After having concluded the comparison of workflows 
as described in Chapter 5, the choice was made to primarily navigate towards the peripheral 
nodule using cone beam CT guidance. By the forthcoming availability of new specific 
navigation bronchoscopy imaging protocols along with becoming increasingly experienced, 
procedural radiation dose could be reduced from an initial 47.5 Gy·cm2 (effective dose: 14.3 
mSv) to 25.4 Gy·cm2 (5.8 mSv). Simultaneously, the diagnostic accuracy went up. The initial 
diagnostic accuracy as described in chapter 5 was 72.4% in the first 87 patients. After a total 
of more than 208 procedures, the last 64 patients (November 2019 – June 2020) resulted in 
a procedural accuracy of 90.6% (navigation success 98.4%). The navigation bronchoscopy 
procedure was thus found subject to a learning curve, with more experience and a tailoring 
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The research described in this thesis was focused on technological innovations in 
endobronchial lung cancer staging and diagnosis. 
Part I of this thesis describes ultrasound strain elastography as a means that can help identify 
likely malignant lymph nodes in both a single center as well as a multi-center study setting. 
Whereas it was found of predictive value in the single center setting, the multi-center study 
further showed that ultrasound strain elastography could be integrated with other clinically 
available predictors such as FDG-PET and lymph node size for enhancing malignancy risk 
prediction. These findings were dissimilar to that of subjectively rated ultrasound B-mode 
characteristics. Subjective B-mode feature scoring was found of limited value for malignancy 
risk stratification because of suboptimal accuracy and inter- and intra-observer variability in 
scoring. 
Part II of this thesis describes the introduction of the cone beam CT guided navigation 
bronchoscopy procedure for the diagnosis of suspected peripheral pulmonary lesions. By 
analysis of two navigation bronchoscopy workflows that comprised a different combination 
of technological assistance, the comparative diagnostic accuracy was assessed. Navigation 
to small lesions showed to be most successful if cone beam CT guidance was used as a 
primary navigation methodology. However, combining the methodologies of both workflows 
after having found an initial unsuccessful navigation in either resulted in highest success. The 
peripheral pulmonary lesions were then successfully reached in 88-90% of cases. Follow-up 
outcome showed this led to an accurate diagnosis in 72% of patients. Additional work was 
performed to assess how different factors affected the outcome of technology enhanced 
navigation bronchoscopies. An evaluation of tissue sampling methodologies in imaging 
verified successful navigations showed that the difference between navigation success 
and diagnostic accuracy can in part be explained by sampling tool error. Not all acquired 
tissue will reveal an adequate pathology outcome. As such, it is concluded that future work 
to increase sampling accuracy is warranted. A secondary evaluation of consecutive cone 
beam CT guided navigation bronchoscopies showed how procedural accuracy and radiation 
exposure can evolve over time. Obtaining additional experience in the cone beam CT guided 
navigation bronchoscopy resulted in an increase in the diagnostic accuracy and navigation 
success. Becoming more experienced in combination with a tailoring of the cone beam CT 
imaging protocols to the procedure also showed to significantly reduce procedural radiation 
dose. Combined, the findings as described in this thesis show that technological guidance 
can help improve the endobronchial diagnostic and staging accuracy in (suspected) lung 
cancer. They are small steps towards improving the outcome of lung cancer patients. On 
basis of these findings, several points for discussion as well as (near) future directives can 
be given. These points are relevant for the field of pulmonary oncology and interventional 
pulmonology, but underline the need of a more diverse and multi-disciplinary approach in 
order to achieve our common goal.
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9.1 Endosonography and strain elastography 
Endoscopic ultrasound evaluation of lymph nodes is routinely performed to stage and therewith 
prove both absence and presence of disease in individual lymph nodes. If a mediastinal 
lymphadenopathy remains unproven after endoscopic needle aspiration while earlier PET-CT 
imaging findings are deemed abnormal, performing a cervical mediastinoscopy is indicated 
[6]. Current recommendations propose to complete a systematic endosonographic staging 
by going from the least to the most suspected site. Sampling of at least stations 4R, 7 and 
4L along with additional imaging suspected nodes should be performed, by combining an 
endoscopic assessment from both the airways as well as the esophagus [6,10]. A widely 
regarded meta-analysis and systematic review by Korevaar et al. (2016) found the pooled 
sensitivity and negative predictive value for detecting metastatic N2/N3 disease in such 
a combined systematic EBUS-EUS (endobronchial ultrasound & esophageal ultrasound) 
approach was 86% and 92%, respectively [15]. However, while the included studies focus 
most on the added value of combining EBUS with EUS for increasing sensitivity, less attention 
is brought upon the individual study criteria for deciding on aspiration in the first place. A 
study by Crombag et al. (2018) for example stated systematic staging, but further defined 
that stations 4R, 7 and 4L only needed to be aspirated if the short axis diameter was ≥8 mm, 
resulting in a sensitivity of 82% and negative predictive value of 87% for staging of N2/N3 
disease [13]. Annema et al. (2010) reported a sensitivity of 85%, where sampling involved 
aspiration of observer interpreted suspicious lymph nodes (≥10 mm size, FDG-PET avid and/
or those with suspicious ultrasound criteria) [12,46]. Hwangbo et al. (2010) found sampling 
of all ≥5 mm lymph nodes had 91% sensitivity and 96% negative predictive value, while 
Ohnishi et al. (2011) had similar methodology and found a slightly lower sensitivity of 84% 
and NPV 94% for identifying malignant N2/N3 disease [151,152]. The similarity of the study 
outcomes are peculiar when considering the findings presented in part I of this thesis. In the 
performed multi-center study, strain elastography lymph node measurements were included 
per judgement of the observer. In total, 31 out of 159 included <8 mm short axis lymph nodes 
were found malignant (disease prevalence 0.19). Several of <8 mm lymph nodes would likely 
not have been considered for aspiration in some of the aforementioned studies. From these 
findings it can be hypothesized that systematic EBUS-EUS should routinely include sampling 
of all ≥5 mm lymph nodes, if clinically possible. The clinician will however also be well aware 
that exhaustive staging of lesser suspected lymph nodes is not always possible, and, that 
there is also the possibility of unrepresentative cytology findings [13,94]. The question then 
becomes what observer decision making should include. As is described in this thesis, even 
experienced endoscopists cannot reproducibly score lymph node risk based on B-mode still 
images. Likely, it is the time-stressed and unrepresentative findings scenario where strain 
elastography is of most immediate clinical relevance. Strain elastography in combination with 
other predictive values could help identify likely malignant nodes which should be subject to 
radiotherapy if exhaustive sampling was not possible, or, could help more objectively decide 
on which nodes to sample within a certain region intra-procedurally. 
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9.2 Endosonographic staging in early disease 
The meta-analysis by Korevaar et al. analyzed all available studies that performed systematic 
endosonographic mediastinal staging for N2/N3 disease and found a pooled sensitivity of 
86% and NPV 92% [15]. Detailed information on PET-CT/CT suspicion and pre-procedural 
imaging based nodal staging in the included studies is lacking. As the intent is to move 
towards earlier diagnosis of lung cancer, knowing its potential improved outcome, an 
imaging negative mediastinum and/or hilum is likely to be more frequently found (cN0/cN1). 
Data on the sensitivity and use of endosonographic staging in these patients is scant. A 
prospective study by Dooms et al. reported using EBUS-TBNA – only sometimes combined 
with EUS-FNA – in a group of 100 patients suspected of cN1 NSCLC disease. Eventual N2/
N3 prevalence was found to be 24%, and endoscopic staging therein identified malignancy 
with a sensitivity of 38% and specificity of 81%. Only 10 out of 24 metastases were correctly 
identified. Five out of 14 lymph nodes were missed because of unrepresentative cytology 
findings or because the lymph nodes were unreachable by endosonography [153]. Ong et 
al. performed a detailed retrospective analysis on 220 patients with cN0 disease. They found 
cN0 was upstaged because of EBUS in 18 cases (N1=11, N2=6, N3=1), because of surgery 
in 27 cases (N1=19, N2=8), and because of imaging follow-up in 4 cases (N1=2, N2=2) 
in a total of 49 out of 220 patients. Overall, this would have resulted in an EBUS sensitivity 
of 36.7% and NPV of 84.7%. However, an exclusion of the lymph nodal stations that were 
anatomically unreachable by EBUS-TBNA would lead to a hypothetical sensitivity of 60% and 
NPV of 93.4% [154]. Yasufuku et al. retrospectively assessed potentially resectable cN0/cN1 
lung cancer of 163 cases and finds a systematic staging of all ≥5 mm lymph nodes awarded 
with a diagnostic accuracy of 96.6% (sensitivity 76.2%). All false negatives were found to be 
located beyond lymph node region 11 [155]. The limitation that endosonographic staging 
does not allow easy sampling of regions 3, 5 and 6 is mainly relevant for N2/N3 disease. If 
we however are able to consistently move towards a need for N0 disease differentiation, a 
similar problem is found. No endoscope is currently able to evaluate or sample any region 
beyond station 11 (left or right). And additionally, it is likely clinical N0 staging will not incur 
(extensive) lymph node evaluation in the first place [32]. Problematic, as our recent in-depth 
analysis of surgically treated patients for resectable lung cancer showed that clinical N0 
staging was found to contain occult nodal involvement (N1/N2) in 23.1% of patients [156]. 
A finding corroborated by DuComb et al. (2020) [157]. Combined, these findings suggest 
that current (endosonographic) staging solutions are inaccurate in assessing lymph nodal 
involvement in suspected early stage (N0/N1) lung cancer. Furthermore, whereas surgery 
would eventually reveal true nodal involvement in case of lobectomy, these adverse findings 
have important consequences for non-surgical therapies and when considering limited 
resection. With no currently available means that fill this gap, it seems there is a great need 
for future technology that would enable more sensitive minimally invasive staging of lung 
cancer.
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9.3 Strain elastography standardization 
Strain elastography can help identify malignant hilar and mediastinal lymph by itself, and, 
in combination with either one or the combination of FDG-PET avidity and short axis size 
measurements. This was concluded in this thesis by performing an international multicenter 
study with a standardized measurement protocol, and, by harmonizing the systems and 
their settings. What should not be disregarded is that ultrasound strain elastography is a 
semi-quantitative measure, relying on ultrasound processing settings and a customizable 
methodology for relaying the output back to the user. The future widespread availability of 
strain elastography will depend on further collaborations with the industry and/or the ability of 
making a stand-alone (standardized) application that can be run alongside the EBUS-TBNA 
procedure. Alternatively, development of imaging options that would allow for objective 
quantification of stiffness would also be of high interest (i.e. shear wave elastography).
9.4 Quantitative ultrasound 
Subjectively scored ultrasound B-mode features have repeatedly been studied as potential 
means of predicting lymph node malignancy [46,47,88,95]. In this thesis it is shown that 
these features individually indeed have some predictive value, but also showed that their 
subjective scoring results in considerable intra- and inter-observer disagreement. Future 
work is needed to assess if subjective means can be replaced by quantitative and therewith 
objective features. Ultrasound system related features that can be of interest are for example 
the attenuation coefficient and speckle size [158]. Image segmentation features such as 
region of interest entropy, volume, and shape can possibly be correlated to earlier studied 
subjective features and are also relevant. Artificial intelligence-based algorithms for lymph 
node recognition and risk prediction are another feasible option – at least to obtain a 
reproducible scoring – but convey the likely need of a large database with standardized image 
settings for high accuracy. The potential information that is contained within (conventional) 
ultrasound imaging for identifying malignancy remains to be (objectively) investigated. 
Moving away from high disease burden will furthermore involve lower lymph node disease 
burden (and therewith possibly micro-metastatic disease), which can also have a profound 
consequence on deductible imaging features.
9.5 Standardized multi-modal staging 
Lymph nodal staging in lung cancer is highly dependent on the different imaging modalities 
used and (subjective) expertise of multiple physicians. Each of these modalities have 
their limitations and detection limits. And while all imaging is performed in (internationally) 
protocolized fashion, no standard way of interpreting results is available. In clinical practice, 
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the multi-disciplinary team will have a leading role in determining staging. The CT is interpreted 
by a radiologist, the PET-CT by the nuclear medicine physician, the EBUS procedure by the 
pulmonologist and sampling results by the pathologist. The pulmonary physician, surgeon, 
radiation oncologist and (pulmonary) oncologists will discuss staging results along with 
patient characteristics in the multi-disciplinary tumor board, from which a strategy is decided 
upon. An algorithm or standardized model that is able to recombine multi-modality imaging 
in an accurate and reproducible staging available to the different specialties in the blink of 
an eye would be of great value.
9.6 Navigation bronchoscopy
The Radboudumc is the first center in the Netherlands to implement the cone beam CT guided 
navigation bronchoscopy procedure in routine clinical care. In Chapter 5 it is described how, 
in an initial experience, an accurate diagnosis is obtained in 72.4% of patients through this 
minimally invasive procedure. Subsequently monitoring how the diagnostic accuracy and 
radiation exposure evolved over time showed that becoming more experienced significantly 
changed procedural characteristics. While reducing radiation dose, the diagnostic accuracy 
was increased. As such, it shows the cone beam CT guided navigation bronchoscopy is an 
adequate methodology for moving towards earlier and improved diagnosis of suspected and/
or proven lung cancer. The intent of a minimally invasive safe and accurate means of diagnosis 
is relevant considering at least 46% of Dutch early stage lung cancer patients in 2017 and 2018 
were treated (by surgery or radiotherapy) for a known or suspected lung cancer without having 
a tissue diagnosis [159]. As the study by IJsseldijk et al. (2019) and an accumulation on wedge 
resection study results also imply, this translates to a significant number of patients receiving 
radiotherapy or surgery with curative intent for a non-malignant pathology [32,45]. Ideally, one 
would omit both watchful waiting and therapeutic applications without a diagnosis only if there 
is a certain benign or malignant finding, respectively. At current, the suboptimal outcome of 
minimally invasive strategies along with their invasiveness however trouble this. Only limited 
(American) health technology assessments are furthermore available on the patient outcome 
and cost-effectiveness of this risk stratification procedure [160–162]. One of aforementioned 
studies concluded that a diagnostic strategy of PET-CT, navigation bronchoscopy or CT-
guided TTNA should be preferred above video-assisted thoracic surgery (VATS) only if chance 
of malignancy is at least 85%. In their health technology assessment they however did not 
consider (non-diagnostic) radiotherapy applications nor did they specify that the QALY is 
reduced in cases where the patient is left with anxiety due to a watchful waiting strategy. 
Moreover, the estimated accuracy of navigation bronchoscopy might be different from that as 
described in this thesis. Future research is required to identify the best work-up and further 
improve the minimally invasive field. One would however expect the cost-effectiveness scenario 
of needing to diagnose yes or no becomes increasingly ill-posed as the means of minimally 
invasive diagnosing lesions becomes an increasingly safe, easy and reliable method. 
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9.7 Clinical navigation technology learning and adoption 
The implementation of techniques in clinical setting is often directed towards either 
simplifying or improving routine clinical practice and its outcome. The cone beam CT guided 
multi-modality navigation bronchoscopy showed the potential to improve clinical outcome, 
especially when performed by experienced hands. It is however to be questioned if the cone 
beam CT guided navigation bronchoscopy procedure as introduced in this thesis is simpler 
(to the less experienced endoscopist) than other previously available means or oncoming 
techniques like robotic assisted bronchoscopy [41,163–165]. Initial in-vivo experience reports 
by robotic bronchoscopy – utilizing pre-procedural CT information and endoscopic imaging 
along with endoscope position sensing – state their immediate navigation success is >95% 
[108,165]. A recently launched integrative guidance system which combines pre-procedural 
CT with radial ultrasound mini probe imaging and 2D fluoroscopy for augmented fluoroscopic 
guidance equally reports a 93-95% navigation success rate [163,164]. As these modalities 
report a higher navigation accuracy than our initial multi-modal cone beam CT experience 
(89%), these could prove valuable in improving or simplifying navigation success. Surely, 
the ease with which the endoscopist is able to navigate towards the lesion and the cost 
of doing so will have a high impact on the choice of modality. To make the cone beam CT 
guided navigation bronchoscopy a more widely accepted and implemented methodology, 
future efforts should be made to improve its intuitiveness. This can for example be done 
by developing a virtual endoscopic view from the available 3D CBCT and 2D fluoroscopic 
imaging, or conversely, providing an automatic overlay of the complete endobronchial tree 
on the 2D fluoroscopic image.
9.8 Representative tissue is the issue 
Based mostly on the study by Lee et al., it is suggested endosonographic lymph node staging 
should involve at least 3-4 needle aspirations of individual lymph nodes. Lee et al. reports 
a 95.3% sensitivity of individual lymph nodes and obtaining a sample adequacy of 100% 
after 3 consecutive aspirations [17,94,166]. Needle aspiration is generally performed under 
direct endosonographic imaging to confirm penetration of the target tissue, supposedly 
leaving little room for error. One could however reckon that needle revolutions inside an 
area of interest are not necessarily representative of the complete region of interest, even 
if several different sites upon consecutive sampling attempts are chosen. This reasoning 
becomes especially relevant as disease burden in the assessed lymph nodes becomes low. 
Sampling in navigation bronchoscopy is similarly but even further complicated as there’s 
currently no real-time exact guidance in acquiring histology or cytology specimens. Real-
time tissue sampling guidance as used in Chapters 5-7 of this thesis was available only by 
external imaging such as X-ray fluoroscopy. With modalities such as fluoroscopy imaging 
from an external reference point in a moving lung, a sampling error is easily made. And with 
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every sampling instrument having a slightly different rigidity in a very soft and deformable 
lung, a change in lesion contact and a suboptimal catheter angulation as a consequence of 
changing catheter shape is easily found. With no means of compensating for this currently 
available – aside of the robotic endoscope which is not yet available to the European market 
– it seems there is room for improvement. These findings are corroborated by the majority of 
studies, which all report a difference between navigation success and diagnostic accuracy 
(i.e. [41,108,164,167]). The needed meticulous positioning is likely one of reasons we and 
others find that extensive sampling using multiple sampling instruments enhances diagnostic 
yield [113,122]. A further reason for this mismatch might be the difficulty in classifying 
pathology outcome based on only small samples wherein nuances are important. Where 
lymph node sampling ought to confine itself to only several microscopic imaging scenarios, 
even the diagnosis of adenocarcinoma in a peripheral pulmonary nodule involves classifying 
it into a range of pathological states [168]. And as Coghlin et al. for example describe in a 
study on sampling in central endobronchial lesions, lesions are heterogeneous in nature 
and only a minority of sampling outcome will reveal the true pathology [142]. Concluding, 
there is a need to develop methodologies for allowing better in-vivo tissue biopsy guidance 
in both endosonographic needle aspiration and navigation bronchoscopy. Secondly, 
reducing the repeated sampling need by introducing a sampling device that would enable 
a complete cross-section biopsy of the entire lymph node and peripheral lesion would also 
be of great help. To help resolve these issues, a plurality of methodologies and devices has 
been ideated, which resulted in two patent applications during the conduct of this thesis 
(P6087546EP, P6091207EP).
9.9 Minimally invasive staging and treatment
While diagnosis is currently the most sought-after goal of navigation bronchoscopy, 
increasing interest is also directed towards enabling local minimally invasive treatment 
(i.e. [125,169–171]). For this, CBCT imaging might prove essential. Meticulous (trans-
parenchymal) positioning and monitoring of treatment area is possible only by having 
detailed 3D information available. Current (commercially sponsored) studies seem to 
suggest a microwave ablation based technique is the optimal means for treating peripheral 
pulmonary lesions (i.e. [170,171]). Indeed, implementation thereof might be of potential use 
as neoadjuvant therapy, in metastatic disease, or patients with limited options because of low 
performance. Its use in early stage disease might however remain limited, as it provides only 
local control (limited to primary tumor). Microwave ablation is unlikely able to (curatively) treat 
metastatic spread to nearby (intralobar) lymph nodes in early stage disease. As described 
in 9.2. ‘Endosonographic staging in early disease’, occult nodal metastatic disease in these 
areas are however frequently found [156,157]. To offer a curative endobronchial treatment 
in early stage disease, both options to endoscopically stage and treat draining lymph 
nodes should be explored. For example, injection and imaging of specific agents might 
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allow for improving staging and/or enabling local treatments in early stage disease. If this 
proves possible, it would allow for a future single minimally invasive diagnosis and curation 
procedure. 
9.10 Low and high fidelity approaches 
In routine clinical practice, different patients and concurrent lesions will be seen. Not all 
cases will require technology utilization to the fullest, especially in an era where containing 
healthcare cost becomes increasingly important. A work-up tailored to case complexity 
seems relevant. Navigation to sub-centimeter nodules or any potential treatment will for 
example benefit from CBCT guidance, while the navigation to a three centimeter peribronchial 
lesion positioned in the apical segment of the upper lobe could also be reached by less 
complex technologies such as x-ray fluoroscopy combined with ultrathin bronchoscopy. 
The first is best performed in an expert center, while the second can also be performed in 
less experienced centers (if properly guided). While the advent of newer (often expensive) 
technologies at the forefront of healthcare is exciting, the translation from expert to less 
experienced centers should not be forgotten. Future technology development should focus 
on also enabling navigation bronchoscopy in less resourceful and experienced centers, and, 
allowing for a clear distinction in case needs. 
9.11 (Multi-disciplinary) Teamwork
The navigation bronchoscopy implies a multiplicity of technology and instruments, often 
handled at the same time. Depending on expertise available, a mix of patient and nodule 
characteristics need to be aligned with ultrasound imaging, electromagnetic tracking, 
fluoroscopy, endoscopic imaging, instrument properties, pre-operative imaging and so on. 
When relying on technology, one needs to be considerate of all individual pitfalls. If a future 
therapeutic or local staging application is also considered, we are yet venturing into another 
new terrain of expertise. The starting point here is interventional pulmonology. However, 
what it concerns is unclear. The expertise which it will need is inter-disciplinary, and might 
be a specialized team of both clinical as well as technical perspective (with a solid base in 
pulmonary medicine). 
9.12 Generalized future perspective 
For achieving lung cancer curation it seems unequivocal to target early identification, 
diagnosis and treatment of peripheral pulmonary lesions. In the upcoming years either one 
or multiple of non-invasive diagnostics such as breath analysis, liquid biopsy or low-dose 
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CT screening supported with novel AI-algorithms will surely allow a cost-effective means of 
at least early identification, and possibly, diagnosis. As current survival numbers show, the 
next frontier then becomes improving early stage lung cancer outcome. Aside of aiding in 
diagnostics, the future of (endobronchial) technology in early stage lung cancer is therein 
possibly two-fold. One is to allow unravelling the mechanisms of early stage lung cancer in-
situ, it’s micro-environment and impact on local immune-oncological phenomena to improve 
diagnostic and staging accuracy. Two is to provide a means of minimally invasive curative 
treatment. Most ideally, future technology and knowledge will allow us to move away from a 
sequential multi-modal diagnostic and treatment work-up and move towards a single stop 
diagnose-and-treat. It would however be short sighted to suggest technology is able to do 
it all. To reach this dot on the horizon, several aspects of lung cancer remain to be studied 
by the different specialties in pulmonary oncology. An intensive collaboration is needed to 








Longkanker is de meest voorkomende vorm van kanker wereldwijd, met meer dan 2.2 
miljoen gevallen per jaar. De incidentie ervan zal ook in de aankomende jaren blijven 
groeien, waarbij in 2035 een toename tot 3.2 miljoen nieuwe gevallen per jaar verwacht 
wordt [2]. In 2019 werden er in Nederland zo’n 13.800 mensen gediagnosticeerd met deze 
ziekte. Patiënten hebben pas laat klachten, wat er helaas toe leidt dat zo’n 50% van de 
patiënten al vergevorderde ziekte (stadium IV) hebben op het moment van diagnose. In 
dit late stadium - waar er ook betrokkenheid is van andere organen - is de overlevingskans 
na vijf jaar ongeveer 5%. Dit in tegenstelling tot een 5-jaars overleving van zo’n 61% als de 
patiënt in het vroegste stadium geïdentificeerd kan worden (stadium I) [1]. Om de kans op 
genezing groter te maken is het derhalve van belang dat longkanker in een zo vroeg mogelijk 
stadium geïdentificeerd wordt en dat daarnaast het stadium van de ziekte accuraat in kaart 
wordt gebracht. In dit proefschrift wordt onderzocht of nieuwe technieken het diagnostische 
traject van longkanker verder kunnen verbeteren, met daarbij de focus op de bijdrage van 
technieken in de flexibele endoscopie.
Deel I - Endoscopische stadiëring van longkanker middels ultrageluid 
technieken
Flexibele endoscopische procedures die gebruik maken van de aanwezige luchtwegen of de 
slokdarm worden frequent uitgevoerd bij een variëteit aan (long)ziekten. Met een stuurbare 
flexibele slang waarop een videocamera gemonteerd zit kan er door bestaande openingen 
genavigeerd worden. Specifiek bij longkanker is het gebruik van flexibele endoscopie voor 
de stadiëring van ziekte aanbevolen zorg. In dat geval is er naast de camera ook nog een 
echokop geplaatst op het uiteinde van de endoscoop, waarmee echo’s gemaakt kunnen 
worden. Bij een verdenking op longkanker zal er allereerst FDG-PET en/of CT beeldvorming 
aangevraagd worden, welke informatie kunnen geven over de anatomie en het metabolisme. 
Laten deze naast een tumor ook zien dat er misschien lymfeklieren betrokken zijn, dan raadt 
men aan een verdere echo geleide evaluatie van de (hilaire en mediastinale) lymfeklieren door 
de luchtwegen en slokdarm uit te voeren [10]. Wanneer op echo een lymfeklier gezien wordt, 
kan deze aangeprikt worden middels een naald die opgevoerd wordt door het werkkanaal. 
Zo kan er naast de ‘beeldende’ diagnose door middel van PET-CT en echo beeldvorming 
ook weefsel verkregen worden voor het stellen van een pathologische diagnose. Tijdens 
deze endoscopische evaluatie procedure (ook wel EBUS-TBNA/EUS-FNA procedures 
genoemd) dienen de lymfeklieren van de verschillende regio’s systematisch geëvalueerd te 
worden, waarbij gestart wordt met de minst verdachte klier en teruggewerkt wordt naar de 
meest nabij gelegen – meer verdachte - klieren. Lymfeklieren worden daarbij aangemerkt als 
verdacht op basis van een verhoogd metabolisme (FDG-aviditeit) en grootte (CT- en echo 
beeldvorming). Klieren met deze kenmerken dienen in ieder geval gepuncteerd te worden 
door middel van een holle naald, om op deze manier cellen voor diagnostiek te verkrijgen. 
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Naast de FDG-aviditeit en kliergrootte worden veelal ook (subjectieve) echo karakteristieken 
gebruikt om te beoordelen welke klieren verdacht zijn en gepuncteerd moeten worden.
 
In hoofdstuk 2 wordt beschreven hoe een relatief nieuwe endoscopische echo techniek, 
genaamd strain elastografie, mogelijk verdachte lymfeklieren kan identificeren. Echo 
strain elastografie is een techniek die de relatieve vervorming van weefsel in beeld brengt. 
Deze vervorming (strain) wordt in kaart gebracht door echo signalen opeenvolgend in tijd 
met elkaar te vergelijken terwijl er een deformatie plaatsvindt. De vervorming geeft een 
karakteristiek vergelijkbaar met die van de klassieke geneeskundige palpatie. Het wordt 
verondersteld dat kwaadaardige lymfeklieren een lagere vervorming (ook wel een lagere 
rek) zullen hebben. In de EBUS-TBNA/EUS-FNA procedures worden deformaties als gevolg 
van het cardiovasculaire systeem gebruikt om de weefselvervorming in kaart te brengen. 
De berekende rek is relatief, het geeft weer hoe het ene gebied ten opzichte van het andere 
vervormt. Omdat de berekende rek een relatieve maat is presenteren we in hoofdstuk 2 
een protocol om een zo reproduceerbaar mogelijke meting te verkrijgen met inachtneming 
van zowel technische als klinische beperkingen. Na het opstellen van het meetprotocol 
worden er in 63 patiënten met een longkanker verdenking een totaal van 120 lymfeklier 
strain elastografie metingen verzameld. Met de verzamelde metingen wordt bepaald dat de 
rek het beste beoordeeld kan worden door het gemiddelde te nemen van de rekwaarden 
in een geselecteerde regio van interesse ten opzichte van het gehele afgebeelde gebied. 
Door de rek te normaliseren – in de afbeelding is er altijd een gebied met geen vervorming 
(0) alsook een gebied met maximale vervorming (255) – krijgt de gebruiker een relatieve 
vervorming terug. In dit hoofdstuk wordt beschreven dat het oppervlakte onder de ROC-
curve voor het voorspellen van kwaadaardige lymfeklieren met deze methodiek 0.846 is. 
Deze beoordelings-methodiek is daarnaast objectief, er wordt alleen aan de endoscopist 
gevraagd om de lymfeklier te selecteren, waarna een waarde teruggegeven wordt. 
Een afkapwaarde van 78 (bereik 0-255) geeft een sensitiviteit van 93%, specificiteit van 
75%, positief voorspellende waarde van 69% en negatief voorspellende waarde van 95% 
(accuraatheid: 82%). Lymfeklieren met een rek van minder dan 78 (een lagere vervorming) 
blijken een hogere kans te hebben op kwaadaardigheid dan klieren met een rek van >78 
(een hogere vervorming). Een eerste verkennende analyse in deze studie laat tevens zien 
dat de rek-waarde tezamen met FDG-PET en CT informatie gebruikt kan worden om de kans 
op kwaadaardigheid beter in te schatten.
Hoofdstuk 3 beschrijft hoe endoscopische echo strain elastografie in een multicenter 
internationale setting (5 centra) van een voorspellende waarde kan zijn in het klinische 
traject van longkankerdiagnostiek. In de periode juni 2016 – juli 2018 worden 525 lymfeklier 
metingen verzameld in een totaal van 327 patiënten. Het verzamelen van metingen gebeurd 
naar inzicht van de endoscopist en resulteert in een kwaadaardige lymfeklier prevalentie van 
0.48. In Receiver Operator Characteristic analyse blijkt strain elastografie een oppervlakte 
onder de curve te hebben van 0.77, welke aangeeft dat strain elastografie een voorspellende 
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waarde heeft. Om de vertaalslag te maken naar de mogelijke toepassing in de reguliere 
kliniek wordt er gekeken naar de voorspellende waarde van verschillende afkappunten van 
vervorming. Omdat de correcte identificatie van maligniteiten het belangrijkst wordt geacht, 
wordt een afkapwaarde geprefereerd voor een hoge sensitiviteit en negatief voorspellende 
waarde. Op basis van deze voorkeur wordt geconcludeerd dat de eerder gevonden 
afkapwaarde van 78 in hoofdstuk 2 naar 115 bijgesteld moet worden. Met deze afkapwaarde 
blijkt strain elastografie voor het identificeren van kwaadaardige lymfeklieren 90% sensitief, 
43% specifiek en heeft het een positief en negatief voorspellende waarde van respectievelijk 
60 en 82% in een internationale multicenter studie. Daarnaast blijkt uit hoofdstuk 3 dat 
deze echo strain elastografie metingen verder gecombineerd kunnen worden met FDG-
PET informatie en echo-gebaseerde kliergrootte om de kans op maligniteit nog beter in te 
schatten. Om dit te vertalen naar klinisch toepasbare scenario’s worden twee beslisbomen 
gepresenteerd; een beslisboom die kliergrootte en gemiddelde vervorming combineert en 
een beslisboom die FDG-PET-aviditeit, kliergrootte en gemiddelde vervorming combineert.
In de huidige klinische praktijk wordt er naast FDG-PET en CT-grootte frequent gebruik gemaakt 
van subjectieve conventionele echo karakteristieken voor het bepalen of lymfeklieren wel of 
niet kwaadaardig zijn, en of de lymfeklier derhalve aangeprikt moet worden. Karakteristieken 
die in verband gebracht worden met kwaadaardige lymfeklieren zijn: heterogene klier 
echogeniciteit, afwezigheid van een centrale klier-hilus, aanwezigheid van centrale klier 
necrose, bolronde kliervorm (t.o.v. langwerpig) en scherp afgrensbare klier marges. In 
hoofdstuk 4 wordt beschreven wat de invloed is van kliergrootte op de voorspellende waarde 
van deze karakteristieken, en, of de endoscopist deze karakteristieken reproduceerbaar 
samen kan vatten om een oordeel te vellen over lymfeklier kwaadaardigheid. Ter beoordeling 
van de individuele voorspellende waarde van deze karakteristieken worden de verzamelde 
lymfeklieren beoordelingen uit de multicenter internationale studie van hoofdstuk 3 gebruikt. 
Wanneer een ≥8 mm korte as van de klier gebruikt word als voorspeller van kwaadaardigheid 
blijken 210 van de 237 kwaadaardige lymfeklieren correct geïdentificeerd, terwijl 110 van de 
253 goedaardige klieren correct als niet kwaadaardig worden geclassificeerd (sensitiviteit 
89%, specificiteit 46%, positief voorspellende waarde 61%, negatief voorspellende 
waarde 81%). Het verder toevoegen van de voorgestelde echo karakteristieken blijkt van 
gelimiteerde waarde, ook wanneer er gekeken wordt naar de reproduceerbaarheid van 
deze beoordelingen. Wanneer experts (>400 procedures, n=5) en ervaren endoscopisten 
(50-400 procedures, n=3) gevraagd worden om een willekeurige subset van in totaal 200 
lymfeklieren te scoren op meest waarschijnlijke diagnose (kwaadaardig of goedaardig), is 
de overeenkomst tussen beoordelaars slechts 71-74% (Gwet’s agreement coëfficiënt 1 0.42-
0.48). Wanneer een beoordelaar de lymfeklier herhaaldelijk scoort, resulteert dit slechts in 80-
86% van de gevallen in dezelfde uitkomst (Gwet’s agreement coëfficiënt 1 0.60-0.76). Omdat 
deze variabiliteit bij verdere analyse verschillend blijkt te zijn voor klieren <8 mm, ≥8 mm en 
goedaardige of kwaardaardige klieren, wordt er geconcludeerd dat een risico stratificatie 
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aan de hand van subjectieve echo karakteristieken geen eenduidige voorspellende waarde 
heeft en van beperkte waarde is.
Deel II - Klinische technologie ter diagnose van perifere afwijkingen in 
de long
Beeldvormende modaliteiten zoals CT waarop de longen afgebeeld staan worden uitgevoerd 
in routinematige klinische zorg voor een veelvoud aan ziekten. In gemiddeld zo’n 13% 
van de CT scans die worden gemaakt voor een reden anders dan longkanker blijkt één 
of meerdere kleine afwijkingen in de longen gezien te worden. Wanneer deze afwijkingen 
bij toeval gevonden worden, dan is de kans op goedaardige ziekte veel groter dan die 
van een kwaadaardigheid. Echter, uiteindelijk blijkt toch zo’n 1.5% van deze scans tot een 
diagnose van longkanker te leiden [32]. Het opvolgen van deze afwijkingen in patiënten 
zonder klachten is gerechtvaardigd omdat het vroeg identificeren van ziekte belangrijke 
gezondheidswinst oplevert. Meerdere studies beschrijven daarnaast ook wat de potentiële 
overlevingswinst zou zijn wanneer een populatie met verhoogde kans op longkanker door 
middel van CT-scans specifiek gescreend zou worden voor deze ziekte. Het blijkt dat een 
dergelijke CT screening de longkanker mortaliteit met tenminste 20% kan verlagen [26,31]. 
De behaalde gezondheidswinst wordt hierin voornamelijk toegeschreven aan het vinden van 
longkanker in een vroeg stadium. Aan de hand van onder andere deze resultaten wordt 
de nationale implementatie van screeningsprogramma’s aanbevolen door talrijke gremia in 
vele landen [25–30]. De CT-scans die in de reguliere klinische diagnostiek alsook die in 
een screeningsprogramma worden gemaakt zullen veel afwijkingen vinden en aanvullende 
weefseldiagnostiek vereisen. De vraag naar een accurate, makkelijke en veilige manier om 
deze afwijkingen te diagnosticeren is dan ook groot. 
De gebruikte strategie voor het diagnosticeren van kleine afwijkingen in de long is momenteel 
onderhevig aan nationale en internationale variatie. Deze variatie is tot stand gekomen 
doordat er momenteel geen simpele en veilige universele methode beschikbaar is om tot een 
diagnose te komen. De keuze voor een diagnostische methode wordt gemaakt aan de hand 
van centrum afhankelijke variabelen zoals de beschikbaarheid over klinische technologie, 
aanwezige expertise en procedurele risico’s. De meest gebruikte minimaal invasieve opties 
zijn de trans-thoracale CT geleide punctie of de trans-bronchiale (flexibel endoscopische) 
benadering. De trans-thoracale CT geleide punctie maakt gebruik van een CT-scanner om 
beeldgestuurd een instrument door de borstkas en in de afwijking te prikken. Deze methode 
heeft een hoge sensitiviteit van 91% en een negatief voorspellende waarde van 80%, maar 
leidt ook tot complicaties zoals een pneumothorax in meer dan 20% van de gevallen [32,44]. 
Het historisch beschikbare alternatief is de flexibele endoscopische benadering waarbij enkel 
gebruikt wordt van conventionele röntgen doorlichting en de natuurlijke luchtwegen. Omdat 
de conventionele endoscopen te groot zijn voor de kleine luchtwegen moet er onder beperkt 
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zicht gezocht worden naar de spreekwoordelijke speld in een hooiberg. Via de natuurlijke 
luchtwegen worden instrumenten opgevoerd tot de plek waar de afwijking verwacht wordt, 
waarna herhaaldelijk weefselbiopten afgenomen worden. Deze benadering is aanzienlijk 
minder traumatisch (kans op pneumothorax <2%), maar heeft in combinatie met röntgen 
doorlichting geleiding ook slechts een sensitiviteit van 34% [34]. In het afgelopen decennium 
zijn er echter technologische ontwikkelingen geweest die de endoscopist kunnen helpen 
bij het endoscopisch bereiken dan wel aanprikken van afwijkingen. Dit heeft de sensitiviteit 
van de procedure omhoog gebracht tot zo’n 70%-80%, waarin nog steeds minder dan 3.0% 
complicaties gerapporteerd worden [39,41]. Deze technieken berusten op het gebruik van 
elektromagnetisme voor het traceren en navigeren van instrumenten, geminiaturiseerde 
echo beeldvorming voor endobronchiale visualisatie van de afwijking in het longparenchym, 
de ontwikkeling van kleinere endoscopen om zodanig verder in de long te kunnen komen 
maar recentelijk ook bijvoorbeeld de introductie van robotica [41,49]. 
Hoofdstuk 5 beschrijft de evaluatie van twee combinaties van technieken voor het 
diagnosticeren van kleine afwijkingen in de longen middels flexibele endoscopie. De 
hypothese is dat deze twee methodieken beide veilig en accuraat een weefsel diagnose 
kunnen verkrijgen. De beide methodologieën verschillen enkel in het eerste gedeelte 
van de procedure, wanneer er getracht wordt naar de afwijking te navigeren. De eerste 
methodologie maakt voor de navigatie naar de afwijking gebruik van een combinatie van 
elektromagnetische navigatie techniek en geminiaturizeerde echo beeldvorming. De tweede 
methodologie maakt gebruik van een zogenaamd cone beam CT systeem ter navigatie, in 
combinatie met eenzelfde echo systeem als in de eerste methodologie. Het cone beam CT 
systeem, welke gesitueerd is op de interventie radiologie alsook de hybride operatiekamer, 
maakt het mogelijk om zowel 2D röntgen als 3D CT-scan gelijkende beeldvorming te 
produceren. Beschikbare software en de kalibratie van dit systeem met de operatietafel maakt 
het verder mogelijk om de opgenomen 3D beelden te segmenteren en intra-procedureel op 
2D beelden te projecteren. Zo kan een aanvankelijk op 2D röntgen onzichtbare afwijking met 
behulp van de segmentatie op eerdere 3D beeldvorming toch gevisualiseerd worden. De 
bewegingsmogelijkheden van het systeem maakt het daarnaast mogelijk om in meerdere 
vlakken deze projecties te verzorgen, zodat de endoscopist in meerdere vlakken onder 
röntgendoorlichting bevestiging kan krijgen. In dit hoofdstuk wordt geëvalueerd of de 
primaire methodiek succesvol of onsuccesvol is door na de navigatie fase een cone beam 
CT-scan te maken ter confirmatie van het bereiken van de afwijking. Met behulp van de cone 
beam CT beeldvorming wordt er vervolgens besloten of het zinvol is om een oversteek naar 
de andere navigatie methodiek te maken. Indien de navigatie succesvol blijkt op cone beam 
CT beeldvorming, wordt er in beide methodieken weefsel afgenomen onder verdere geleide 
van cone beam CT beeldvorming en röntgendoorlichting. In totaal worden 87 patiënten 
met 107 afwijkingen geïncludeerd. De gemiddelde lange as diameter van de afwijkingen 
is 14.2 mm in de elektromagnetische navigatie arm en 16.6 mm in de cone beam CT arm. 
Het blijkt dat de elektromagnetische navigatie techniek minder vaak succesvol is dan de 
CHAPTER 10156
navigatie onder geleide van cone beam CT en bijbehorende röntgendoorlichting, leidend 
tot een succesvolle navigatie in respectievelijk 52.2% en 76.3%. Het verder combineren van 
de technieken als de navigatie eerder onsuccesvol blijkt resulteert dat uiteindelijk in beide 
armen 87.5-89.9% van de afwijkingen succesvol bereikt worden. Het weefsel dat door middel 
van een navigatie afgenomen wordt resulteert echter slechts in 72.4% van de gevallen in een 
accurate diagnose. In 3.4% van de patiënten leidt deze procedure tot een pneumothorax. 
Er wordt geconcludeerd dat een navigatie bronchoscopie een veilige diagnose kan stellen 
in meer dan 70% van de gevallen, en dat een primaire cone beam CT geleide navigatie 
hierin de voorkeur heeft. Om daarnaast nog betere resultaten te bereiken in de toekomst 
zal er - naast het verbeteren van de navigatietechniek – een verbeterslag gemaakt moeten 
worden in het verkrijgen van voldoende adequaat weefsel voor het stellen van een correcte 
diagnose.
In hoofdstuk 5 blijkt dat het verkrijgen van een accurate diagnose na een succesvolle navigatie 
niet vanzelfsprekend is. Er wordt een discrepantie tussen het bereiken van de afwijking 
en een adequate diagnose gezien. Dit kan veroorzaakt worden door meerdere factoren. 
Kleine afwijkingen vereisen een minutieuze positionering van instrumenten ter accurate 
afname van weefsel. Daarnaast is een afwijking vaak heterogeen van aard, niet elk biopt zal 
een diagnose geven die correspondeert met de oorspronkelijke aard van de afwijking. In 
hoofdstuk 6 wordt geanalyseerd hoe de verschillende beschikbare instrumenten voor het 
verkrijgen van weefsel (cytologie alsook histologie) bijdragen aan een accurate diagnose 
na een succesvolle navigatie. Tevens wordt er gekeken naar de accuraatheid van ROSE, 
een methodiek die intra-procedureel direct uitsluitsel kan geven over het representatief zijn 
van cytologie en de aanwezigheid van kwaadaardige aandoeningen daarin. Het blijkt dat 
de forceps biopteur (een grijper-achtig instrument) bij gebruik het vaakst weefsel oplevert 
wat tot de diagnose leidt (70.6%), daarna volgen de 1.1 mm cryoprobe (68.4%), de holle 
naald (46.7%), de 1.9 mm cryoprobe (41.2%), de borstel (30.3%) en de lavage (23.7%). 
Met deze resultaten blijkt dat histologische weefsel afname technieken verhoudingsgewijs 
vaker tot een correcte diagnose leiden dan cytologische weefseldiagnostiek (respectievelijk 
72.4% versus 49.3%). Ook blijkt dat het afnemen van meer biopten dan aanvankelijk 
nodig geacht een verbeterde kans geeft op een adequate uitkomst. Omdat cytologie in 
slechts 49.3% van de gevallen tot een accurate diagnose leidt, kan ROSE (een analyse van 
cytologie) ook in minder dan de helft van de kwaadaardige afwijkingen correct uitsluitsel 
geven. Met deze uitkomsten wordt er geconcludeerd dat er geen enkele weefselafname 
methodiek is die garant staat voor een accurate diagnose. Vooralsnog blijft een multi-modale 
manier van weefseldiagnostiek in de navigatie bronchoscopie aan te raden. Hiermee wordt 
tevens gesuggereerd dat onderzoek naar een verbetering van de weefseldiagnostiek een 
belangrijke factor is in de verdere ontwikkeling van de navigatie bronchoscopie procedure.
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Hoofdstuk 7 beschrijft de veranderingen van de diagnostische accuraatheid en de 
procedurele stralingsdosis van de navigatie bronchoscopie naarmate de ervaring toeneemt. 
Door alle patiënten zoals geïncludeerd voor een navigatie bronchoscopie procedure op 
chronologische volgorde te bekijken, kan een potentiële leercurve afgeleid worden. Na de 
initiële introductie van de navigatie bronchoscopie zoals beschreven in hoofdstuk 5 wordt er 
nadien bewust gekozen voor een cone beam CT geleide methodiek als primaire navigatie 
methode. Dit hoofdstuk laat zien dat specifiekere instellingen van de röntgenapparatuur voor 
deze procedure leidt tot een significante reductie in procedurele stralingsdosis van zowel 
3D cone beam CT-scans als 2D röntgen doorlichting, van in totaal 47.5 Gy·cm2 (effectieve 
dosis: 14.3 mSv) tot 25.4 Gy·cm2 (5.8 mSv) per procedure. De reductie is het grootst in 
stralingsdosis als gevolg van röntgendoorlichting. De accuraatheid van de procedure laat 
eveneens een leercurve zien. In hoofdstuk 5 (de eerste 87 patiënten) wordt een accurate 
diagnose gesteld in 72.4% van de patiënten. Na 208 procedures (248 afwijkingen) loopt 
deze inmiddels op tot 76.4%. Als we daarbij verder opsplitsen naar periodes zien we dat in 
de laatste 64 patiënten (november 2019 – juni 2020) een accuraatheid van 90.6% gehaald 
wordt (en een succesvolle navigatie in 98.4% van de gevallen). Een toenemende ervaring 
met het uitvoeren van de navigatie bronchoscopie procedure leidt dus vaker tot zowel een 
accurate navigatie alsook een accurate diagnose, terwijl de stralingsdosis af kan nemen.
Discussie en toekomstperspectief
De bevindingen in het eerste deel van dit proefschrift laten zien dat echo strain elastografie 
van een toegevoegde waarde kan zijn voor de systematische stadiëring van longkanker met 
een verdenking op lymfeklier metastasen. Er wordt gezien dat deze techniek als individuele 
voorspellende waarde alsook in combinatie met andere technieken gebruikt kan worden 
om kwaadaardige lymfeklieren beter te identificeren. Er worden echter ook verschillende 
uitdagingen blootgelegd. De endoscoop is op dit moment niet geschikt voor evaluatie van 
de meest perifeer gelegen lymfeklieren. Echo-geleide endoscopische evaluaties worden 
daarnaast mogelijk nog niet voldoende uitputtend uitgevoerd, met name minder verdachte 
klieren zouden mogelijkerwijs vaker aangeprikt moeten worden. Additioneel onderzoek is 
daarnaast nodig om echo strain elastografie als een gestandardiseerde (meet-)methode 
beschikbaar te maken voor het brede publiek. En alhoewel subjectieve echo karakteristieken 
in dit proefschrift van gelimiteerde waarde blijken te zijn, zou een methode om deze objectief 
te kwantificeren mogelijk toch een voorspellende waarde van deze karakteristieken kunnen 
laten zien.
In het tweede deel van dit proefschrift wordt beschreven dat de flexibele endoscopisch 
diagnose van kleine afwijkingen in de long belangrijk significant kan worden door 
gebruik te maken van technologische hulpmiddelen. Door het gebruik van cone beam 
CT beeldvorming en een uitvoerige analyse van de diagnostiek worden er echter ook 
belangrijke verbetermogelijkheden vastgesteld. Om de prestatie van deze navigatie 
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bronchoscopie procedures te verbeteren is niet alleen ervaring benodigd. Er blijkt een 
belangrijke discrepantie te zitten tussen het bereiken van de afwijking en het verkrijgen van 
een accurate diagnose. Derhalve zullen de methoden om weefsel te verkrijgen verbeterd 
moeten worden. De cone beam CT systemen blijken daarnaast geschikt voor minutieuze 
positionering van instrumenten, maar ook onderhevig aan een leercurve. Om de leercurve 
te verkleinen en adoptie van deze techniek te vergroten is verdere ontwikkeling van de 
navigatie bronchoscopie techniek en haar gebruikers wenselijk. Tegelijkertijd is de cone 
beam CT geleide navigatie bronchoscopie nu al een platform wat zich zou kunnen lenen 
voor de toekomstige beantwoording van een pluraliteit aan vraagstukken. Één daarvan is 
bijvoorbeeld de mogelijkheid van flexibele endoscopische behandelingen van vroege stadia 
longkanker. Omdat de werkingsmechanismen van (long)kanker echter nog steeds niet 
volledig ontrafeld zijn, zullen de verschillende specialismen de handen op korte termijn ineen 
moeten slaan om meerdere vraagstukken samen te beantwoorden. Met het ontrafelen van 
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This thesis is based on the results of human studies, which were conducted in accordance 
with the principles of the Declaration of Helsinki. The medical and ethical review board 
Committee on Research Involving Human Subjects Region Arnhem Nijmegen, (Nijmegen, 
the Netherlands) gave approval to conduct all of these studies. In case of the multi-center 
studies as described in Chapters 3-4, participating other centers also had local ethical 
committee approval. 
All standardized paper case report forms collected during the studies as described in this 
thesis were entered into the computer by use of Castor EDC. Imaging and clinical data which 
need not or could not be captured by Castor EDC were collected through direct exports 
of (image and clinical) data from their respective sources. The Castor EDC database and 
additional source data were correlated and analyzed with R and Rstudio. 
Analog files and digital files as collected in the studies described in this thesis have been 
stored at the department of Pulmonary diseases (route 614). Binders containing analog 
documentation are stored in the Pulmonary diseases research archive closets, and will 
be relocated with the movement of the department of Pulmonary Diseases (expected to 
happen in less than 3 years). Both RLJ Verhoeven and EHFM van der Heijden will assure 
that all of the research data are then properly and coherently moved. Digital source files of 
manageable size (<50 Gb) and files related to the analysis of the study are stored at the 
research server of the department of Pulmonary Diseases (\\umcms033\Researchafdeling 
Longziekten) under their acronym, of which a back-up is continuously made. Chapter 2-4 
acronym; E-predict, Chapter 5 acronym; CONTROL A & CONTROL E, Chapter 6-7 acronym; 
Navigation bronchoscopy database. Source files of more than 50 Gb size and not deemed 
directly necessary to answer the primary or secondary questions nor relevant for analysis of 
the studies described in this thesis are stored on external hard disks in two-fold, which are 
kept together with their respective analog study files. 
The privacy of the participants in this study is warranted by use of encrypted and unique 
individual subject codes. This code correspondents with the code on the case report form, 
image data and other source files. The code is stored separately from the study data. 
The data will be saved for 15 years after termination of the studies. Using the patient data in 
future research is possible if it is research directly related to the original subject and does 
not require additional patient contact or imply additional patient burden, as is recorded in 
the informed consent. The datasets analyzed during the studies as described in this thesis 
are available from both RLJ Verhoeven and EHFM van der Heijden upon reasonable request. 
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Dankwoord
Een promotietraject heeft in mijn optiek enige gelijkenis met de koers; een uitgezet traject 
met een start en als het goed is ook een finish. Maar waar ik aanvankelijk dacht dat het 
traject veel weg had van een wegkoers, bleek het toch al vrij vlot meer weg te hebben van 
een mountainbike marathon. De ene keer moest er vanwege obstakels op de baan een klein 
stukje afgeweken worden van het oorspronkelijke traject, terwijl er de andere keer überhaupt 
geen andere keus was dan een complete nieuwe weg. Achteraf gezien ook de langste en 
meest uitdagende koers waar ik tot nu toe aan begonnen ben. Misschien is het geen toeval 
dat ik in deze een sterke persoonlijke voorkeur heb voor de mountainbike boven die van de 
racefiets. Gebaande paden zijn té makkelijk en weinig avontuurlijk. De afleiding, de vrijheid 
om te ontdekken, de benodigde keuze in focus en de coaching van langs de kant maken ook 
dat ik het promotietraject als plezierig heb ervaren. En dat laatste is mogelijkerwijs wel een van 
de belangrijkste factoren. Jezelf jarenlang vastbijten op een traject (of; probleem) is alleen 
leuk in een stimulerende omgeving die resulteert in (incrementele) vordering en uitdaging. 
In het promotietraject van de afgelopen jaren heb ik ontzettend veel geluk gehad. Naast 
het vanzelfsprekend interessante onderwerp voelde het alsof er veel mensen betrokken en 
geïnteresseerd waren in het Radboudumc en daarbuiten. Ik zou daarvoor graag iedereen 
die betrokken was willen bedanken. 
Allereerst Chris. Mijn eerste 10 weekse stage was onder jouw en MUSIC’s hoede. Het was 
het begin van de rest van dit proefschrift. Wat was ik verbaasd over hoe gezellig en hecht de 
MUSIC groep was en wat vond ik jouw manier van begeleiden fijn. Kwam het eenmaal op de 
inhoud aan dan kon je kritisch zijn en liet je je kennis voor je spreken, maar dat kon pas nadat 
er eerst een goed informeel gesprek geweest was. En alhoewel ik nooit veel heb gekund met 
je koffiemok gezien mijn gebrek aan het volgen van de voetbalsport, hebben we 2 van onze 
3 buitenlandse congressen samen toch goed weten te combineren met ook een aantal niet 
werk-gerelateerde activiteiten. Op de weg kon ik je bijhouden, maar op de latten was je mij 
te snel af ;-) . Daarnaast was er natuurlijk ook altijd gezelligheid tijdens het aanvullen van de 
energietekorten. Ontzettend bedankt voor je sturing, je begeleiding alsook jou als persoon.
Ook tijdens mijn allereerste stage leerde ik Erik kennen. Aan de ene kant neig ik nu naar 
het maken van een geintje, aan de andere kant slechts naar het tonen van respect. Maar 
misschien moet ik het een tikkeltje serieus houden, zodat we het in het normale leven des 
te luchtiger kunnen houden en ik misschien nog een keer met jou en Barbara op vakantie 
mag ;-) . Erik, ik blijf jou vooralsnog dag in dag uit lastig vallen met mijn eeuwige vragen. Ik 
ben je bijzonder dankbaar voor je geduld, de vrijheden en kansen die je mij tot nu toe hebt 
gegeven. Voor mij en elke patiënt zijn je praktische aanpak en eeuwige inzet voor zowel 
onderzoek en kliniek goud waard. Ik verbaas me elke keer weer over je reacties op mijn 
vragen om 1u ’s nachts, om vervolgens om 07.50 weer de OK binnen te komen (‘Is de patiënt 




je aanmanen om jezelf koest te houden. Erik, ik heb bewondering voor wat jij voor elkaar 
krijgt en ik hoop dat we in de toekomst samen nog vele uitdagingen mogen ondernemen. 
Prof. Verhagen, beste Ad, als voorzitter van de manuscript commissie wil ik je bedanken 
voor de tijd en moeite die je genomen hebt om dit manuscript te lezen en beoordelen. 
Daarnaast wil ik je ontzettend graag bedanken voor je kennis en kunde waarmee je niet 
alleen op dagelijkse basis patiënten levens redt, maar ook de onwetende onderzoeker zoals 
ik verder op weg helpt. Hopelijk zullen we na afloop van een volgend congres of symposium 
samen niet wéér in een vreemde stad eindigen, ook al was het (late) etentje onverwachts 
meer dan het benoemen waard.
Prof. Roovers, beste Maroeska, bedankt dat je de moeite en tijd genomen hebt om dit 
manuscript te lezen en beoordelen. Daarnaast ook een welgemeend dankjewel voor je 
inzet en expertise omtrent de Health Evidence en Health Technology Assessment. Ik blijf 
mij keer op keer verbazen over de ondoorzichtigheid van het zorgsysteem en het uitblijven 
van objectief bewijs voor de effectiviteit of ineffectiviteit van het een of het ander. Jij bent 
een boegbeeld in dit gebied en kietelt de zorg om alleen voor betaalbaar en effectief beter 
te gaan. Ik hoop dat dit onderwerp steeds meer zal gaan leven, zodat we als zorgverleners 
maar ook als maatschappij kritisch blijven acteren. Een goede aanzet tot dit doel vind ik het 
onder de loep nemen van de navigatie bronchoscopie, zoals we dit nu met Tim Govers doen. 
Dank voor deze samenwerking, ook richting Tim, en hopelijk op naar meer.
Prof. Slebos, beste Dirk Jan, als buitenlid van de manuscriptcommissie en vooraanstaand 
lid van de interventie longziekten wil ik ook jou graag bedanken voor de tijd en moeite die 
je hebt genomen om dit manuscript te beoordelen en je inzet in de dagelijkse zorg. Een 
eerste kennismaking vond plaats toen jij onze posters over de navigatie bronchoscopie in 
Madrid tijdens het ERS congres beoordeelde. Daarop volgde een levendig gesprek welke 
interessante mogelijkheden aanstippelde voor verder onderzoek. Het is bewonderenswaardig 
hoe jij een volledig nieuw procedure in Nederland op de kaart hebt gezet en eigen hebt 
gemaakt, en, daar niet bij stopt. Ondanks dat het inmiddels even geleden is, hoop ik dat de 
uitnodiging tot een bezoek nog steeds staat. Het is een stukje reizen, maar ik denk dat het 
een leerzame en interessante reis zou zijn! 
As the defense of the work described in this thesis wouldn’t be worth much without critical 
questions, I’d like to thank the corona for their time and efforts in studying the manuscript and 
participating in this defense.  
Prof. Fütterer, beste Jurgen, naast het plaatsnemen in de corona zou ik je graag willen 
bedanken voor je aandeel in het opzetten van de navigatie bronchoscopie procedure en de 
wetenschappelijke beargumentatie daarachter. Ik ben positief verbaasd over hoe jij zoveel 
dingen weet te begeleiden en hoop vanzelfsprekend dat er in de toekomst een verdere 
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samenwerking inzit wanneer we de mogelijkheden van de navigatie bronchoscopie kunnen 
uitbreiden.
Prof. Trisolini, dear Rocco, thank you for all the kindness and hospitality during my visit of 
Italy, the occasional memorable meet (and lovely dinners) at conferences, but also the fruitful 
collaborations we had. Your positiveness and everlasting enthusiasm is admirable. Also, a 
thank you for taking the time to participate in my defense. I’m sure all your interesting ideas 
will certainly point us towards more collaborations in the future.
Prof. Mischi, dear Massimo, we’ve only briefly met in Granada, but I’m honored that you 
are willing to invest your time and efforts to take place in the corona. Although the work 
presented in this manuscript is mostly based on clinical measurements, I hope you see 
room for discussing possible improvements on the technology and signal processing side 
of things. 
Dear E-predict study team; Rocco, Fausto, Piero, Michela, Alessandro, Mark, Chris, Jouke 
and Erik. Thank you all for your hospitality during the visits of your centers, your teamwork 
and the significant time and effort you put in to successfully complete this trial. 
Dear Fausto, thank you for the nice conversations, good company and the teamwork. Your 
input has been of high value for this manuscript and your unrelentless motivation is admirable. 
Let’s hope that we can team up again in the future. 
Klinische diagnoses zijn aardig maar er is er eigenlijk maar één die echt het laatste woord 
heeft; de patholoog. Shoko, naast je waardevolle klinische werk zou ik je ook graag willen 
bedanken voor je vriendelijkheid, wetenschappelijke input en je interesse. Elke keer als wij 
elkaar spreken leer ik weer ontzettend veel. Hopelijk heb ik je niet al te veel belast met alle 
vragen. 
Tijdens zo’n beetje elk endoscopieprogramma bellen we ze plat en moeten ze heel wat 
meters maken om ons van een advies te voorzien; de analisten van de pathologie. Lia, Anne, 
Danny en Tini, heel erg bedankt voor jullie inzet maar ook jullie interesse en behulpzaamheid. 
Ontzettend leuk dat ik af en toe mee mag kijken en weer van jullie observaties mag leren. 
Overigens, mijn excuses dat ik jullie af en toe een beetje vervloek als jullie zeggen dat er 
geen representatief materiaal uitkomt. ;)
Je ziet ze niet vaak rondlopen, maar ze zijn een stille kracht die de ziekenhuis faciliteiten 
op de been houden; de klinische fysici. Bedankt Pieternel, Wens, Joost en Erik voor jullie 
dagelijkse inzet maar ook het meedenken, of dat nou enkel wetenschappelijk of klinisch 




gekomen. Joost en Erik, een ander domein, maar net zo belangrijk. Bedankt voor jullie advies 
en behulpzaamheid. 
Toen het navigatie bronchoscopie programma van de grond kwam was het wennen. Het 
pad dat we bewandelde was eigenlijk voor niemand bekend. Een dankwoord zou ik daarbij 
uit willen spreken richting de laboranten van de interventie radiologie. Tom, Gretha, Ichelle, 
Mark, Peggy en Thessa maar ook de rest van de collega’s, jullie hulp en inzet was en is van 
grote waarde. Het specialisme longziekten is misschien niet jullie meest logische gast, maar 
fijn dat jullie ons de weg laten zien.
Graag wil ik ook de endoscopie verpleegkundigen bedanken. Ineke, Beppie, Annelou en 
Hennie maar natuurlijk ook de rest van de afdeling. Het is altijd gezellig met jullie als collega’s, 
ook al is het vaak flink doorwerken. Jullie bijdrage is onmisbaar groot en is tenminste elke 
week bij het navigatie programma een kleine volksverhuizing. Ik beloof plechtig dat ik 
niemand van jullie meer op de kast zal zetten. 
Veel tijd bracht ik gedurende het schrijven van dit manuscript door op route 614, 
Longziekten. Allereerst wil ik het stafsecretariaat bedanken; Rob, Hilda en Joyce. Jullie 
regelen meer dan dat ik waarschijnlijk ooit door zal hebben en krijgen het ook maar elke keer 
weer voor elkaar. Ook zou ik de verpleegkundige specialisten, back-office, stafleden, 
research verpleegkundigen maar ook de AIOS en ANIOS en alle andere collega’s van 
de longziekten willen bedanken. Er wordt altijd tijd gemaakt voor een gezellige kop koffie, 
samen lunchen, of het kleine praatje op de gang. Pauzes zijn over het algemeen niet mijn 
sterkste punt, maar ik doe mijn best. Specifiek wil ik graag nog Wouter en Olga bedanken, 
voor de dingen die jullie mij geleerd hebben alsook de vriendelijke en collegiale sfeer die 
er altijd hing tijdens de endoscopie programma’s. Ik ben blij dat jullie ruimte zagen voor mij 
als vreemde klinische technoloog en dat jullie haast vanzelfsprekend willen bijdragen aan 
de wetenschappelijke vragen die ter discussie staan. En Wouter, misschien dat ik in de 
toekomst ooit nog zo’n gekke hersenkronkel krijg zoals jij en dat we nog een keer samen 
ergens gaan trailrunnen. Tot die tijd hou ik het even bij dat moment in Belgrado, waarna ik 
na 3 dagen nog steeds krom liep van de spierpijn. Olga, ontzettend fijn dat je er weer bent. 
Ook verdienen Petra en Michel een specifieke benoeming. Ontzettend veel dank voor jullie 
vertrouwen alsook steun. De positiviteit van jullie beiden zorgt voor inzet en slagkracht. Met 
jullie aan het roer krijgt de afdeling Longziekten veel voor elkaar. Milou, je bent een fijne 
kamergenoot en sparringpartner. Soms hard werken, maar soms ook even gewoon niet. 
Die blessures met al dat hardlopen, ik snap dat gewoon nog steeds niet. Een fiets is toch 
gewoon sneller, kost minder moeite, en, minder blessuregevoelig? Ineke, jij verdient het om 
nogmaals genoemd te worden. Jouw tomeloze inzet voor de longziekten is gigantisch, je 
kwebbel oneindig, en de vrolijkheid en drukte waarmee je altijd rondstormt is een gezicht op 
zich. Bedankt!
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Toen ik voor het eerst stage ging lopen in het Radboudumc deed ik dat voornamelijk bij de 
MUSIC groep. Ik voelde mij destijds vrijwel direct op mijn plek in een gezellige en hechte 
groep. Een gevoel van thuiskomen.  In mijn latere afstudeerstage alsook het vervolg heb ik 
ontzettend veel mogen leren van de verschillende MUSICi. De technische kennis staat er 
buiten kijf en het groepsgevoel is sterk. Ik kijk met veel plezier terug op zo’n beetje elk moment 
dat ik weer tussen de MUSICi verbleef, ondanks dat ik zeker vaker de tijd had moeten nemen 
om te socializen. Mooi om te zien hoe deze onderzoeksgroep zichzelf zo vormt en stuurt. 
Graag wil ik ieder van hen bedanken voor hun oprechte interesse, gezelligheid, kennis en 
ook de samenwerkingen. Specifiek wil ik daarbij Gert noemen voor zijn hulp en expertise 
op het gebied van quantitatieve echo. Bedankt voor jouw behulpzaamheid en inzet voor het 
exploreren van de waarde hiervan binnen de longkanker diagnostiek Gert. Hopelijk blijf ik 
ondanks mijn aanstelling binnen de Longziekten ook in de toekomst nog welkom binnen de 
groep.
Tijdens dit promotietraject heb ik de eer gehad om meerdere stages te mogen begeleiden. 
De verschillende studie en bachelor opdracht groepjes wil ik graag bedanken voor hun 
telkens unieke kijk op de stof, jullie enthousiasme maar ook de uitdagende vragen die jullie 
soms stelden. Nienke, Eline en Irene, bedankt voor jullie individuele bijdragen aan de 
verschillende onderwerpen binnen dit proefschrift. Jorik, de resultaten in dit manuscript zijn 
ook zeker voor een deel jouw werk, waarvoor dank. Jij ging als een gemotiveerde sneltrein, 
en je was bereidwillig om zelfs na je stage periode nog even door te denderen. Ik waardeerde 
onze gesprekken, discussies en gezamenlijke leermomenten enorm. Renée, meermaals heb 
ik mij verbaasd over jouw oprechte interesses in iedereen, dat ontzettend grote en snel 
lerende geheugen en je actiepunten afwerk tempo. Op de Longziekten wachten we allemaal 
op je wederkeren als AIOS ;-). Desi, je begon ontzettend enthousiast aan het ontrafelen van 
taal met rare tekens en circuitjes. Volgens mij hebben we samen nogal wat uitgeprobeerd 
(en wat frustraties geuit). Inmiddels succesvol bezig met een andere opdracht met en na je 
afstuderen; je opgewektheid en eerlijkheid brengen leven in de brouwerij en kunnen nog wel 
eens veel impact gaan hebben! Nienke, jij laat je niet gauw uit het veld slaan. Binnen een 
mum van tijd heb je technisch ingewikkelde dingen aan elkaar weten te knopen (letterlijk en 
figuurlijk) om die dan ook nog eens naast de patiënt te kunnen valideren. Een mooi voorbeeld 
van de TG’er. Succes met je vervolg onderzoek in een nieuw veld! Ferhat en Souraya, ik 
beschrijf jullie samen omdat ik jullie ook een beetje als een (ambitieus) duo zie. Was de een 
er, dan de ander ook. Jullie werk is echt een ontzettend mooie basis die de wetenschap 
ook in de toekomst nog vooruit gaat helpen, dank daarvoor. Ferhat, ook na je stage ben je 
aan je onderwerp blijven doorwerken om het richting een succesvolle publicatie te krijgen. 
Een mooi resultaat, wat een van de problemen van de huidige longkankerdiagnostiek goed 
blootlegt.
My research has been supported in different ways by Pentax Medical Europe, the Ankie 




Radboudumc (MITeC) itself. I am very gratefull to all for their support. I’d furthermore like to 
thank several people individually. Amilcar, ever since we met in Strasbourg you’ve never 
stopped to challenge and question me. Thank you for your kindness and hospitality, even 
though we are now both in a different place and into different body parts. Sander, thank 
you for the never-ending information exchange, the help, the good conversations, straight 
forwardness and hands-on mentality. Stephanie, William, Marco, Lucia, Alessandro but 
also the rest of the team; thank you for the intensive collaboration, the nice conversations 
and the continuous progress you are making, it really helps both the patients and clinicians 
a whole lot.
Zo af en toe moet je je uitleven, en een significante noemer daarvoor is mijn fiets. Bedankt 
ook richting het KMC mountainbike team voor hun support. Martin, blij met je nuchtere 
blik op de wereld en het aangrijpen van elke uitdaging, hoe extreem dan ook. Een eer dat 
ik onderdeel van je equipe uit mag maken en mezelf daarin tot het uiterste mag drijven. Ook 
een specifiek dankwoord aan (oud-)ploeggenoten Gerben en Tim. Tim omdat ik nog krediet 
op moet bouwen voor de aankomende duo meerdaagsen (hij gaat me toch uitwringen..) 
en Gerben omdat ik nog steeds hoop dat ie terug komt.. Ramses moet ik misschien ook 
bedanken, maar het zit vaker toch meer tussen een mening over krankzinnigheid en inspiratie 
in. Maar natuurlijk ook aan de andere concullega’s; ik hoop nog veel mooie momenten samen 
met jullie mee te mogen maken.
Al sinds jaar en dag vanaf het moment dat ik naar Enschede verhuisde kan ik van hun op aan; 
studievrienden. Inmiddels enigszins verspreid over Nederland, maar de afstand voelt nooit 
groot. Fijn om altijd op jullie terug te kunnen vallen Sander, Simon, Ruben, Ruud (en jullie 
wederhelften natuurlijk!).  Samen hebben we veel geleerd maar ook veel beleefd. Bedankt 
voor de goede discussies onder een glas whisky, het samen tot ‘rust’ te komen op vakanties 
of dagen weg, het meedenken, maar ook bijvoorbeeld bedankt voor de onverwachte support 
op het WK in Singen of de meer dan avontuurlijke support in Combloux. Daarnaast ook 
richting alle andere vrienden om mij heen; bedankt, jullie verrijken mijn leven!
Last but not least wil ik graag ons thuis bedanken. Dat kan ik in heel veel woorden doen, 
maar over het algemeen weet ik dat het bij ons juist vaak onuitgesproken blijft. Renée en 
Martijn, ondanks onze verschillende richtingen heb ik toch altijd wat aan jullie advies en is 
het altijd gezellig als we elkaar weer zien. Een gesprek met jullie richt je hart en hersenen 
weer de goede kant op en houdt je met beide benen op de grond. Pap, mam, zonder jullie 
was ik nooit tot hier gekomen. Ik ben jullie dankbaar voor de normen en waarden, opvoeding, 
de ontelbare keren hulp, jullie enthousiasme, support, en, het feit dat jullie meer dan 24 uur 
in één dag weten te krijgen om ons als kinderen te helpen. Kelly, samen zijn wij een nieuw 
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